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ABSTRACT 
Role of Aggregation Conditions and Presence of Small Heat Shock Proteins on Aβ 
Structure, Stability and Toxicity.  (May 2005) 
Sung Mun Lee, 
B.S., Korea University; 
M.S., Seoul National University 
 
Co-Chairs of Advisory Committee:  Dr. Theresa A. Good 
                                                          Dr. Daniel F. Shantz 
 
Alzheimer’s disease (AD) is a neurodegenerative disorder that is one of such 
diseases associated with protein aggregation. Aβ is the main protein component of senile 
plaques in AD, and is neurotoxic when aggregated.  In particular, soluble oligomeric 
forms of Aβ are closely related to neurotoxicity.  In this dissertation, we examine the 
differences in Aβ aggregation intermediates, and final structures formed when only a 
simple modification in Aβ aggregation conditions is made, the presence or absence of 
mixing during aggregation.  We show that intermediates in the aggregation pathway 
show significantly different structural rearrangements.  The protein stabilities of Αβ 
species show that spherical aggregates corresponding to the most toxic Αβ species 
change their structure the most rapidly in denaturant, and that in general, increased 
toxicity correlated with decreased aggregate stability. 
In Alzheimer’s disease, even delaying Aβ aggregation onset or slowing its 
progression might be therapeutically useful, as disease onset is late in life.  Small heat 
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shock proteins (sHsps) may be useful for prevention of Αβ aggregation, since sHsps can 
interact with partly folded intermediate states of proteins to prevent incorrect folding and 
aggregation. In this research, several small heat shock proteins (sHsps) are tested to 
prevent Aβ aggregation and toxicity.  sHsps used in this research are Hsp17.7, Hsp27, 
and Hsp20.  All types of Hsp20, Hsp20-MBP, His-Hsp20 and His-Hsp20 without 11 
residues in C-terminus, can prevent Aβ1-40 aggregation.  Hsp20 also prevents Aβ 
toxicity in the same concentration ranges of it aggregation prevention activity. Hsp17.7 
and Hsp27, however, can inhibit Αβ1-40 aggregation but not toxicity.  A number of 
experiments to examine the mechanism of Hsp20 suggest that multivalent binding of 
sHsp to Aβ is necessary for the toxicity prevention activity. 
Conclusively, different Aβ incubation conditions in vitro can affect the rate of Aβ 
fibril formation, the morphology, the toxicity and the conformation of intermediates in 
the aggregation pathway.  Hsp20 rather than other sHsps may be a useful molecular 
model for the drug design of the next generation of Aβ aggregation inhibitors to be used 
in the treatment of AD. 
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CHAPTER I 
INTRODUCTION 
Due to the passing of the former U.S. president, Ronald Reagan, last year, 
Alzheimer’s disease (AD) is once again in the limelight.  Currently, over 4.5 million 
people in United States suffer with AD and about 360,000 new cases occur each year. 
(Brookmeyer et al. 1998; Hebert et al. 2003)  Alzheimer’s disease (AD) is defined as a 
neurodegenerative disease that causes dementia and gradual loss of brain cells.   AD is 
an age dependent disease.  Scientists estimate that more than 10% of Americans over the 
age of 65 and half of those over the age 85 are afflicted by AD. (Jorm et al. 1987; Evans 
et al. 1989) The dramatically longer life span of people during the 20th century has 
resulted in a much greater number of individuals suffering from neurodegenerative 
disorders that are common in the elderly.   
AD is a disease associated with protein aggregation.  The two hallmarks of AD are 
neuritic plaques and neurofibrillary tangles.  These hallmarks result from the deposition 
of sticky β-amyloid (Aβ) and the aggregation of hyperphosphorylated tau proteins 
respectively.  What causes AD is still mystery.  However, increasing evidence shows that 
aggregated Aβ causes toxicity to neuron cells in vitro. (Lambert et al. 1998; Walsh et al. 
1999; Ward et al. 2000; Klein et al. 2001; Walsh et al. 2002; Chromy et al. 2003) Many 
believe that aggregation of Aβ is one of the initiating factors in AD.  Aβ is produced by  
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APP (β-Amyloid Precursor Protein) as a proteolytic cleavage product with 39-43 
residues. (Joachim et al. 1989; Rogers et al. 1992)  The 40- and 42-residue Aβ are the 
main components of senile or neuritic plaques found in AD.  The highly hydrophobic 
Aβ1-42 is implicated in amyloid fibril nucleation, while the more soluble Αβ1-40 is the 
main form circulating in normal plasma and cerebrospinal fluid. (Seubert et al. 1992; 
Shoji et al. 1992)  Accumulating data show that while Aβ aggregates readily into 
amyloid fibrils, the Aβ species in soluble oligomeric forms rather than fibrils are closely 
associated with the neurotoxicity in vivo and in vitro. (Dahlgren et al. 2002)  Toxicity has 
been attributed to Aβ-derived diffusible ligands (ADDLs) composed of Aβ1-42, with 
molecular weights between 17 to 42kDa (Lambert et al. 1998; Klein et al. 2001) and 
heterogeneous globular species (also described as ADDLs) with hydrodynamic radii 
between 3 to 8nm (Chromy et al. 2003). Spherical aggregates, not described at ADDLs, 
with radii over 15 nm have also been reported to be toxic (Hoshi et al. 2003). Toxic 
protofibrils of Αβ1-40 have been described with hydrodynamic radii ranging from 9 nm 
to over 300 nm (Walsh et al. 1999; Ward et al. 2000; Wang et al. 2002).  Understanding 
the relationship between Aβ features such as structure that are associated with toxicity 
will be essential if we hope to develop new strategies to prevent the formation of Aβ 
toxic species.  An improved understanding of structure function relationships in Aβ may 
provide cues to the mechanism of action of Aβ in the central nervous system. 
Prevailing thought over the past several decades has been that Aβ aggregation is 
associated with toxicity, therefore much research has gone into understanding the 
mechanism of Aβ aggregation.  Several studies show that Aβ forms fibrils via a 
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conformational transition from α-helix/random coil to β-sheet.(Walsh et al. 1997; Walsh 
et al. 1999)   The secondary structure and fibril elongation of Aβ depends on multiple 
factors, such as pH, temperature, peptide concentration, and ionic strength.α-helical 
and/or random coil content has been shown to be coincident with high solubility and 
protease susceptibility whereas a β-sheet content has been shown to be correlated with 
poor solubility and resistance to proteolysis. (Barrow and Zagorski 1991; Barrow et al. 
1992; Snyder et al. 1994; Shen and Murphy 1995; Soto and Castano 1996; Fezoui and 
Teplow 2002; Kawooya et al. 2003; Stine et al. 2003; Manning and Colon 2004) Aβ 
fibril formation is basically self-initiated because no other chemicals or side reactions 
are involved.   Much research has been performed to elucidate how Aβ monomers are 
converted to fibrils.  One probable mechanism is a nucleation-dependent model. 
(Lomakin et al. 1997; Serio et al. 2000)  In the nucleation-dependent model, the initial 
aggregation rate is very slow until a critical size called nuclei is reached. Once the 
nucleus is formed, rapid aggregation proceeds by addition of monomers.  Any agents 
which could prevent nuclei formation and eliminate Aβ nuclei from solution once 
formed may be very useful as an Aβ aggregation (and toxicity) inhibitor.   
In this dissertation, we examined several questions associated with understanding 
the mechanism of Aβ aggregation under different conditions, the relationship between 
structure, toxicity, and stability of different aggregation species, and investigated a class 
of small heat shock proteins as a means to alter that Aβ aggregation pathway.  We 
examined the differences in Aβ aggregation intermediates, and final structures formed 
when only a simple modification in Aβ aggregation conditions was made, the presence 
 
 4
of absence of mixing during aggregation.  We show, that while the final structures in the 
Aβ aggregation pathway are comparable by measures such as electron microscopy, the 
toxicity of fibrils formed are significantly different.  In addition, intermediates in the 
aggregation pathway show significantly different structural rearrangements.  We 
examined the stabilities of the different Αβ species formed during aggregation using 
change in conformation in the denaturants, urea and guanidine hydrochloride (GuHCl).  
The changes in structure of Αβ species upon exposure to denaturants were monitored by 
circular dichroism (CD) at 220nm.   When guanidine hydrochloride unfolding was used 
as a simple measure of stability of different aggregated species, the structures that 
changed conformation at the lowest concentrations of guanidine hydrochloride were also 
the most toxic structures.  In urea, the stabilities were expressed as free energy 
differences between native and unfolded states of Αβ as a function of urea concentration 
and in pure water. The trends in stabilities of Αβ aggregation species upon exposure to 
urea were similar to that observed in GuHCl, although the differences in urea were not 
drastic in GuHCl. Spherical aggregates, corresponding to the most toxic Αβ species 
examined, changed structure at the lowest urea concentrations (which would correspond 
to the greatest instability).  These results suggest that other characteristics besides 
tertiary structure as can be measured by electron micrograph are more indicative of 
toxicity of Aβ species. 
Small heat shock proteins (sHsps) are expressed in almost all organisms when cells 
get stressed in unfavorable environments.  They exist as large oligomeric complexes of 
300-800kDa with monomeric molecular mass of 15-43kDa. (van den et al. 1999; Clark 
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and Muchowski 2000; MacRae 2000)  Important roles of sHsps are to stabilize other 
proteins during stress conditions and to protect them from aggregation. (van den et al. 
1999; Bruey et al. 2000)  A novel small heat shock protein, Hsp20, isolated from the 
bovine erythrocyte parasite Babesia bovis has chaperone like properties. Preliminary 
results showed that this novel protein inhibited the aggregation of denatured alcohol 
dehydrogenase (ADH).  Thus, Hsp20 was examined for its ability to prevent aggregation 
and toxicity of Aβ. 
Using three different Hsp20 constructs, a maltose binding protein fusion (Hsp20-
MBP), a polyhistidine fusion (His-Hsp20) and His-Hsp20 without 11 residues in C-
terminus, we showed that all types of Hsp20 prevented aggregation of Aβ and Aβ 
toxicity.  Hsp20 was able to prevent amyloid formation of Aβ with optimal activites at 
molar ratios of Hsp20 to Aβ of 1:1000 as indicated by Congo red binding.  Hsp20 
attenuated the toxicity of Aβ in SH-SY5Y and PC12 neuronal cells at analogous molar 
ratios.  His-Hsp20 was more active than Hsp20-MBP, but His-Hsp20s showed almost the 
same activities regardless of the existence of 11 residues in the C-terminus which appear 
to play a role in the self assembly of Hsp20.  Hsp20 seems to be able to prevent Aβ 
aggregation via a stoichiometric binding or a novel mechanism.  Hsp20 prevents Aβ 
aggregation at much lower concentrations than have been observed with other Aβ 
aggregation inhibitors. Other types of sHsps such as Hsp17.7 from carrot, and human 
recombinant Hsp27 were also tested in Aβ aggregation and toxicity assays. Both carrot 
and human sHsps inhibited Αβ1-40 aggregation but did not prevent toxicity.  
Conclusively, Hsp20 may be a useful molecular model for the design of the next 
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generation of Aβ aggregation inhibitors to be used in the treatment of AD. 
This body of work adds to our understanding of how Aβ aggregates, how novel 
proteins interact with Aβ to prevent its aggregation, and how Aβ aggregation, structure, 
and stability is related to Aβ toxicity.   
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CHAPTER II 
LITERATURE REVIEW 
AMYLOIDOSES - DISEASE RELATED TO PROTEIN AGGREGATION   
Proteins are synthesized on ribosomes from mRNA carrying genetic information of 
DNA. Proteins have only biological activity when they are correctly folded. However, 
the mechanism of folding of polypeptides into specific three-dimensional structures has 
been a mystery. Proteins are susceptible to environmental changes such as temperature, 
pH, pressure, and denaturants. (Creighton 1993)  Unfolded proteins could be formed by 
unfavorable environments, or misfolded or mutated proteins could be produced 
associated with mutations in genes (DNA), or problems in transcription (mRNA), 
translation (ribosome), or in chaperones or other folding machinery in the cell. The 
unfolded, misfolded or mutated proteins are targeted for degradation. (Dobson 2003; 
Goldberg 2003; Sitia and Braakman 2003) Those proteins are refolded by chaperone 
proteins or degraded by the ubiquitin-proteasome pathway.(Goldberg 2003)  The 
misfolded or unfolded proteins are prone to form aggregates via inappropriate interaction 
with other proteins because hydrophobic regions are exposed to the hydrophilic cell 
environment. (Fig. 2.1)   
The aggregates can damage or kill cells through mechanisms that are under 
investigation.  A variety of unrelated diseases have common pathological features 
associated with aggregated protein deposits. In all of these diseases, proteins that are 
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Figure 2. 1. The conversion of normal soluble proteins into insoluble aggregates. (A) 
stabilizing native protein, (B) Inhibiting the protein from aggregation by enzyme 
degradation, (C) Protein synthesis, (D) Clearance of misfolded protein, (E) Formation of 
fibril, (F) Accumulation of fibril precursor. (Dobson 2003)  
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normally soluble convert into insoluble aggregates that form toxic deposits.  
Amyloidosis is the extracellular deposition of insoluble protein fibrils leading to tissue 
damage and disease. (Serpell 2000)  More than 20 unique proteins such as β-amyloid 
(Aβ), α-synuclein, calcitonin, transthyretin, and β2-macroglobulin are involved in 
amyloidoses. (Tan and Pepys 1994; Carrell and Gooptu 1998; Kelly 1998) 
Neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, 
Huntington’s disease, amyotrophic lateral sclerosis, and prion disease are caused by 
aggregation of such proteins. (Taylor et al. 2002; Ross and Poirier 2004) (Table 2. 1) 
While the precursor proteins from which the aggregated proteins associated with disease 
listed in Table 2. 1 all differ from each other in biological function, primary sequences, 
and morphologies (from intact globular proteins to unstructured peptide molecules), the 
protein aggregates that form during amyloidosis share many common features such as 
relative insolubility, protease resistance, specific optical behavior (e.g. birefringence) 
with certain dye molecules like Congo red and characteristic cross-β pattern in X-ray 
diffraction. (Sipe 1992; 1994; Taubes 1996; Lansbury 1999)  The aggregates of those 
proteins also form similar macroscopic structures characterized by long straight and 
unbranched fibrils.(Serpell 2000; Serpell et al. 2000; Smith et al. 2003; Jansen et al. 
2004)   Because of the insolubility and the inability of the amyloids to be crystallized, 
the structure of aggregates at a molecular and nano scale is still under veil, but the 
structure is slowly being uncovered with the help of some techniques such as X-ray 
diffraction and solid NMR. (Petkova et al. 2002; Thompson 2003)  In this dissertation, 
β-amyloid (Aβ) related to Alzheimer’s disease will be discussed.   
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 Table 2. 1 Diseases related to aggregation and deposition of abnormal protein. (Tan 
and Pepys 1994; Carrell and Gooptu 1998; Kelly 1998; Taylor et al. 2002; 
Ross and Poirier 2004)  
Disease Toxic Proteins Involved 
Alzheimer's disease Aβ and tau 
Parkinson's disease α-Synuclein 
Huntington’s disease Huntingtin 
Prion disease PrPSc 
Tauopathy tau 
Familial amyotrophic lateral sclerosis SOD1 
Other polyglutamine disease (DRPLA, SAC1-3, etc., SBMA) Atrophin-1, ataxins or AR 
Fronto-temporal dementia with Parkinsonism tau  
Primary Systemic Amyloidosis Immunoglobulin Light Chain 
Senile Systemic Amyloidosis WT Transthyretin (TTR) 
Familial Amyloid Polyneuropathy I Variant Transthyretin (TTR) 
Familial Mediterranean Fever Serum Amyloid A 
Secondary Systemic Amyloidosis Serum Amyloid A 
Hereditary (Icelandic) Cerebral Angiopathy Cystatin C 
Familial Amyloid Polyneuropathy (III) Apolipoprotein A1 
Hemodialysis Amyloidosis β2-Microglobulin 
Finish Hereditary Systemic Amyloidosis Gelsolin 
Type II Diabetes Islet Amyloid Polypeptide (IAPP) 
Medullary Carcinoma of the Thyroid Calcitonin 
Hereditary Renal Amyloidosis Fibrinogen 
Injection-Localized Amyloidosis Insulin 
Atrial Amyloidosis Atrial Natriuretic Factor (ANF) 
Autosomal Dominant Hereditary Amyloidosis Variant Lysozyme 
Familial Visceral Amyloidosis Lysozyme 
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ALZHEIMER’S DISEASE 
Alzheimer’s disease (AD) is a neurodegenerative disorder that causes progressive 
memory loss and severe dementia in the late stage of AD.  Many of the symptoms 
resulting from brain cell death keep patients from having appropriate social relationships 
with others.  The common symptoms of AD are dementia, a gradual loss of memory, 
problems with reasoning or judgment, disorientation, difficulty in learning, loss of 
language skills, and decline in the ability to perform routine tasks.  According to 
statistics from the Alzheimer’s Association, approximately 4.5 million Americans have 
AD and 13.2 million Americans will have AD by the middle of this century (2050) 
unless appropriate drugs are developed to prevent the disease. (Hebert et al. 2003)  The 
increasing numbers of patients with AD are in part a result of the longer life expectancy 
of people in this century, as the greatest risk factor for AD is age.  One in 10 people over 
65 and nearly half of those over 85 have AD. (Jorm et al. 1987; Evans et al. 1989)  U.S. 
society spends at least $100 billion a year on AD. (Meek et al. 1998)    
The majority of AD cases are sporadic forms of the disease. Only 5–10% of AD 
patients have familial Alzheimer’s disease (FAD) with a defined inheritance pattern. (van 
Duijn et al. 1991; Barinaga 1995; Hutton et al. 1996)    There are two abnormal 
structures in the brain associated with AD. As shown if Fig. 2.2, the two hallmarks of 
Alzheimer’s disease are amyloid plaques, which are clumps of protein fragments (β-
amyloid) that accumulate outside of cells, and neurofibrillary tangles, which are clumps 
of altered protein (tau) inside cells. (Selkoe 2001) Besides these two main proteins (β-
amyloid and tau), many other factors are related to AD. (Farlow 1998; Selkoe 2001; 
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Figure 2. 2. Neuritic plaques and neurofibrillary tangles in Alzheimer’s disease. (from 
American Health Assistance Foundation - http://www.ahaf.org/alzdis/about/Amyloid 
Plaques .htm, Accessed on March 30, 2005) 
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 Butterfield et al. 2002; Poirier 2003) 
 
Risk Factors in Alzheimer’s Disease  
The major genes related to AD are those for the amyloid precursor protein (APP), 
presenilins 1 and 2 and ApoE.  Genetic factors (APP, Presenilin 1 and 2) are associated 
with familial Alzheimer’s disease (FAD) or early onset of AD,(Tanzi et al. 1996; Lippa 
1999) whereas other factors such as oxidative stress, cholesterol, and inflammation are 
related to sporadic AD. (Farlow 1998; Butterfield et al. 2002; Poirier 2003) 
 
GENETIC FACTORS 
APP (β-Amyloid Precursor Protein): The APP gene is on chromosome 21. (Goate 
et al. 1991; Selkoe 2001)  APP contains the Aβ sequence at the C terminus as shown in 
Fig.2.3. (Neve et al. 2000; Selkoe 2001)  Mutations in APP or alterations of its normal 
function may cause AD. (Tanzi et al. 1992; Campion et al. 1996)  A high proportion of 
people with Down syndrome, who inherit an extra copy of chromosome 21, develop AD 
at an early age. (Tanzi 1996; Petronis 1999; Lott and Head 2001; Head and Lott 2004)  
These facts suggest that mutations in APP or extra copies of chromosome 21 are strongly 
linked to AD.  APP is an integral plasma membrane protein. It is thought to mediate the 
transduction of extracellular signals into the cell via its C-terminal tail. (Neve et al. 
2001)  APP is normally cleaved endoproteolytically at the cell surface within the Aβ 
sequence by an α-secretase such as TACE (tumor necrosis factor alpha converting 
enzyme, also referred to ADAM17) and ADAM10 (a disintegrin and metalloprotease  
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1
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β-turn β-turnα or β conformation High probability for β-sheet
31 4136
Highly hydrophobic region
11 216 16 26
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KGAIIGLMVGGVVIA
COOHNH2
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Structural and Functional Domain of APP695 
      1-17        Signal peptides 
      38-187    Cystein rich domain 
      190-285  Anionic domain 
      328-332  Cell growth 
      444-612  Neuroprotection, Calcium regulation 
     597-637 or 639 β-amyloid   
 
Figure 2. 3. Schematic figure of structural and functional domain of APP695. (Neve et 
al. 2000) and the primary and secondary structure of Αβ (Serpell 2000) 
 
 15
domain 10). (Allinson et al. 2003; Allinson et al. 2004)  The α-secretase produces two 
soluble fragments: one is the neuroprotective secreted amyloid precursor protein 
(APPsα) and the other is nonamyloidogenic 3kDa Aβ secreted products. (Neve et al. 
2000)  β−secretase and γ− secretase cleave APP at the N-terminus and C-terminus of the 
Aβ protein sequence. (Sinha and Lieberburg 1999)  The principal β−secretase in neurons 
is the aspartic protease BACE1 (β-site APP cleaving enzyme 1).(Vassar 2004)  The 
γ− secretase is a high molecular weight complex composed of Presenilin 1 (PS1), mature 
Nicastrin, APH-1, and Pen-2. (Kimberly et al. 2003)  Mutations in both APP and 
presenilins (PS) increase overall secretion of Aβ or secretion of the long (42~43 amino 
acid) form of Αβ (Αβ1-42) relative to the shorter 40 amino acid form. (Borchelt et al. 
1996; Mehta et al. 1998; Neve et al. 2000; Selkoe 2001)    
Presenilin: Presenilins 1 (PS1) and 2 (PS2) genes which are linked to early onset 
AD, are on the chromosomes 14 and 1, respectively. (Levy-Lahad et al. 1995; Hardy 
1997; Rohan de Silva and Patel 1997; Selkoe 2001)  Presenilin knock-out mice show the 
normal levels of APP protein expression as well as normal secretory derivatives from the 
α- and β-secretase cleavages but have abnormal γ-secretase function. (Czech et al. 2000; 
Fraser et al. 2000; Zimmer 2000)  The mutations of these genes can increase the 
production of longer form of Αβ1-42 rather than relatively short form of Αβ1-40. 
(Borchelt et al. 1996; Czech et al. 2000; Fraser et al. 2000; Zimmer 2000)  Presenilins 
could interact with glycogen synthase kinase 3β (GSK-3β) which is one of the kinases 
related to phosphorylation of tau protein. (Ishiguro et al. 1992; Mandelkow et al. 1993) 
Mutation of PS1 in some FAD cases appear to increase the interaction between PS1 and 
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GSK-3β, which also increase phosphorylation of tau. (Irving and Miller 1997; Gantier et 
al. 2000)  Conclusively, hyperphosphorylated tau proteins lose their ability to associate 
with the cytoskeleton and form paired helical filaments.  There are a number of tau-
pathies that lead to neurodegeneration unrelated to Alzheimer’s disease. 
ApoE4 (Apolipoprotein E4): The apolipoprotein E (ApoE) gene is located on 
chromosome 19. (Saunders 2001; Sorbi et al. 2001) ApoE is responsible for moving fats 
between cells and absorbing cholesterol from food in the intestine. The ApoE gene has 
three alleles, ε2, ε3, and ε4. ε2 allele protects the cell and reduces the risk of developing 
AD but it is rare. (Aleshkov et al. 1997; Manelli et al. 2004)  The most prevalent form, 
the ε4 allele of ApoE, is a major risk factor for late onset AD. (Neve et al. 2000; Selkoe 
2001; Combarros et al. 2002)  ApoE4 enhances the deposition of Aβ peptides in both the 
cerebral cortex and microvasculature. (Holtzman et al. 2000)  ApoE4 also increases the 
steady state Αβ level in brain by inhibiting its degradation. (Rebeck et al. 2001)   
 
NON GENETIC FACTORS RELATED TO SPORADIC ALZHEIMER’S DISEASE  
Oxidative Stress: Several studies show that oxidative stress is one of major 
pathological mechanism in AD. (Good et al. 1996; Mark et al. 1996)  Oxidative stress 
refers to the state in which oxidant agents (free radicals) are overproduced and exceed 
the antioxidant capacities.  Aβ peptide has been reported to produce hydrogen peroxide 
(H2O2) through metal ion reduction, resulting in the formation of hydroxy free radical. 
(Zimmer 2000)  Free radicals peroxidize membrane lipids and oxidize proteins 
producing a variety of catostrophic cellular damages. (Schubert et al. 1995; Aksenov et 
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al. 2001)  As such, there is increasing interest in the protective role of different 
antioxidants in AD such as vitamin E, glutathione, ascorbate, catalase, melatonin and 
estrogen because antioxidants are known to be free radical scavengers. (Miranda et al. 
2000)  Reactive astrocytes and microglial cells around neuritic plaques are common in 
the pathology of AD.  These activated glia overexpress a number of proteins that may 
propagate inflammatory and oxidative stress responses that may contribute to the disease. 
(Dandrea et al. 2001) 
Inflammation: Inflammation is a normal immune response to injury or disease. 
Chronic inflammation can itself cause damage to tissues. Inflammation in the brain may, 
therefore, contribute to nerve damage. Two facts strongly suggest the involvement of 
inflammation in AD.  First, inflammatory proteins such as amyloid P (McGeer et al. 
2001) and α1-antichymotrypsin (Aisen 1996) have been observed in brain regions 
affected by AD.  The other fact is that nonsteroidal anti-inflammatory drugs (NSAIDs) 
are associated with a reduced risk of developing AD. (Hoozemans et al. 2003; Minghetti 
2004)  Many believe that inflammation is strongly related to Αβ. (Butterfield et al. 2002; 
Barger 2004; Broytman and Malter 2004; Zhang et al. 2004)  
Cholesterol: High blood cholesterol levels may be one risk factor for AD, possibly 
because high cholesterol enhances Aβ production. (Marx 2001)  The high cholesterol 
level in the cell membrane also increases the Aβ toxicity to neurons.  The role of 
cholesterol in AD is still under research. (Hartmann 2001; Simons and Ehehalt 2002)  
However, there is growing evidence that cholesterol plays an important role in regulation 
of α- and β-secretase. (Simons et al. 2001) Recent research shows that α-secretase 
 
 18
(ADAM10) cleavage of APP is favored over other secretase cleavage when cholesterol 
lowering agents such as methyl-β-cyclodextrin are used. (Kojro et al. 2001)  When 
elevated cholesterol levels are delivered to the central nervous system (CNS) by ε4 allele 
of ApoE, it could result in changes in the membrane fluidity and the composition of lipid 
rafts. (Simons and Ehehalt 2002) Cholesterol concentration at the cellular level is 
controlled by transcriptional regulation (Simons and Ikonen 2000) because of its toxicity, 
but elevated dietary cholesterol uptake can increase the level of Αβ through promoting 
β-secretase activity. 
Other Factors: Metals such as aluminum, zinc and copper are suspected to be 
associated with AD. (Gouras and Beal 2001; Becaria et al. 2002) Traces of aluminum are 
found in the brain of Alzheimer’s patients. (Basun et al. 1991)  However the role of 
aluminum in risk for AD is uncertain. Zinc and copper ions are believed to accelerate the 
Αβ aggregation and have been proposed as important in AD. (Miura et al. 2000; Huang 
et al. 2004) Other factors under investigation as risk factors in AD include head 
injury,(Hinkebein et al. 2003) infectious organisms (e.g. herpesvirus (HSV) 1 (Dobson 
and Itzhaki 1999)), depression,(Sheline et al. 2002), and ethnicity and/or race.(Tang et al. 
1996)  
 
PROTEINS INVOLVED IN ALZHEIMER’S DISEASE  
Protein tau: Neurofibrillary tangles contain insoluble paired helical filaments 
(PHFs) consisting of a ropelike section composed of 2 fibers twisted around each other. 
(Friedhoff et al. 2000; Iqbal et al. 2003) PHF are mainly composed of the abnormal 
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hyperphosphorylated microtubule-associated protein (MAP) tau. (Selkoe 2001; Iqbal et 
al. 2003)  From the results of electrophoresis, tau proteins in AD have a higher molecular 
weight than normal proteins.  The slower migration was shown to result from increased 
phosphorylation of tau. (Greenberg and Davies 1990; Iqbal et al. 1991)  Tau, 
multifunctional MAP, plays roles in the organization of microtubules via stabilizing the 
microtubules against instability, and bridging these polymers with other cytoskeletal 
filaments. (Kosik et al. 1986; Cross et al. 1993; Maccioni and Cambiazo 1995; 
Mandelkow et al. 1995; Saragoni et al. 2000)  The most relevant protein kinases 
involved in tau phosphorylation are GSK-3β (Ishiguro et al. 1992; Takashima et al. 
1993; Imahori and Uchida 1997) and Cyclin-dependent kinase 5 (Cdk5) (Tsai et al. 
1994; Michel et al. 1998; Alvarez et al. 1999; Patrick et al. 1999)  
β-Amyloid (Aβ): Aβ is produced by the cleavage of APP in the activity of β- and γ-
secretase. (Sinha and Lieberburg 1999) One of the most plausible hypotheses in AD is 
Αβ hypothesis.  In this hypothesis, Αβ initiates the pathological cascade that leads to 
amyloid plaques, neuronal dysfunction, and the complex symptoms related to AD.  
(Hardy 1997; Selkoe 1999)  The Aβ hypothesis has been strengthened by research that 
indicates that aggregates of Aβ show toxicity in in vitro experiments, and that most risk 
factors in AD are related to Aβ. (Hensley et al. 1994; Festy et al. 2001)  Strong evidence 
comes from the studies that overexpression of mutant APP, mutant presenilin 1 (γ-
secretase) and 2 result in age-dependent Αβ plaque formation that is related to the 
cognitive impairment. (Neve et al. 2000)  Interestingly, many people with Down 
syndrome develop AD at an early age. (Petronis 1999; Lott and Head 2001; Head and 
 
 20
Lott 2004)  Mutations of the tau gene cause a spectrum of neurodegenerative disease, but 
not AD. (Murrell et al. 1999; Nacharaju et al. 1999; Sahara et al. 2000; Rosso et al. 
2002; van Herpen et al. 2003) This series of these facts indicate that Αβ is a key factor in 
AD.  However, a drawback of this hypothesis is that amyloid deposits are not precisely 
colocated with neuronal dysfunction. (Lee et al. 2004) Many transgenic mice model 
show some discrepancies between amyloid deposits and neurodegeneration. (Price et al. 
1998)  Although some important pieces in the puzzle are still missing, e.g. the 
relationship between Αβ and tau proteins and between Αβ and neurodegeneration in vivo, 
many researchers believe that AD can be stopped or delayed if Αβ aggregation is 
blocked or reduced. Therefore, it is very important to investigate the properties of β-
amyloid and its aggregation in order to understand AD.  In this dissertation, we will 
focus on understanding the relationship between Aβ aggregation and toxicity, and the 
prevention of Αβ aggregation and toxicity by using various small heat shock proteins.  
 
β-Amyloid (Aβ) Protein in Alzheimer’s Disease  
THE STRUCTURE OF Aβ AS A MAJOR FACTOR IN AD 
A number of studies show that Αβ is found in the cerebrospinal fluid of AD patient 
and at comparable concentrations in age-matched control patients.  Aβ is also found in 
the plasma of healthy individuals.  This shows that Αβ is normally produced and is 
soluble under certain conditions. (Seubert et al. 1992; Shoji et al. 1992; Gursky and 
Aleshkov 2000)   Aβ is produced from APP with isoforms of 39-43 residues, (Bayer et al. 
2001; Turner et al. 2003) but the 40- and 42-residue amyloid β-peptides are the main 
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components of neuritic plaques in AD  The highly hydrophobic Aβ1-42 is implicated in 
amyloid fibril nucleation and plaque formation, while the more soluble Aβ1-40 is the 
main form circulating in normal plasma and cerebrospinal fluid. (Seubert et al. 1992; 
Shoji et al. 1992)   
As seen in Fig. 2.3, the sequence of the amyloid peptides can be split into four 
clusters, two hydrophilic segments from 1-16 and 22-28 and two hydrophobic segments 
from17-21 and 29-42. Two β-turns are predicted between residues 6 and 8, and residue 
23 and 27. (Kowalewski and Holtzman 1999; Lynn and Meredith 2000; Serpell et al. 
2000)  Residues 1-10 that have the negative charge are involved in electrostatic 
interactions. N terminal truncated peptides of Aβ have been used to demonstrate  that 
residues 1-9 were not necessary for fibril formation.  But the N terminus is thought to be 
important for initiating the α-β conformational switching and possibly in copper binding.  
Residues 29-42 are critical for amyloid aggregation and fibril stabilization.  The C 
terminus from residue 28 shows a high probability for β-sheet structure.  Fragments of 
10-23 and 29-42 amino acid residues were both found to form β-sheet structure by FTIR, 
but 29-42 is less soluble and formed only very short fibrils, whereas 14-23 formed long 
fibrils.  Residues 17-21 are hydrophobic and a crucial fragment for the fibril formation, 
but at least 10 residues, 14-23, is necessary for the long fibril formation. (Tjernberg et al. 
1999) 
α-helical and/or random coil content has been shown to be associated with high 
solubility and protease susceptibility whereas a β-sheet content has been shown to be 
associated with poor solubility and resistance to proteolysis. (Jacchieri 1998) The 
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transformation of Aβ from α-helix to β-sheet triggers aggregation and fibril formation. 
(Otvos et al. 1993; Roher et al. 2000)  One cause of protein misfolding and aggregation 
is thought to be the exposure of the hydrophobic region of such unstably folded proteins 
to an aqueous environment. (Dobson 2003; Goldberg 2003)  The secondary structure and 
fibril elongation of Aβ depends on multiple factors, such as pH, temperature, peptides 
concentration, and ionic strength. (Barrow and Zagorski 1991; Barrow et al. 1992; 
Snyder et al. 1994; Shen and Murphy 1995; Fezoui and Teplow 2002; Kawooya et al. 
2003; Stine et al. 2003)  Aβ has different secondary structures in different solvents. 
Some organic solvents that dissolve Aβ are generally used in in vitro experiments 
because Aβ is hard to dissolve in the aqueous solvent. Aβ has no detectable β-sheet 
content in pure Dimethylsulfoxide (DMSO), one third β-sheet in 0.1% trifluoroacetate 
(TFA), and two third β-sheet in 35% acetonitrile/0.1% TFA. (Shen and Murphy 1995)  
Recent studies found that higher Aβ concentration and stronger ionic strength increase 
the Αβ fibril elongation. Higher contents of β-sheet and longer fibrils are induced at 
37oC rather than 0oC and pH 5.8 rather than pH 7.4. (Fraser et al. 1991; Barrow et al. 
1992; Shen and Murphy 1995; Wood et al. 1996; Harper et al. 1999; Szabo et al. 1999; 
Gursky and Aleshkov 2000) 
Aβ is known to be toxic when Aβ monomers aggregate to form small oligomers, 
protofibrils, and fibrils. (Lambert et al. 1998; Ward et al. 2000)  Toxicity has been 
attributed to Aβ-derived diffusible ligands (ADDLs) composed of Aβ1-42, with 
molecular weights between 17 to 42kDa (Lambert et al. 1998; Klein et al. 2001) and 
heterogeneous globular species (also described as ADDLs) with hydrodynamic radii 
 
 23
between 3 to 8nm. (Chromy et al. 2003) Spherical aggregates, not described at ADDLs, 
with radii over 15 nm have also been reported to be toxic. (Hoshi et al. 2003) Toxic 
protofibrils of Αβ1-40 have been described with hydrodynamic radii ranging from 9 nm 
to over 300 nm. (Walsh et al. 1999; Ward et al. 2000; Wang et al. 2002)  When 
investigators have compared toxicity of fibril and oligomer Aβ species, they have found 
that the oligomeric species were more toxic. (Dahlgren et al. 2002)   
 
FIBRIL FORMATION MECHANISMS OF Aβ 
Aβ monomers undergo a conformational transformation from α-helix to β-sheet 
aggregate to form fibrils. (Jacchieri 1998; Koteiche and McHaourab 1999; Takahashi et 
al. 2000a; Takahashi et al. 2000b)  General Αβ aggregates are 6-10nm in diameter, 
nonbranching fibrils, with three to six laterally associated filaments. (Fraser et al. 1991; 
Stine et al. 1996; Harper et al. 1997; Walsh et al. 1997; Serpell 2000)  A great deal of 
research has been performed in order to elucidate how small peptides- Αβ monomers are 
converted to fibrils. Αβ fibril formation is self-initiated because no other chemicals are 
involved. Thoughts about the mechanism of fibril formation can be classified into three 
classes; one is a nucleation-dependent model, another is a template-assisted model, and 
the final one is a micelle-formation model. 
In the nucleation-dependent model, the initial aggregation rate is very slow until a 
critically sized nuclei is reached.  The kinetic barrier to ordered aggregation results from 
the thermodynamically unfavorable assembly of the nucleus.  Once the nucleus is 
formed, rapid aggregation by addition of monomers follows. (Jarrett et al. 1993; Gorman 
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and Chakrabartty 2001; Pallitto and Murphy 2001; Murphy 2002; Souillac et al. 2002)  
This model was proposed from the results of turbidity measurements.  Turbidity changes 
during Αβ fibril formation indicate that a lag phase exists in the beginning of incubation 
or aggregation, followed by a rapid increase in turbidity associated with fibril growth.  In 
the template-assisted model, the conformational change of Αβ from non β-sheet to β-
sheet is catalyzed by the presence of preformed aggregates. β-sheet conformation 
monomers are added to form longer fibrils. (Tomski and Murphy 1992; Inouye and 
Kirschner 1998)  In the micelle-formation model, above the critical micelle 
concentration (CMC), Αβ monomers form a micelle before they form nuclei.  The 
equilibrium between the monomer and micelles occurs rapidly.  Fibrils are grown by the 
addition of monomers. (Lomakin et al. 1997; Murphy and Pallitto 2000) 
 
Trends in Drug Developments for AD  
DRUGS APPROVED BY FOOD & DRUG ADMINISTRATION (FDA) FOR AD 
 Until now, five drugs for AD have been approved by FDA. One of them – 
memantine, an N-methyl-D-asparate (NMDA) antagonist - is thought to work by 
blocking the action of the neurotransmitter glutamate.(Religa and Winblad 2003; Farlow 
2004) Glutamate is used in areas of the brain affected by AD, and excess glutamate is 
toxic to neurons.  Memantine is for the treatment of moderate to severe AD, (Religa and 
Winblad 2003) whereas the other drugs approved  are for mild to moderate AD. (Birks et 
al. 2000; Doody 2003)  Four drugs - tacrine, (Kurz 1998; Qizilbash et al. 2000) 
donepezil, (Birks and Harvey 2003; Smith Doody 2003; Roman and Rogers 2004) 
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rivastigmine, (Farlow 2003; Gabelli 2003) and galantamine (Olin and Schneider 2002; 
Loy and Schneider 2004) - inhibit the breakdown of acetylcholine, a neurotansmitter 
which is important in cognitive function in areas of the brain affected by AD. 
 
CHEMICALS OR PROTEINS TO PREVENT Αβ AGGREGATION & TOXICITY  
Based on the Αβ aggregation hypothesis, many research groups have focused on 
finding agents that prevent or reduce Αβ aggregation and toxicity. (Ghanta et al. 1996; 
Lansbury 1997; Pallitto et al. 1999; Cairo et al. 2002)  Some chemicals such as 
polyphenol (Choi et al. 2001; Ono et al. 2004), apomorphine (Lashuel et al. 2002) and 
hexadecyl-N-methylpiperidinium (HMP) bromide (Wood et al. 1996) are reported to 
prevent Αβ aggregation and toxicity. Congo red and Chrysamine G, a more lipophilic 
variant of Congo red, disrupt Aβ aggregation and toxicity. (Lorenzo and Yankner 1994; 
Kisilevsky et al. 1995; Klunk et al. 1998)  Daunomycin, rifampicin, and benzofurans can 
also interfere with Aβ aggregation and toxicity (Tomiyama et al. 1996; Howlett et al. 
1999). Pentamer peptides, KLVFF (Tjernberg et al. 1996; Pallitto et al. 1999), LPFFD 
(Soto et al. 1998), GVVIN, and RVVIA (Hetenyi et al. 2002)  have been used to prevent 
Aβ aggregation.  All of these compounds are used at fairly high levels suggesting that 
they interact with a monomer of Aβ, and that high levels would have to be administered 
for in vivo treatment. 
 
ENZYMES INVOLVED IN Αβ DEGRADATION AND ANTIBODY FOR Αβ 
In a physiological system, excessive Aβ proteins can be cleared by several 
degrading enzymes such as insulin-degrading enzyme, neprilysin and plasmin. (Carson 
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and Turner 2002; Turner et al. 2004) The research into enzymatic Αβ degradation could 
be good target for drug development for AD and might lead to improved understanding 
of Αβ aggregation in vivo. (Saito et al. 2003)  A new immunotherapeutic approach has 
been developed which is based on vaccination with Aβ1-42.   Immunization of APP-
transgenic mice showed significant reduction of Αβ and cognitive improvement. 
(Schenk 2002; Robinson et al. 2004)  However, Aβ vaccines are still controversial 
because of safety concerns associated with inflammation in the brain. (Munch and 
Robinson 2002; Mathews and Nixon 2003; Orgogozo et al. 2003) 
 
SMALL HEAT SHOCK PROTEIN IN Αβ AGGREGATION & TOXICITY   
Small heat shock proteins (sHsp) which have chaperone like activity have also 
been investigated to prevent Aβ aggregation or toxicity. Human sHsp27 inhibited Aβ1-
42 fibril formation (Kudva et al. 1997).  αB-crystallin, one of α−crystallin subunits 
prevented Aβ fibril formation in vitro, but increased the toxicity of Aβ1-40 (Stege et al. 
1999). 
 
Protein Stability Based on Two Transition States 
While many biophysical tools have been used to study Aβ structure and 
aggregation, there have been no reports of measurements of protein stability using 
structure change in denaturants to study properties of Aβ and its aggregated species.   
The free energy for the stability of any protein in urea can be obtained by the 
assumption that protein is in equilibrium of two states, folded or native state (N) and 
completely unfolded state (U) with no partially unfolded intermediates. (Pace 1990) 
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UN ↔                                                              (2-1) 
 Based upon the equilibrium of two states, the fraction of unfolded state can be 
calculated by  
UN
obsN
U yy
yyf −
−=                                                         (2-2) 
where fU is the fraction of unfolded state, yobs is the observed variable, and yN, and yU are 
linear characteristics of native and unfolded states.  The equilibrium constant for the 
transition between native and unfolded states can be expressed by the fraction of 
unfolded protein and the characteristics of native and unfolded states    
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U
U
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f
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where K is equilibrium constant between N and U, [U] and [N] are the concentration of 
unfolded and native states.  The free energy difference, ∆G, between native and unfolded 
states can be obtained by the thermodynamic relationship between Gibbs free energy and 
equilibrium constant. 
uobs
obsN
yy
yylnTRKlnTRG −
−−=−=∆                                  (2-4) 
where ∆G is the free energy difference between unfolding and native states, R is gas 
constant and T is the absolute temperature.  The free energy change upon unfolding can 
be determined experimentally and denaturant concentration is generally linearly 
relationship with the free energy change. (Pace and Shaw 2000) 
  ]Urea[mGG O2H −∆=∆                                                (2-5) 
where [Urea] is the concentration of urea, m is the slope of this equation, and ∆GH2O is 
the free energy change in the environment without urea.  ∆GH2O refers to the 
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conformational stability of the protein without denaturant and m denotes the difference 
in accessible hydrophobic surface area in native and unfolded states. (Tanford 1970; 
Myers et al. 1995; Spudich and Marqusee 2000)  
We believe that application of the analysis of stability to Aβ may be useful in 
understanding properties of Aβ aggregates and their toxicity. 
 
SMALL HEAT SHOCK PROTEINS (sHsps)  
General Characteristics of Small Heat Shock Proteins (sHsps)   
Molecular chaperones interact with partly folded intermediate states of proteins to 
prevent incorrect folding and aggregation. (Ehrnsperger et al. 1997; Kudva et al. 1997; 
Clark and Muchowski 2000; Hatters et al. 2001; Hartl and Hayer-Hartl 2002; 
Muchowski 2002)  The first identified chaperone was a heat shock protein, since the 
protein was induced by elevated temperature. Small heat shock proteins (sHsps) are 
expressed in almost all organisms when cells become stressed during unfavorable 
environmental conditions.  They exist as large oligomeric complexes of 300-800kDa 
with monomeric molecular mass of 15-43kDa. (van den et al. 1999; Clark and 
Muchowski 2000; MacRae 2000)  Important roles of sHsps are to stabilize other proteins 
under the stressed condition and protect them from aggregation. (van den et al. 1999; 
Bruey et al. 2000) sHsps prevent the aggregation of substrate proteins in an ATP 
independent manner. (Ganea 2001; Narberhaus 2002) sHsps are composed of three parts 
in the primary sequence, the N-terminal domain, the α-crystallin domain, and the C-
termial extension. α-crystallin domains, highly conserved 80-100 amino acid sequences 
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located in the C-terminal regions, are very important for the self assembly of sHsps and 
the binding of sHsps to their substrates. (Fig. 2.4) (de Jong et al. 1993; Caspers et al. 
1995; Koteiche and McHaourab 1999; Clark and Muchowski 2000)  Mutations of 
various substrate binding sites suggest that sHsps bind substrate proteins through 
multiple contacts within the α-crystallin domain.  N-terminal domain has variable 
sequence and length.  This domain is responsible for sHsp assembly, which results in 
polydisperse sHsp.  The C-terminal extension shares no homologous sequence, but this 
domain has common polar and flexible properties which are probably related to protein 
solubility.  sHsps protect substrate proteins from unfolding when they are under 
unfavorable environments such as higher temperature, denaturants, and UV. (Ganea 
2001)  
 
Small Heat Shock Proteins - Hsp20 (Novel α-Crystallin), Hsp17.7, and Hsp27 
α-crystallin is 12~43kDa member of the small heat-shock protein family that is 
able to prevents irreversible aggregation.  In the lens, α-crystallin contributes to lens 
transparency and has chaperone like activity. (Horwitz 1992; 2000)  There are two 
oligomeric subunits, A and B.  Outside the lens, only αB-crystallin is induced in 
response to stress. (Stege et al. 1999; Liang 2000; Abgar et al. 2001)   
A novel protein (Hsp20) was isolated from the erythrocyte parasite Babesia bovis. 
(Dr. Allison C. Rice-Ficht, Department of Medical Biochemistry and Genetics, Texas 
A&M University, College Station, Texas). (Brown et al. 2001)  According to the 
sequence homology (BLAST search of the NCBI), the sequence of this protein is similar 
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Figure 2. 4. Schematic drawing of three domains in small heat shock proteins.  
(     N-terminus,      α-crystallin domain, and      C-termial extension)  αB-crystallin and 
Hsp16.5 are from (Salerno et al. 2003), and Hsp17.7 (carrot), Hsp20 (B. Bovis), and 
Hsp27 (human) are obtained by BLAST in the NIH web server. 
  
 
 31
 to that of the plant sHsp, α-crystallins, and Toxoplasma gondii hsp30/bag1.  This novel 
protein has shown α-crystallin activity in in vitro studies.  Alcohol dehydrogenase 
(ADH), when heat denatured, aggregates and shows increased turbidity with time.  
However the addition of the novel protein (Hsp20) at the beginning of ADH incubation 
can reduce the turbidity of the ADH.  The novel protein is known to form oligomers in 
solution, but the structure and the form of this protein at various solvents are under 
research. 
Hsp17.7 isolated from carrot can protect the carrot from thermal stress. (Dr. Lynn 
Zimmerman, Department of Biological Science, University of Maryland Baltimore 
County, Baltimore, Maryland)  It suggests that Hsp17.7 has chaperone like activity. 
(Malik et al. 1999) Many small heat shock proteins such as Hsp16.5 act as chaperones 
when unfolded proteins are generated.  However, some proteins such as Hsp12.6 do not 
have any molecular chaperone function.  
Hsp 27 purified from human has more than 80% sequence homology with Hsp25 
from mouse. Hsp27 is expressed in variety of cells such as muscle, skin, motor, and 
sensory neurons.  In AD, increased expression of αB-crystallin and Hsp27 was found.  
Hsp27 prevents Αβ1-42 aggregation in vitro, although it has less activity to inhibit 
preformed amyloid. (Kudva et al. 1997)  
Because small heat shock proteins are known to prevent protein aggregation, it is 
possible that they may be useful in preventing aggregation and toxicity of Aβ.  All small 
heat shock proteins used in this research have chaperone like properties and an α-
crystallin domain in common.  
 
 32
In summary, while much has been learned concerning Aβ and the role of Aβ 
aggregation in toxicity associated with AD, there is still much to learn.  There is still no 
clear understanding of the relationship between Aβ size, structure, and toxicity and how 
aggregated Aβ leads to toxicity.  Mechanisms of Aβ aggregation are still spectulative.  
While agents have been developed which reduce Aβ aggregation, none are useful at low 
concentrations that might be accessible therapeutically.  New tools, new approaches and 
new compounds are needed in research into the role of Aβ aggregataion and toxicity.  
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CHAPTER III 
ROLE OF AGGREGATION CONDITIONS IN STRUCTURE, 
STABILITY AND TOXICITY OF INTERMEDIATES IN THE Aβ 
FIBRIL FORMATION PATHWAY 
 
OVERVIEW 
β-amyloid peptide (Aβ) is among the main protein components of senile plaques 
that are one of the histopathological hallmarks in Alzheimer’s disease (AD). Aβ readily 
forms fibrils that have high β-sheet content, and it is this fibril or aggregated structure of 
Αβ that is associated with senile plaques in AD. From recent studies, it is known that Aβ 
is toxic when aggregated. In particular, soluble oligomers have comparable neurotoxicity. 
However, the relationship between neurotoxicity and the size of Aβ aggregates or 
oligomers is still under investigation.  Here, I show that different Aβ incubation 
conditions in vitro can affect both the rate of Aβ fibril formation and the conformation of 
intermediates in the aggregation pathway. When mixed, Aβ aggregates faster than non-
mixed Aβ as determined by Congo red binding, however, the morphology of fibrils 
formed at the end of aggregation with or without mixing, as observed in electron 
micrographs, are comparable. Interestingly, intermediates formed during Aβ aggregation 
as examined via circular dichroism spectroscopy, size exclusion chromatography, and 
electron microscopy, differ greatly under mixing and non-mixing conditions. Data 
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suggest that without mixing, Aβ undergoes a significant conformational change upon 
aggregation to a fibril form that is not seen when Aβ is mixed during aggregation.  
Unfolding studies in guanidine hydrochloride indicate that fibrils formed without mixing 
are more stable to unfolding in detergent than aggregation intermediates or Aβ fibrils 
formed with mixing.  In addition, Aβ fibrils formed without mixing were less toxic to 
differentiated SH-SY5Y cells than the Aβ aggregation intermediates of fibrils formed 
with mixing. These results suggest that it is not the tertiary structure alone of Aβ that 
correlates with its toxicity, but possibly other characteristics such as stability to 
unfolding in detergent that influence the toxic properties of Aβ.  Given that aggregation 
of Aβ in vivo may differ significantly from in vitro aggregation conditions, 
understanding the other factors that influence toxicity outside of tertiary structure may 
help guide development of agents to prevent Aβ toxicity associated with Alzheimer’s 
disease. 
 
INTRODUCTION 
Alzheimer’s disease (AD) is a progressive, neurodegenerative disease of the central 
nervous system and the leading cause of dementia in aging population. One of the 
histopathological hallmarks of AD is the formation of neuritic plaques, the major protein 
component of which is β-amyloid peptide (Aβ).  Two variants of Aβ, Aβ1-40 and Aβ1-
42, are the most abundant forms found in AD. (Bayer et al. 2001; Turner et al. 2003)  
Accumulating data show that while Aβ aggregates readily into amyloid fibrils, the 
Aβ species in soluble oligomeric forms rather than fibrils are closely associated with the 
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neurotoxicity in vivo and in vitro. Toxicity has been attributed to Aβ-derived diffusible 
ligands (ADDLs) composed of Aβ1-42, with molecular weights between  17 to 42kDa 
(Lambert et al. 1998; Klein et al. 2001) and heterogeneous globular species (also 
described as ADDLs) with hydrodynamic radii between 3 to 8nm. (Chromy et al. 2003) 
Spherical aggregates, not described at ADDLs, with radii over 15 nm have also been 
reported to be toxic. (Hoshi et al. 2003) Toxic protofibrils of Αβ1-40 have been 
described with hydrodynamic radii ranging from 9 nm to over 300 nm. (Walsh et al. 
1999; Ward et al. 2000; Wang et al. 2002)  When investigators have compared toxicity of 
fibril and oligomer Aβ species, they have found that the oligomeric species were more 
toxic. (Dahlgren et al. 2002)  While some investigators in general believe that there is a 
common structure associated with amyloid toxicity, (Kayed et al. 2003) a careful 
characterization of such a common structure is still not available.  
Part of the challenge in elucidating the relationship between Aβ structure and 
toxicity are the numerous environmental factors such as solvents, pH, temperature, and 
ionic strength that are associated with how investigators aggregate Aβ in vitro that affect 
Aβ structure. (Barrow and Zagorski 1991; Barrow et al. 1992; Snyder et al. 1994; Shen 
and Murphy 1995; Fezoui and Teplow 2002; Kawooya et al. 2003; Stine et al. 2003)  
In work presented here, I examined the differences in Aβ aggregation intermediates, 
and final structures formed when only a simple modification in Aβ aggregation 
conditions was made, the presence of absence of mixing during aggregation.  I show, 
that while the final structures in the Aβ aggregation pathway are comparable by 
measures such as electron microscopy, the toxicity of fibrils formed are significantly 
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different.  In addition, intermediates in the aggregation pathway show significantly 
different structural rearrangements.  When guanidine hydrochloride unfolding was used 
as a simple measure of stability of different aggregated species, the structures that 
changed conformation at the lowest concentrations of guanidine hydrochloride were also 
the most toxic structures.  Thus it appears that other characteristics besides tertiary 
structure as can be measured by electron microscopy are more indicative of toxicity of 
Aβ species.  
 
MATERIALS AND METHODS 
Materials 
β-Amyloid (Aβ)–(1-40) was purchased from AnaSpec (San Jose, CA).  Human 
neuroblastoma SH-SY5Y cells (ATCC number: CRL-2266) were purchased from ATCC 
(Manassas, VA). Cell culture reagents were purchased from Invitrogen Life Technologies 
(Carlsbad, CA). Superose6 HR 10/30 Column was purchased from Amersham 
Pharmacia Biotech. (Piscataway, NJ). All other disposable supplies for FPLC were 
purchased from Amersham Pharmacia Biotech. Congo red was purchased from Fisher 
Chemicals. (Pittsburgh, PA). All other chemicals, unless otherwise specified were 
obtained from Sigma-Aldrich Co.. 
 
Protein Sample Preparation 
Aβ1-40 was dissolved in 0.1% (v/v) Trifluoroacetic acid (TFA) solvent at the 
concentration of 10mg/ml. This solution was incubated at room temperature for 20~30 
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minutes in order to completely dissolve the Aβ.  Filtered phosphate-buffered saline (PBS, 
4.3 mM Na2HPO4, 137 mM NaCl, 2.7 mM KCl and 1.4 mM KH2PO4, pH 7.4) was 
added to the Aβ solution to make the final concentrations used in experiments. For cell 
viability assays, MEM medium was used instead of PBS buffer. For aggregation with 
mixing, Aβ samples were mixed on the rotator at 18 rpm and 37oC, and samples were 
taken out with time. For aggregation without mixing, Aβ samples were incubated 
without disturbance in a 37oC incubator. 
 
Congo Red Binding 
Congo red was dissolved in PBS at the concentration of 120µM and syringe 
filtered. The Congo red solution was mixed with protein samples at 1:9 ratios to make 
the final concentration of Congo red 12µM. After a short vortex, the mixtures were 
incubated at room temperature for 30~40 minutes. Absorbance measurements from 
400nm to 700nm (UV-Vis spectrometer model UV2101, Shimadzu Corp.; Kyoto, Japan).  
Alternatively, Congo red absorbance was read at 405 nm and 540 nm using an Emax 
Microplate Reader (Molecular Devices, Sunnyvale, CA). In both cases, PBS buffer was 
used as blank control. The concentration of Aβ fibrils was estimated from Congo red 
binding via equation 3-1:  
[AβFIB] =(541At/4780) −(403At/6830) −(403ACR/8620)  (3-1) 
where 541At and 403At are the absorbances of the Congo red-Aβ mixtures at 541 nm and 
403 nm,  respectively, and 403ACR is the absorbance of Congo red alone in phosphate 
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buffer. (Klunk et al. 1999) In the Microplate reader, absorbances at 405nm and 540nm 
were assumed to be same as those at 403nm and 541nm.   
 
Size Exclusion Chromatography (SEC) 
A Superose6 HR 10/30 Column attached to FPLC (Fast Performance Liquid 
Chromatography) (Pharmacia; Piscataway, NJ) was used to determine the molecular size 
of Aβ  species. PBS buffer was used as a mobile phase with flow rate of 0.5mL/min. A 
100µL sample loop was used. For Aβ samples where aggregation with mixing occured, 
100µL of the Aβ samples were centrifuged at 7,000rpm for 3 minutes prior to SEC 
analysis.  For the aggregation without mixing samples (non-mixed), samples were 
centrifuged at 7,000rpm and 30 seconds.  Supernatants of centrifuged samples were 
loaded in the 100µL loop and injected into the column. Aβ species were detected by UV 
detector at 254nm. The following proteins were used for calibration standards: 
ribonuclease (13.7kDa), chymotrypsin (25kDa), ovalbumin (43kDa), and albumin 
(67kDa), aldolase (158kDa), catalase (232kDa), ferritin (440kDa), thyroglobulin 
(660kDa), and BD 2000 (2,000kDa). To calculate relative areas of Aβ in peaks from the 
SEC chromatograms, first the total area of a 100 µM Aβ sample was obtained from a 
chromatogram obtained without a column in the FPLC system. On the basis of this total 
area, relative areas from the SEC spectrum was calculated  
 
Circular Dichroism (CD) 
Secondary structure of Aβ was measured using a PiStar-180 Circular Dichroism 
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Spectrometer (Applied Photophysics; Leatherhead, United Kingdom). CD spectra in the 
far UV range (190~260nm) were obtained using a 1 cm quartz cell, at 37oC, using a Xe 
lamp as a light source, a 1.0nm bandwidth, 1.0nm step interval, and 1.5 second/nm 
scanning speed. The spectrometer was purged with nitrogen gas during measurement. 
PBS buffer was used for the calibration.  
 
Electron Micrograph (EM) 
200µl of Aβ peptide solution, prepared as described above, was mixed, placed on 
glow discharged grids, and then negatively stained with 1% aqueous ammonium 
molybdate (pH 7.0). Grids were examined in a Zeiss 10C transmission electron 
microscope at an accelerating voltage of 80 kV. Calibration of magnification was done 
with a 2,160 lines/mm crossed line grating replica (Electron Microscopy Sciences, Fort 
Washington, PA). 
 
Aβ Stability with Guanidine Hydrochloride (GuHCl) 
100µM Aβ samples were prepared as described in the protein sample preparation. 
Aβ samples at 37oC incubator were taken out in 0 (fresh Aβ), and 24 hours for mixed 
samples and 4, 8, and 72 hours for non-mixed samples.  GuHCl was dissolved in PBS 
buffer and prepared in different concentrations.  Aβ samples were mixed with GuHCl 
solution at the ratio of 1:9.  The final Aβ concentration in each sample was 10µM.  The 
final GuHCl concentrations varied from 0.5M to 7M.    Aβ samples in different GuHCl 
concentrations were incubated at 37oC for 2 hours such that the protein could come to 
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equilibrium with the GuHCl.  CD spectra were taken of the incubated Aβ-GuHCl 
samples and each were calibrated against a solutions of GuHCl at the same concentration 
in PBS buffer.  CD intensity at 220 nm is typically a minimum for β-sheet structures 
such as would be found in aggregated Aβ, and thus was used as an indicator of change in 
protein structure with detergent addition.  
 
Cell Culture 
SH-SY5Y cells were grown in Minimum Essential Medium (MEM) supplemented 
with 10% (v/v) Fetal Bovine Serum (FBS), 25mM Sodium bicarbonate, 100units/ml 
penicillin, and 100mg/ml streptomycin.  Cells were cultured in a 5% (v/v) CO2 
environment at 37oC incubator.  Low passage number cells were used ( <p20) in all 
experiments to reduce instability of cell line. 
 
Biological Activity Assay 
For biological activity tests, SH-SY5Y cells at a density of 1x105cells/well were 
grown in 96 well plates.  Cells were fully differentiated by addition of 20ng/mL NGF for 
8 days.  Aβ samples in MEM medium were added to the differentiated SH-SY5Y cells 
and the cells were incubated with Aβ samples at 37oC for 2 hours.  Negative controls 
(cells in medium with no Aβ) and positive controls (cells treated with 800µM H2O2 in 
50% (v/v) medium for 2 hours) were also prepared.  At least 3 wells were prepared for 
each Aβ treatment, and each positive and negative control.  
Cell viability was determined by using 2 fluorescent dyes, Annexin V-PE and 7-
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Amino-actinomycin (7-AAD). Annexin V-PE is a Ca2+ dependent phospholipid binding 
protein that has high binding affinity for phosphatidylserine on apoptotic cells.  7-AAD 
is taken up by necrotic or damaged cells, whereas live cells exclude 7-ADD. In this 
experiment, cells unstained for both Annexin V-PE and 7-AAD were taken as live cells. 
In order to stain the dead cells, Aβ treated cells were washed with PBS 1~2 times and 1x 
binding buffer was added to the cells.  (1x binding buffer: 10mM Hepes/NaOH (pH 7.4), 
140mM NaCl, 2.5mM CaCl2) 5µL of Annexin V-PE and 5µL of 7-AAD were added to 
the cells and cells were incubated for 15~20 minutes at room temperature in the dark 
room.  150µL of 2x binding buffer was added to the cells, and cells were collected using 
a scrapper. Stained cells in 96 well plates were loaded in the FACS array (BD 
FACSArray, BD Bioscience; San Jose, CA) and fluorescence histograms for cells were 
obtained.  To set up compensation and gates for the cell viability assays, 3 sets of 
staining controls were prepared, unstained cells, cells stained with Annexin V-PE alone, 
and cells stained with 7-AAD alone. Cells not stained with either dye (population with 
low fluorescence intensities for Annexin V-PE and 7-AAD) were taken as live cells, and 
the relative cell viabilities were calculated using equation 3-2. 
100x
)L.C.(L.C.
)L.C.(L.C.
(%)ViabilityCellRelative
H2O2NControl
H2O2sample
−
−=   (3-2) 
where L.C.sample is live cells (%) of Aβ treatment,  L.C.Ncontrol is live cells (%) of negative 
control, and L.C.H2O2 is live cells (%) of H2O2 treatment (positive control).  
 
Statistical Analysis 
For each experiment, at least three independent determinations were made.  
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Significance of results was determined via the paired t test with p<0.05 (95% confidence 
interval) unless otherwise indicated. Data are plotted as the mean plus or minus the 
standard error of the measurement. 
 
RESULTS 
Kinetics of Aβ Aggregation with and without Mixing   
We examined the structure of 100µM Αβ samples when aggregated with mixing 
and without mixing.  Congo red binding was used as an indicator of extended β-sheet 
structure and changes in Αβ aggregation with time.  As seen in Figure 3. 1, the kinetics 
of Aβ fibril formation, as indicated by Congo red binding, follow a similar trend with 
and without mixing, however the time scales for fibril formation under the two 
conditions differ by a factor of two to four. In both cases, fibril formation follows a 
characteristic sigmoidal curve, with a lag phase at early incubation times, followed by a 
fibril growth phase, then a saturation phase.  The phase lags are about 4 hours and 16 
hours for mixing and non-mixing conditions, respectively.   
 
Size Characterization of Αβ Species during Aggregation   
I used SEC to characterize the size of Aβ species associated with fibril formation 
when Aβ was aggregated with and without mixing to try to determine if significant 
differences occurred during aggregation under the different conditions.  When freshly 
prepared, Aβ species that eluted at volumes consistent with monomer and dimer species 
were observed with an approximate 1:2 ratio of absorbance of monomer to dimer. When  
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Figure 3. 1.  Aβ aggregation scanning with time by using Congo red.  100µM Aβ was 
incubated at 37oC in the (A) presence and (B) absence of mixing.   
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mixing was employed during aggregation, large Aβ species (>1,500kDa) appeared in 
chromatograms along with monomer and dimer as early as 2 hours after the beginning of 
aggregation (Figure 3. 2). These large species were also seen at 4 hours into aggregation, 
however, after 4 hours, only monomer and dimer appeared on chromatograms as sample 
pretreatment (centrifugation at 7000rpm for 3 minutes) removed the largest aggregates 
formed.  At 8 hours and 24 hours, the only Aβ species recorded in SEC chromatograms 
were monomer and dimer, however, the total amount of monomer and dimer species 
decreased with time, indicating that more of the Aβ initially present was incorporated 
into large aggregated species that were removed via centrifugation prior to 
chromatography at later times during aggregation.  Throughout aggregation, the relative 
ratio of monomer to dimer appeared constant, suggesting the two species were in 
equilibrium.  
Analogous to that observed in chromatograms taken during aggregation with 
mixing, in chromatograms taken of samples when aggregation proceeded without mixing, 
species eluting at volumes consistent with monomer and dimer of Aβ were present at all 
times, in an approximate 1:2 absorbance ratio, with their relative amount decreasing with 
time during aggregation (Figure 3. 2).  Unlike aggregation with mixing, when 
aggregation proceeded without mixing, a species that eluted with an approximate 
molecular weight of a dodecamer was observed at 4 and 8 hours after the beginning of 
aggregation.  At later times this species was no longer present. The relative amounts of 
Aβ species observed during aggregation with and without mixing were calculated and 
are displayed in Table 3. 1.  
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Figure 3. 2. Size characterization of Aβ species - representative SEC. 100µM Aβ 
samples were incubated at 37oC for (A) 2, 4, 8 and 24 hours in mixing condition and (B) 
4, 8, 24, 72 hours in non-mixing condition.  
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Table 3. 1. Relative amount of Aβ species in percentage 
 Mixing Condition Non-Mixing Condition 
 
Mono- 
mer 
Di- 
mer 
Dodeca-
mer 
Big 
species* 
Mono-
mer 
Di-
mer 
Dodeca-
mer 
Big 
species* 
2 hrs 21.3** 55.3**  2.0**     
4 hrs 14.7 38.7  15.3 18.0 40.7 41.3  
8 hrs 8.7 22.0   6.0 28.0 35.3 12.7 
24 hrs 4.7 14.7   3.3 29.3   
72 hrs     2.0 26.7   
 
* Big species mean Aβ species that have the molecular masses of 1,500-2,000kDa.  
** All values used in this table are percentage calculated by the equation of (Each 
species area/total 100µM Aβ area) x 100  
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Electron Micrographic Images of Αβ Species during Aggregation   
Electron microscopy was used to visualize the images of Αβ species formed during 
aggregation with and without mixing. As seen in Figure 3. 3A, there were no distinct 
structures observed in micrographs of fresh Αβ.  At times 2 hours after aggregation with 
mixing (Figure 3. 3B), small globular species with diameters under 5 nm could be 
observed.   
At 4 and 8 hours after the initiation of aggregation with mixing, small globular 
species along with some fibril species could be seen in micrographs (data not shown).  
At 24 hours, dense mats of fibrils could be observed (Figure 3. 3C).  When aggregation 
proceeded without mixing, at 8 hours after initiation of aggregation, uniform spherical 
species with diameters of 20~30nm were seen (Figure 3. 3D). Species with this size and 
structure were never seen when aggregation proceeded with mixing.  At 72 hours, fibrils 
could be seen in micrographs that appeared more crystalline than fibrils observed under 
mixing conditions (Figure 3. 3E). 
 
Changes in Αβ Secondary Structure during Aggregation   
Circular dichroism (CD) was used to examine secondary structure changes of Αβ 
during aggregation. As seen in Figure 3. 4, the CD spectrum of fresh Αβ indicated that 
the fresh peptide contained a β-sheet rich structure with some α-helix and random coil 
contribution.  When aggregation proceeded with mixing, while changes in the CD 
spectrum were observed, they did not indicate a change in the basic secondary structure 
elements of the aggregating peptide (Figure 3. 4A).  However, when Aβ was aggregated  
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Figure 3. 3.  Representative EM images of 100µM Aβ with time.  (A) fresh Aβ, (B) 2 
hours in mixing condition, (C) 24 hours in mixing condition, (D) 8 hours in non-mixing 
condition, and (E) 72 hours in non-mixing condition. 
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without mixing, a significant spectral shift in the CD spectrum was observed at times 
between 4 and 10 hours after initiation of aggregation, consistent with a decrease in β 
sheet and and increase in random coil structure (Figure 3. 4B).  The appearance of the 
spectral shift in CD structure at intermediate times during aggregation without mixing 
coincides with the observation of the large (20 nm) globular species on electron 
micrographs and the peak that elutes at an approximate molecular weight of 53kDa on 
SEC chromatograms.  At longer times after initiation of aggregation, the secondary 
structure of the aggregating Aβ took on more β-sheet content.  
 
Stability of Aβ Species to Structure Change in Denaturant  
In order to obtain a relative measure of stability of different Aβ species that were 
intermediates or end points during aggregation under different conditions, I examined 
structural changes of the Aβ species upon incubation with a denaturant, guanidine 
hydrochloride, somewhat analogous to typical protein unfolding experiments that would 
be used to examine stability of folded proteins. (Pace 1990)  I made no attempt to 
quantify changes in energy associated with unfolding as it is not clear that equilibrium 
folding models apply to Aβ aggregation, however, in Figure 3. 5, I present the change in 
Aβ structure as measured by CD as a function of different concentrations of detergent.  
Fresh Aβ and Aβ fibrils formed without mixing require more denaturant before 
undergoing the maximum observed structural change, while Aβ fibrils formed with 
mixing and intermediate species formed during Aβ aggregation without mixing required 
the least amount of denaturant to undergo the maximum observed structural change.  
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 Figure 3. 4.  Conformational changes in Aβ aggregation with time.  100µM Aβ at 37oC 
in the (A) presence, and (B) absence of mixing [light thin solid line- fresh Aβ; dark thin 
solid line- 2 hours; light thick solid line- 4 hours; dark thick solid line- 8 hours; light 
thick broken line- 10 hours; dark thick broken line- 12 hours] 
 
 
 51
 
 
-1400
-1200
-1000
-800
-600
-400
-200
0
200
400
0 1 2 3 4 5 6 7 8
GuHCl Concentration (M)
[ θ]
22
0 (
de
gr
ee
 c
m
2 /d
m
ol
)
 
Figure 3. 5. Aβ stability with guanidine hydrochloride (GuHCl).  Aβ samples were 
mixed with GuHCl to final concentration of 10µM Aβ and 0.5 - 7M GuHCl.  Aβ 
samples in GuHCl were incubated for 2 hours at 37oC until it reached equilibrium.  CD 
intensities at 220nm were used for Aβ stability tests. [open circles - Fresh Aβ; open 
squares – mixed Aβ for 24 hours; closed triangles – non mixed Aβ for 4 hours; closed 
circles – non mixed Aβ for 8 hours; closed squares - non mixed Aβ for 72 hours] 
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Biological Activities of Αβ Species   
Aβ is known to be toxic to neuron-like cells when aggregated, however it is not 
clear if fibrils or aggregation intermediates formed by different pathways have the same 
toxicity.  I therefore examined viability of, differentiated SH-SY5Y cells were treated 
with Αβ samples prepared with or without mixing using a relatively fast viability assay 
(2 hour incubation with Aβ) in order to minimize structural and morphological changes 
of Αβ during incubation with cells.   
Two markers were used for viability, annexin-V-PE which binds to phophatidyl 
serine on the surface of early apoptotic cells and 7-AAD which binds to membrane 
permeable (late apoptotic or nectrotic) cells.  Viable cells were taken as those that were 
both annexin-PE and 7-AAD negative.  A positive and negative controls were used to 
determine assay sensitivity over the short incubation time, with viable cells 23% ± 1% 
and 54% ± 3% of total cells in the positive and negative control samples, respectively. 
Relative cell viabilities were calculated by using the equation described in the methods. 
Relative cell viabilities of cells treated with Aβ samples aggregated under different 
conditions are shown in Figure 3. 6. Cells treated with fresh Αβ had almost the same cell 
viability (102% ± 9%) as negative control population (p>0.05). Aβ species prepared at 
different times of aggregation with mixing were significantly more toxic than controls  
(p<0.05), and toxicity increased with time of aggregation of the peptide. When Aβ was 
aggregated without mixing, a different pattern of toxicity with time of aggregation was 
observed.   The toxicity of species formed within the first 8 hours of aggregation without 
mixing increased to a maximum observed toxicity at 8 hours.  Species formed after 24 or  
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Figure 3. 6.  Relative cell viability of differentiated SH-SY5Y cells.  SH-SY5Y cells 
were treated with 100µM Aβ samples with time; [dark solid bar- mixing condition; stripe 
bar- non-mixing condition; light solid bar- negative control and fresh Aβ]  
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more hours of aggregation, however, had significantly less toxicity than those formed at 
earlier times.  In addition, the toxicity of fibrils formed with mixing (24 hours) was 
significantly greater than fibrils formed without mixing (72 hours) (p<0.05). 
 
DISCUSSION 
In the effort to develop new methods of preventing toxicity associated with Aβ of 
Alzheimer’s disease, many investigators have sought to elucidate both the mechanism of 
Aβ aggregation (Lomakin et al. 1997; Esler et al. 2000; Pallitto and Murphy 2001) and 
the relationship between Aβ structure and toxicity. (Lambert et al. 1998; Walsh et al. 
1999; Ward et al. 2000; Klein et al. 2001; Walsh et al. 2002; Chromy et al. 2003; Hoshi 
et al. 2003)  In this work, I show that when Aβ is aggregated under different conditions, 
different mechanisms of aggregation appear to occur, and structures formed during 
aggregation, that appear to have similar morphology, have different toxicities.   
As seen in Figure 3. 1, kinetics of Aβ aggregation, regardless of the presence or 
absence of mixing, appears similar.  The characteristic lag in development of extended 
β-sheet structure to which Congo red binds is typical of a nucleation mechanism of 
aggregation that a number of investigators propose for Aβ fibril formation. (Lomakin et 
al. 1997; Tseng et al. 1999; Esler et al. 2000; Serio et al. 2000; Pallitto and Murphy 
2001)  However, data obtained from size exclusion chromatography, CD spectroscopy 
and electron microscopy (Figures 3. 2 – 3. 4) suggests that there are significant 
differences in the mechanism of aggregation with and without mixing of Aβ.   
SEC chromatograms indicate that throughout aggregation under conditions with or 
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without mixing, species that elute at volumes consistent with monomer and dimer 
species were in equilibrium as the ratio of peak areas for both species was constant in all 
chromatograms.  Others have made similar observations of Aβ aggregation. (Pallitto and 
Murphy 2001)  The relative amounts of monomer and dimer decreased with time, 
corresponding to increases in fibril formation as indicated by Congo red binding. (Table 
3. 1)  Different investigators have suggested that monomer or dimer are the building 
blocks for fibril nucleation or growth. (Garzon-Rodriguez et al. 1997; Roher et al. 2000; 
Hwang et al. 2004)   
In the solvent used in our studies, Aβ was initially in a largely β-sheet 
conformation. CD data suggest that Aβ did not undergo significant structural 
rearrangements when aggregated with mixing, however, when aggregated without 
mixing, a dramatic shift in structure was observed at intermediate times (approximately 
4-8 hours after aggregation is initiated), which corresponds to the presence of a 
intermediate sized species in chromatograms (approximate molecular weight as 
estimated from elution volume on SEC of 53kDa) and large globular species in electron 
micrographs.  None of these intermediate species were observed when aggregation 
proceeded with mixing.   
A number of investigators have observed Aβ aggregation intermediates, formed 
either at low temperature or via a particular preparation method, sometimes referred to 
as Αβ derived diffusible ligands (ADDLs) (Lambert et al. 1998; Klein et al. 2001) that 
have molecular weights within the range I observed via SEC.  A number of reports 
indicate that these ADDLs are the (or one of the) toxic Aβ oligomers. (Lambert et al. 
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1998)  Others have described spherical species of various sizes (Harper et al. 1999; 
Westlind-Danielsson and Arnerup 2001; Hoshi et al. 2003) that are Aβ aggregation 
intermediates with sizes ranging from 3 to 20 nm, and some up to 100 nm depending on 
starting peptide and preparation method. (Lambert et al. 1998; Harper et al. 1999; Klein 
et al. 2001; Westlind-Danielsson and Arnerup 2001; Hoshi et al. 2003) Toxicity of the 
spherical Aβ species has also been reported. (Hoshi et al. 2003)  The approximate 53kDa 
species observed via SEC may be distinct from the spherical species observed via 
electron microscopy, however, it is not possible to tell from our data.  Others have 
observed the formation of Aβ micelles (Soreghan et al. 1994; Lomakin et al. 1996; Yong 
et al. 2002; Kim and Lee 2004), which might appear as a large globular species via EM, 
but would certainly change apparent molecular size during chromatography.   Alternately, 
it is probably that via SEC I would not be able to detect a globular protein aggregate of 
20 nm diameter as it would be removed from our sample during our pretreatment, nor 
would I be able to detect 53kDa proteins via EM as they would be below the resolution 
of the microscope used. 
That I observe dramatic structural rearrangements with aggregation when mixing 
was not used, but did not observe the same structural rearrangements when aggregation 
occurred with mixing is not surprising.  If Aβ aggregation is nucleation dependent as 
others propose (Lomakin et al. 1997; Serio et al. 2000), then with mixing, one would 
expect more rapid collisions of molecules are faster nucleation.  The faster rate of 
nucleation would mean that Aβ would have less time to undergo any intramolecular 
structural rearrangements that might be energetically favorable and increase stability of 
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the fibril formed.  Without mixing, the rate of peptide collision with other peptides 
would be slower, allowing more time for intramolecular rearrangement of the peptide 
before combining with other peptides to form an aggregation intermediate. In short, 
mixing would favor intermolecular rearrangements to bury hydrophobic surfaces which 
would lead to aggregation, while static (or non-mixed) conditions would favor 
intramolecular rearrangements to bury hydrophobic surfaces. These intramolecular 
rearrangements could lead to formation of aggregation intermediates not seen when 
intermolecular interactions predominate.  
Based on the results presented, I propose the mechanism for Aβ aggregation with 
and without mixing depicted in Figure 3. 7.  Initially, a mixture of Aβ monomer and 
dimer are present, in predominantly β-sheet form.  As demonstrated by others, the 
solvent used to initially dissolve Aβ would certainly affect this initial peptide 
conformation. (Barrow and Zagorski 1991; Barrow et al. 1992; Snyder et al. 1994; Shen 
and Murphy 1995; Fezoui and Teplow 2002; Kawooya et al. 2003; Stine et al. 2003)  
With mixing, either monomer or dimer combine, without structural rearrangement, to 
form nucleating species, from which fibrils grow.  Under static conditions where no 
mixing is present, small Aβ species, possibly monomer as suggested by others (Pallitto 
and Murphy 2001), undergo a structural rearrangement, forming a larger oligomeric 
species or possibly micelles.  It is from this larger oligomeric species or micelle that 
fibrils are initiated.  There is some support for the role of Aβ micelles in fibril formation. 
(Soreghan et al. 1994; Lomakin et al. 1996; Yong et al. 2002; Kim and Lee 2004)  
Aβ critical micelle concentration is reported to be 100µM (Yong et al. 2002), the  
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Figure 3. 7.  Schematic mechanism and energy barrier of Aβ aggregation.  (A) in mixing 
condition and (B) in non-mixing condition.  
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concentration used in studies reported here.  When analogous experiments were 
performed of Aβ aggregation without mixing at lower concentrations of Aβ (20µΜ and 
50µΜ), the same intermediate species were not observed via either SEC or EM. (data 
not shown) 
The relative stability of species formed during aggregation in the presence and 
absence of mixing can be inferred from data collected on conformation change of Aβ in 
a denaturant (Figure 3. 5).  When Aβ was aggregated with mixing, fibrils underwent 
conformation change in denaturant more readily than monomer, suggesting that a less 
stable or higher energy species was formed.  When Aβ was aggregated without mixing, 
aggregation intermediates underwent conformation change more easily than either fresh 
or fibril Aβ suggesting the intermediate was least stable or had the highest energy.  This 
interpretation is reflected in the mechanism of aggregation presented in Figure 3. 7.   
However, given that changes in free energy associated with unfolding (Pace 1990) or 
conformation change were not calculated given the difficulties in defining an 
equilibrium model for Aβ aggregation or unfolding, the interpretation of the stability 
data is only qualitative. 
I examined biological activity or toxicity of fibrils and aggregation intermediates 
formed with mixing and without mixing (Figure 3. 6).  Fibril toxicity was greater when 
formed with mixing, while toxicity of aggregation intermediates formed between 4 and 8 
hours after initiation of aggregation without mixing were more toxic than other species 
formed.  Fibrils formed with mixing and aggregation intermediates formed without 
mixing changed structure more readily in denaturant than other species examined 
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(Figure 3. 5).  It is tempting to claim that the difference in stability in denaturants 
correlates with toxicity.  A number of investigators have suggested that Aβ membrane 
interactions via Aβ conformational changes are important in the mechanism of Aβ 
toxicity. (McLaurin and Chakrabartty 1997; Terzi et al. 1997; Ege and Lee 2004)  
Behavior of Aβ in a membrane and in a denaturant might be analogous.  Thus, one could 
speculate that toxicity of an Aβ species may be related to its ability to change structure 
within the cell membrane. 
There are several alternative explanations of the data presented.  Others have 
reported that Aβ oligomers with structures similar to those I describe forming during 
aggregation without mixing are more toxic than fibrils. (Hoshi et al. 2003)  When 
comparing toxicity of fibrils formed via different methods, it has been very difficult to 
characterize concentration or number of fibrils in a solution. Others have shown that the 
average length of fibrils changes with aggregation condition (Walsh et al. 1999; Ward et 
al. 2000), so number of fibrils might also change.  With mixing, one would expect larger 
numbers of smaller fibrils than would be formed without mixing.  Thus differences in 
toxicity observed may simply be due to differences in oligomer or fibril concentrations 
in solution  
In summary, I report structure and toxicity of Aβ species formed during 
aggregation via different methods.  I show that fibrils formed via different methods, 
while structurally similar, do not have the same toxicity or the same apparent stability to 
denaturants. Aggregation intermediates which are similar to Aβ oligomer species 
reported by others such as ADDLs, were of comparable toxicity and stability to 
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denaturants as fibrils formed during mixing.  This work contributes to the understanding 
of the relationship between Aβ structure, stability and toxicity. 
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CHAPTER IV 
THE STABILITY OF Aβ SPECIES IN UREA AND CORRELATION 
WITH Aβ TOXICITY 
 
OVERVIEW 
β-Amyloid (Aβ) is a main protein component of senile plaques in Alzheimer’s 
disease.  Αβ aggregation is important in Αβ toxicity.  Recently I found that Αβ 
aggregated via different pathways when incubated under different environmental 
conditions of mixing and non-mixing. Aggregation under the different environmental 
conditions resulted in different aggregation intermediates, and aggregates with different 
morphologies, and biological activity.   In the current work, I use urea unfolding of the 
Aβ aggregation species to estimate the stability of different Aβ oligomers and the role of 
accessible hydrophobic surface in biological activity.  I find a significant correlation 
between toxicity of the aggregated species and the change in Gibbs free energy of 
unfolding in water, and the parameter “m” which relates the free energy change upon 
unfolding with change in urea concentration and is taken as a measure of change in 
accessible hydrophobic surface when the protein goes from water to detergent.  The 
Aβ sample that was most toxic had the greatest Gibbs free energy of unfolding and m 
values of all peptide samples tested, 3658.07 ± 228.48 cal/mol and 846.01 ± 55.17 
cal/mol M, respectively.  These results suggest that Aβ stability in detergent, or possibly 
membrane environments, may be key in determining Aβ biological activity.  This work 
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contributes to our understanding of the relationship between Aβ structure and other 
biophysical properties and Aβ toxicity and may help guide our understanding of the 
mechanism of toxicity of Aβ.  
 
INTRODUCTION 
Proteins are susceptible to environmental changes such as temperature, pH, 
pressure, and denaturants. (Creighton 1993) Protein stability is very important for 
therapeutic proteins and industrial enzymes, as well as in other protein applications. 
(Fersht et al. 1992; Creighton 1993)  Protein stability has also been linked to the ability 
of a number of disease associated proteins to form amyloid fibrils (Hammarstrom et al. 
2001; Dahlgren et al. 2002; Foguel et al. 2003).  Much research has been performed over 
the past two decades to develop a framework in which to study protein stability (Pace 
1990).   
The classic approach to examining protein stability is to assume that there are two 
equilibrium states for a protein, a native and an unfolded state, and by measuring what 
fraction of a protein population is in either state, the equilibrium constant and the change 
in Gibbs free energy for unfolding can be estimated. (Pace and Shaw 2000)  ∆GH2O and 
m in the free energy difference equation (∆G =∆GH2O – m [Urea]) can be used to 
describe protein stability; ∆GH2O is a measure of the conformational stability of the 
protein without denaturant and m denotes the difference in accessible hydrophobic 
surface area between native and unfolded states. (Tanford 1970; Myers et al. 1995; 
Spudich and Marqusee 2000)   
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Many diseases are related to protein unfolding and aggregation such as 
Huntington’s disease which is associated with polyglutamine aggregation, and 
Parkinson’s disease which is associated with α-synuclein aggregation. (Ross and Poirier 
2004) One of the diseases in this category is Alzheimer’s disease (AD), a 
neurodegenerative disease of central nervous system that is associated with the 
aggregation and accumulation of β-amyloid (Aβ). One of the hypotheses in AD 
pathology is that AD is caused by the toxicity of Aβ aggregates, especially Αβ soluble 
oligomeric species.  Αβ is the main protein component of senile plaques in AD. Several 
studies show that Aβ forms fibrils via conformational transition from α-helix/random 
coil to β-sheet.(Walsh et al. 1997; Walsh et al. 1999)  Aβ conformation depends on 
environmental factors such as solvents, pH, temperature, and ionic strength. (Stine et al. 
2003). Recent research indicates that Αβ conformational change can be induced by 
membrane mimicking lipid vesicles. (McLaurin and Chakrabartty 1997; Terzi et al. 
1997)  Acidic phospholipids such as phosphatidylinositol induce an Αβ conformational 
change from random coil to β-sheet efficiently at low lipid to protein ratios. (Terzi et al. 
1995; McLaurin and Chakrabartty 1997) At higher lipid to protein ratios, the Αβ 
conformational transition is observed from β-sheet to α-helix. (Terzi et al. 1997)  These 
data suggest that Αβ conformational changes are strongly related to its interaction with 
lipid membranes.  Other work suggests Aβ toxicity is also related to its interaction with 
lipid membranes. Cellular responses to Aβ that have been postulated to result in toxicity 
encompass destabilization of calcium homeostasis, membrane depolarization, increased 
vulnerability to excitotoxins, increased membrane permeability due to free radical 
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generation, blockage or functional loss of potassium channels, and direct disruption of 
membrane integrity (Busciglio et al., 1993, Koh et al., 1990, Arispe et al., 1993, Behl et 
al., 1994, Butterfield et al., 1994, Butterfield, 1997, Good et al., 1996, Hensley et al., 
1994, Mattson et al., 1997, McLaurin et al., 1998, Pike et al., 1993, Simmons and 
Schneider, 1993). Changing membrane properties by altering the electrostatic potential 
of the membrane was shown to inhibit Aβ neurotoxicity. (Hertel et al. 1997).   
In this research, Αβ conformational change and Αβ stability in urea was monitored 
by circular dichroism (CD) at 220nm. The free energy difference between native and 
unfolded states of Αβ was calculated by linear regression.  In urea Aβ conformation 
changes from β-sheet to random coil.(Kawooya et al. 2003; Stine et al. 2003)  These 
differences in structure were used to estimate equilibrium constants and free energies of 
unfolding or structure change as a function of urea concentration.  Structures of Aβ that 
had the lowest free energy of structure change and smallest change in energy in 
detergent, fresh Aβ and Aβ fibrils formed without mixing, also had the lowest toxicity.  
Aβ species with the largest free energy of structure change and largest change in energy 
in detergent, aggregation intermediates formed without mixing at 4 and 8 hours after the 
beginning of aggregation, were the most toxic. These data suggest that Αβ structural 
change, or Αβ stability is very closely related to the biological activity of Αβ.   Structural 
stability in detergent may be related to Aβ changes in structure in lipid environments.  
This work may provide insights into the mechanism of toxicity of Aβ. 
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MATERIALS AND METHODS 
Materials  
β-Amyloid (Aβ)–(1-40) was purchased from AnaSpec (San Jose, CA). Urea was 
purchased from Sigma-Aldrich Co.. (St. Louis, MO). All other chemicals, unless 
otherwise specified were obtained from Sigma-Aldrich Co.. 
 
Protein Sample Preparation  
Aβ1-40 was dissolved in 0.1% (v/v) Trifluoroacetic acid (TFA) solvent at the 
concentration of 10mg/ml. This solution was incubated at room temperature for 20~30 
minutes in order to dissolve Aβ into the solvent efficiently.  Filtered phosphate-buffered 
saline (PBS, 4.3 mM Na2HPO4, 137 mM NaCl, 2.7 mM KCl and 1.4 mM KH2PO4, pH 
7.4) was added to the Aβ solution to make final concentrations of 100µM. For 
aggregation with mixing, Aβ samples were mixed on the rotator at 18 rpm and 37oC, and 
samples were taken out with time. For aggregation without mixing, Aβ samples were 
incubated without disturbance in a 37oC incubator. 
 
Aβ Stability with Urea 
100µM Αβ samples were prepared as described in protein sample preparation. Αβ 
samples at 37oC incubator were taken out in 0 (fresh Αβ), 2, 4, and 24 hours for mixed 
samples and 4, 8, and 72 hours for non-mixed samples.  Urea was dissolved in PBS 
buffer and prepared in different concentrations.  Αβ samples were mixed with urea 
solution at the ratio of 1:9 (v/v).  The final Aβ concentration in each sample was 10µM.  
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The final urea concentrations varied from 0.5M to 10M with 0.5M intervals.  Aβ 
samples in different urea concentrations were incubated at 37oC for 2 hours such that the 
protein could come to equilibrium with the urea. 
 
Circular Dichroism (CD)  
Secondary structures for Aβ were measured using PiStar-180 Circular Dichroism 
Spectrometer (Applied Photophysics; Leatherhead, United Kingdom). CD spectrum at 
220nm for Aβ were obtained using a 1 cm quartz cell, at 37oC, using a Xe lamp as a light 
source, a 1.0nm bandwidth, 1.0nm step interval.  The spectrometer was purged with 
nitrogen gas during measurement. PBS buffer was used for the calibration.   
 
Free Energy Differences with Equilibrium Constant or Urea Concentraion 
The free energy for the Αβ stability in urea can be obtained by the assumption that 
Αβ is in equilibrium of two states, folded or native state (N) and completely unfolded 
state (U) with no partially unfolded intermediates.  
UN ↔                                                          (4-1) 
 Based upon the equilibrium of two states, the fraction of unfolded state can be 
calculated by  
UN
obsN
U yy
yy
f −
−=                                                         (4-2) 
where fU is the fraction of unfolded state, yobs is the observed variable, and yN, and yU are 
linear characteristics of native and unfolded states.  The equilibrium constant for two 
transition states can be expressed by the fraction of unfolded protein and the 
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characteristics of native and unfolded states    
uobs
obsN
U
U
yy
yy
f1
f
]N[
]U[K −
−=−==                                            (4-3)  
where K is the equilibrium constant between N and U, [U] and [N] are the 
concentrations of unfolded and native states.  The free energy difference, ∆G, between 
native and unfolded states can be obtained by thermodynamic relationship between 
Gibbs free energy and the equilibrium constant. 
uobs
obsN
yy
yylnTRKlnTRG −
−−=−=∆                                  (4-4) 
where ∆G is the free energy difference between unfolded and native states, R is the gas 
constant and T is the absolute temperature.  The free energy difference can be 
determined experimentally as a function of denaturant concentration.   The denaturant 
concentration is generally in linear relationship with the free energy difference. 
  ]Urea[mGG O2H −∆=∆                                                (4-5) 
where [Urea] is the concentration of urea, m is the slope of this equation, and ∆GH2O is 
the free energy difference in the environment without urea.  (the symbol of slope m has 
been given by Greene and Pace. (Greene and Pace, 1974) 
 
Linear Regression of Αβ Denaturation with Urea and Data Fitting for ∆GH2O and m   
Experimental data of CD intensities of Αβ with urea were used for data fitting   of 
∆GH20 and m in equation (4-5).   Prior to this calculation, ∆G values were obtained from 
equation (4-4).  yN and yU were calculated by linear regression of native and unfolding 
states respectively.  Data of 0.5M-2.5M and 0.5M-2.0M urea concentration were taken 
as raw data for yN linear regression for mixed Αβ, and non-mixed Αβ samples 
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respectively.  Data of 6.5M - 10.0M urea were used for yU linear regression.  ∆GH20 and 
m in equation (4-5) were estimated from a linear regression of ∆G with urea 
concentration.  ∆GH20 was obtained by extrapolation at zero denaturant concentration. 
 
Statistical Analysis   
For each experiment, at least 3 independent determinations were made. 
Significance of results was determined via the student t test with p<0.05 (95% 
confidence interval) unless otherwise indicated.  Data are plotted as the mean plus or 
minus the standard error of the measurement.  
 
RESULTS    
Secondary Structures of Αβ in Buffer or in Urea Solution  
Fresh Αβ in PBS buffer and 10M urea solution were incubated at 37oC for 2 hours.  
The structure of Αβ samples was assessed by measuring CD in the range of 190nm and 
260nm.  In Fig. 4. 1, fresh Αβ in PBS buffer (solid line) had a minimum CD intensity 
around 210nm, corresponding to β-sheet structure in the peptide, along with a spectral 
features between 200 to 220nm, corresponding to α-helix structure in the peptide.  The 
CD spectrum of Αβ in 10M urea had blue shift relative to the spectrum of Αβ sample in 
buffer, with a minimum intensity around 200nm.  The CD spectrum suggests that the 
dominant structure of Aβ samples in 10 M urea is random coil. The large difference in 
spectral characteristics between native Aβ and Aβ treated with urea (unfolded Aβ) in the 
region of 220 nm was used to characterize stability of Aβ to unfolding in urea.  
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Figure 4. 1. Secondary structures of Aβ in buffer or urea solution.  100µM of fresh Aβ 
was mixed with buffer or urea solution to be final concentration of 10µM Aβ and 10M 
urea.  Aβ samples were incubated at 37oC for 2 hours.  Aβ samples in buffer (solid line) 
and in urea (broken line) were scanned by CD from 190nm to 260nm.  
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Αβ Stabilities with Urea in Different Incubation Conditions   
Αβ aggregation depends on the environmental conditions such as temperature, pH, 
concentration, and ionic strength.  Recently I found that different Αβ incubation 
condition affected the rate of fibril formation and intermediate Αβ species.  Αβ formed 
fibrils in 24 hours when it was mixed. However fibrils formed more slowly, and unique 
aggregation intermediates were observed when Aβ was aggregated without mixing. 
Conformational stabilities of these Αβ species were estimated using urea unfolding. 
 
MIXED Αβ STABILITIES WITH UREA   
100µM Αβ was aggregataed as described in a previous chapter. The CD intensities 
at 220 nm of Αβ samples in urea were measured.  As shown in Fig. 4. 2A, CD intensities 
decreased as urea concentration increased at low concentrations; from 0.5M to 2.5M 
urea.   In 2.5M – 6M urea, CD intensities increased with urea concentration.  All samples 
had a maximum CD intensity in around 6.5M urea.  CD intensity reduced again with 
urea from 6.5M to 10M.  The region from 0.5 M to 2.5 M urea was taken as the folded 
state of the peptide, while the region from 6.5M to 10 M urea was taken as the unfolded 
state.  At concentrations of urea between 2.5 M and 6.5M, equilibrium constants and ∆G 
of unfolding were estimated.  In this region, fresh Aβ structure changed at higher 
concentrations of urea than did any of the aggregated Aβ structures.    
Linear regressions in the folded and unfolded regions were performed to estimate 
yN and yU.  The regression results were displayed in Table 4. 1.  At lower concentration 
between 0.5M and 2.5M, all mixed Αβ samples had similar slopes in yN from –5.43 to – 
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Figure 4. 2.  Representative Aβ stabilities with urea concentrations.  Aβ samples were 
mixed with urea to final concentration of 10µM Aβ and 0.5 - 10M urea with 0.5M 
intervals.  Aβ samples in urea were incubated for 2 hours at 37oC until it reached 
equilibrium.  CD intensities at 220nm were used for Aβ stability tests. (A) Mixed Aβ 
stability with urea [open diamonds – fresh Αβ, closed squares – 2 hours, closed triangles 
– 4hours, closed circles – 24 hours; All lines are regressions for experimental data, thin 
solid line – fresh Αβ, dark large broken line – 2 hours, light small broken line – 4 hours, 
thick solid line – 24 hours]   
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Figure 4. 2 Continued. (B) Non-mixed Αβ stability with urea [open diamonds – fresh 
Αβ, open squares – 4 hours, open triangles – 4hours, open circles – 24 hours; All lines 
are regressions for experimental data, thin solid line – fresh Αβ, dark large broken line – 
4 hours, light small broken line – 8 hours, thick solid line – 72 hours] 
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5.81 and intercepts from –6.01 to –8.94.  However the slopes and intercepts in yU had 
more variation from –1.28 to –5.82 in slope and from 19.44 to 57.83.  The 24-hour 
sample had the steepest yU (yU = -5.82 [urea] + 57.83) and fresh Αβ had the gentlest one 
(yU = -1.28 [urea] + 19.44).   
 
NON-MIXED Αβ STABILITIES WITH UREA   
As seen in Fig. 4. 2B, Αβ samples prepared during aggregation without mixing 
displayed similar behavior in CD spectra exposed to urea as did Aβ samples prepared 
during aggregation with mixing. In the region associated with the change in structure 
from folded to unfolded state, both fresh and 72 hour aggregated fibril Aβ changed 
concentration at higher concentrations of urea than the aggregation intermediates formed 
without mixing. Given the variability of the CD measurements, it was not possible to 
discern if only two structure states were present in the Aβ samples in urea (native and 
unfolded) or if other folding intermediates were formed.  Thus, the simplest two state 
model was used to estimate ∆G of unfolding in urea for the aggregated Aβ samples. 
 
Free Energy Difference Calculation of Αβ Stabilities with Urea   
Free energy differences were calculated by the assumption of two folding states - 
native and unfolded states were in equilibrium.  Equilibrium was assumed because the 
analysis was performed several times, with different incubation times from 30 minutes to 
2 hours allowed for unfolding in urea, all yielding similar unfolding curves.  Equilibrium 
constants were estimated from concentration ratios of two folding states.  The Free  
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Table 4. 1. Linear regression of native and unfolding Aβ with urea concentration 
 
Mixed Aβ yN* yU** 
0 hr –Fresh Aβ yN  = -135.83 [Urea]** - 223.38 yU  = -32.115  [Urea] + 486.00
2hrs y = -133.19  [Urea] - 169.25 y = -90.895  [Urea] + 969.65 
4hrs y = -136.49  [Urea] - 213.73 y = -117.75  [Urea] + 1259.3 
24hrs y = -145.37  [Urea] - 215.58 y = -145.55  [Urea] + 1445.8 
Non-Mixed Aβ yN yU 
4hrs  y = -194.4  [Urea] - 144.25 y = -99.306  [Urea] + 1166.4 
8hrs  y = -206.95  [Urea] - 154.50 y = -140.94  [Urea] + 1385.6 
72hrs  y = -99.35  [Urea] - 230.50 y = -44.206  [Urea] + 564.15 
 
* yN : Linear regression of native Aβ with urea. CD signals of Aβ in 0.5M-2.5M 
urea were taken for mixed Aβ and non-mixed 72-hour samples and those in 
0.5M - 2.0M urea were taken for non-mixed 4- and 8-hour samples. 
** yU : Linear regression of unfolding Aβ with urea.  CD signals of Aβ in 6.5M - 
10.0M urea were used for this regression. 
*** [Urea] : Urea concentrations in M 
 
 
 
 76
energy difference between two states was obtained from equation 4-4, and   ∆GH2O and 
m were calculated by linear regression of the data to equation 4-5.  
 
FREE ENERGY DIFFERENCES OF MIXED Αβ   
Free energy for unfolding was estimated as a function of urea concentration for 
aggregated Aβ samples prepared with mixing (Fig. 4. 3A). The slope of ∆G for 
unfolding of fresh Αβ as a function of urea was less than that for any of the aggregated 
Aβ samples. The slope m, and intercept ∆GH2O of the equation, ∆G = ∆GH2O – m [Urea], 
are summarized in Table 4. 2.  ∆GH2O values were the intercept of free energy equation 
and obtained by extrapolation.  A total of 3 experiments were performed independently 
for reproducibility and statistical analysis.  Results are plotted in Fig. 4. 4.  In Fig. 4. 4, 
slope m value of fresh Αβ was 470.19 ± 20.26 cal/mol M, whereas m values of other 
mixed samples were between 604.96 ± 26.94 cal/mol M (24-hour sample) and 642.26 ± 
42.17 cal/mol M (4-hour sample).  Two-tailed T-test showed that m value of fresh Αβ 
was statistically different from those of other samples. (p = 0.0033, 0.0032, and 0.0023 < 
0.05; with 2-, 4- and 24-hour samples respectively)  m values between 2-, 4-, and 24-
hour samples were not statistically different.  ∆GH2O values between the mixed samples 
were not statistically different.  
 
FREE ENERGY DIFFERENCES OF MIXED Αβ   
As shown in Fig. 4. 3B, slope m and intercept ∆GH2O for the fresh Αβ and 72-hour 
sample were almost same, suggesting that the conformational stability of the two  
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Figure 4. 3.  Representative ∆G plot as a function of urea concentration. ∆G values were 
obtained by experimental data from Figure 4. 1 and linear regressions were done to 
predict the extrapolation.  See the results in detail. (A) Mixed Aβ stability with urea 
[open diamonds – fresh Αβ, closed squares – 2 hours, closed triangles – 4hours, closed 
circles – 24 hours; All lines are regressions for experimental data, thin solid line – fresh 
Αβ, dark large broken line – 2 hours, light small broken line – 4 hours, thick solid line – 
24 hours] 
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Figure 4. 3 Continued. (B) Non-mixed Αβ stability with urea [open diamonds – fresh 
Αβ, open squares – 4 hours, open triangles – 4hours, open circles – 24 hours; All lines 
are regressions for experimental data, thin solid line – fresh Αβ, dark large broken line – 
4 hours, light small broken line – 8 hours, thick solid line – 72 hours] 
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Figure 4. 4. Average and standard deviation plot for m and ∆GH2O. Three independent 
experiments were done to get average and standard deviation of m (bar plot) and ∆GH2O 
(scatter plot composed of circles).   
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Table 4. 2. Representative slope m, and intercept ∆GH2O in the equation of ∆G = 
∆GH2O – m [Urea] 
Mixed Aβ m (cal/mol M) ∆GH2O (cal/mol) 
0 hr –Fresh Aβ 477.72 1796.3 
2hrs 673.33 2656.9 
4hrs 675.77 2818.3 
24hrs 632.00 2708.5 
Non-Mixed Aβ m (cal/mol M) ∆GH2O (cal/mol) 
4hrs  712.77 2880.0 
8hrs  859.36 3725.0 
72hrs  521.91 2158.6 
 
This table was obtained by the linear regression of the data from Figure 4. 1. 
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 samples in urea were similar.  For aggregated Aβ samples prepared without mixing and 
collected 4 and 8 hours after the beginning of aggregation, the slope of the free energy 
curve with urea concentration was steepest. (Figure 4. 3B, Figure 4. 4)  A two-tailed T-
test showed that the m value of fresh Αβ (470.19 ± 20.26 cal/mol M) was not 
statistically different from that of the 72 hour-sample (487.35 ± 31.89 cal/mol M) (p = 
0.48 > 0.05).  The 8-hour sample was statistically different from that of 4-hour sample, 
and 4- and 8-hour samples were different from fresh and 72-hour samples in m and 
∆GH2O values.   
In summary, ∆GH2O and m values for the 8-hour non-mixed sample were 
statistically different from those of all other mixed samples.  Mixed Αβ samples at 2, 4, 
and 24 hours were not different from each other.  Fresh Αβ was not different from the 
72-hour non-mixed sample, but was different from the other samples. 
 
DISCUSSION 
Proteins are very sensitive to their environmental conditions such as temperature, 
pH, pressure and denaturants. (Creighton 1993)  They are in folded and native states 
when they are in optimum environments.  However small environmental changes can 
cause structural change in proteins, which lead to protein unfolding or denaturation.  
Proteins in unfolded states lose their physiological activity. Protein aggregation can 
occur via transition from folded to unfolded or partially unfolded states. (Dobson 2003; 
Selkoe 2003)    
While a number of other researchers in the past have studied unfolding and 
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stability of proteins associated with amyloid disease in order to understand factors 
associated with protein stability that lead to amyloidosis or protein aggregation 
(Hammarstrom et al. 2001; Foguel et al. 2003), in this work, I am interested in stability 
of Aβ after aggregation and the relationship between Aβ aggregate stability and its 
biological activity.  
Depending on the aggregation state and how Aβ was aggregated, Aβ has different 
structures. Αβ is known to aggregate to form fibrils via conformational change to a β-
sheet rich structure. (Walsh et al. 1997; Walsh et al. 1999)  HoIver, other Aβ aggregation 
states that I have reported in earlier chapters have a mixture of secondary structures 
including random coil, especially for Aβ aggregation states produces without mixing at 
intermediate times (i.e. the large spherical species described previously). In urea, Aβ has 
a predominantly random coil structure.  In this research, I use an analysis that typically is 
used to describe a transition form native to unfolded states.  However, in this work, I are 
measuring a transition from aggregated species and unfolded.  
AD is called a conformational disease since Αβ conformational changes are closely 
related to Αβ aggregation and toxicity.  The mechanism by which Aβ aggregates cause 
toxicity and how Αβ conformational changes are related to cell toxicity is still unclear.  
Some investigators have suggested that lipid membrane induce Αβ conformational 
changes and Αβ aggregate - membrane interactions are important in the mechanism of 
Aβ toxicity. (McLaurin and Chakrabartty 1997; Terzi et al. 1997)  Recently I examined 
the relationship between Αβ aggregation and toxicity using aggregation conditions 
analogous to those used in this work. Non-mixed Αβ samples formed large spherical 
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species during aggregation via a different mechanism of aggregation than that which 
mixed Αβ samples undergo upon aggregation. The biological activity of Αβ aggregated 
species were as follows:  fresh Aβ samples and those aggregated for 72 hours without 
mixing were non toxic; mixed aggregated samples prepared between 4 and 24 hours 
after initiation of aggregation resulted in 30-50% cell toxicity; Aβ samples prepared 
without mixing at 8 hours after initiation of aggregation (large spherical species in 
electron micrographs) were the most toxic with 74% cell toxicity. In this work, I show 
that the toxicity of Aβ species is related to conformational change in denaturant and 
stability of Aβ. ∆GH2O and m were estimated for the different Aβ aggregated species. 
∆GH2O represents the conformational stability of the protein without denaturant and m 
denotes the average change in accessibility of the protein groups upon denaturation. In 
Table 4. 2, fresh Αβ and 72-hour non-mixed samples have lower ∆GH2O values (1780.4, 
and 2158.7 cal/mol), other samples have the values between 2656.9 and 2818.2 cal/mol, 
and 8-hour non-mixed sample has the highest value (3272.2 cal/mol).  KH2O which can 
be obtained by KH2O = exp (-∆GH2O /RT) makes ∆GH2O meaning more clear.  Fresh Αβ 
and 72-hour non-mixed samples have higher KH2O values (0.056, and 0.030), other 
samples have the values between 0.009 and 0.013, and the 8-hour non-mixed sample has 
the lowest value (0.005).  All of the samples tend to stay in the native or aggregated state 
in water relative to the unfolded state.    Among Αβ samples used, the 8-hour non-mixed 
sample was most stable (had the greatest tendency to stay in the  “native” state.   The 8-
hour sample also had the greatest m value (859.36 cal/mol M) and was different from 
other samples.  Fresh Αβ and 72-hour non-mixed samples had lower m values (477.72, 
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and 521.91 cal/mol M), and other samples had m values between 632.00 and 712.77 
cal/mol M.  These results imply that there was the greatest change in accessible surface 
when the 8 hour Aβ sample was exposed to denaturant.  Its structure was more readily 
disrupted in denaturant than the other samples.  
The two-state transition model has some drawbacks to explain Αβ conformational 
change and stability.  First of all, the data of CD intensities with urea (Fig. 4. 2) are 
scattered in the middle of the urea concentration range and do not have a single inflexion 
point.  Another denaturant, Guanidine hydrochloride (GuHCl), shows this result more 
clearly; the data are less scattered therefore the lack of a single inflection point is easier 
to verify. The lack of a single inflection point in the data implies that there are more than 
two states (more than simply folded and unfolded states).  The analysis is based on 
equilibrium calculations, however, it is not clear that aggregation states of Aβ, the initial 
states in these studies, can be in true equilibrium.  Also, I start with aggregated species, 
not natively folded proteins, and it is likely that there is more than a single transition 
from aggregated to unfolded Aβ.   
In order to avoid these dilemmas, a three-transition states model is proposed for 
analysis of Αβ stability.  
UIN ↔↔                                                   (4-6) 
where N is the native state which has α-helix or random coil conformation.  N is in 
equilibrium with I (intermediate state) which has a β-sheet structure.  U is the unfolded 
state which has random coil structure upon exposure to the denaturant.  Three-transition 
states will result in different estimates for m and ∆GH2O, but the observed trends would 
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still be the same.  
The results of this research suggest that the most toxic Αβ species, the 8-hour non-
mixed sample, has the least stability and undergoes the most ready conformation change 
in denaturant, where as the other samples are more stable and less toxic. In addition, I 
examined stability of Αβ structures that morphologically appear similar in electron 
micrographs, and found that similar looking structures (mixed 24 hours and non-mixed 
72 hours) had very different stabilities and toxicities. The protein stability of Αβ related 
to conformational change is strongly associated with biological activity.    
This work may have other implications.  Many speculate that Aβ biological 
activity or toxicity is associated with membrane interactions (Arispe et al., 1993, 
Butterfield et al., 1994, Butterfield, 1997, Good et al., 1996, Hensley et al., 1994, 
Mattson et al., 1997, McLaurin et al., 1998, Hertel et al., 1997). While I have measured 
stability in detergent, I postulate that change in conformation in detergent may correlate 
with protein changes in conformation in a phospholipid membrane.  If this is true, then 
those Αβ aggregated species that most easily change structure in the cell membrane may 
cause the most damage to cells.  
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CHAPTER V 
HSP20 PREVENTS Aβ FIBRIL FORMATION AND TOXICITY* 
 
OVERVIEW    
β-Amyloid (Aβ) is a major protein component of senile plaques in Alzheimer’s 
disease, and is neurotoxic when aggregated. The size of aggregated Aβ responsible for 
the observed neurotoxicity and the mechanism of aggregation are still under 
investigation; however, prevention of Aβ aggregation still holds promise as a means to 
reduce Aβ neurotoxicity.  In research presented here, I show that Hsp20, a novel α-
crystallin isolated from the bovine erythrocyte parasite Babesia bovis, was able to 
prevent aggregation of denatured alcohol dehydrogenase when the two proteins are 
present at near equimolar levels.  I then examined the ability of Hsp20 produced as two 
different fusion proteins to prevent Aβ amyloid formation as indicated by Congo red 
binding; I found that not only was Hsp20 able to dramatically reduce Congo red binding, 
but it was able to do so at molar ratios of Hsp20 to Aβ of 1 to 1000.  Electron 
microscopy confirmed that Hsp20 does prevent Aβ fibril formation.  Hsp20 was also 
able to significantly reduce Aβ toxicity to both SH-SY5Y and PC12 neuronal cells at 
similar molar ratios.  At high concentrations of Hsp20, the protein no longer displays its 
 
*Reprinted with permission from “Hsp20, a novel α-crystallin, prevents Aβ fibril 
formation and toxicity” by Sungmun Lee, Kenneth Carson, Allison Rice-Ficht, and 
Theresa Good, 2005. Protein Science, 14, 593-601. 
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aggregation inhibition and toxicity attenuation properties.  Size exclusion 
chromatography indicated that Hsp20 was active at low concentrations in which dimer 
was present.  Loss of activity at high concentrations was associated with the presence of 
higher oligomers of Hsp20.  This work could contribute to the development of a novel 
aggregation inhibitor for the treatment of Alzheimer’s disease. 
 
INTRODUCTION 
Alzheimer’s disease (AD), the leading cause of dementia in the aging population, 
is accompanied by the accumulation of β-amyloid peptide (Aβ) as amyloid fibrils in 
senile plaques in the cerebral cortex.  It is hypothesized by many that Aβ contributes to 
the neurodegeneration associated with AD via the toxicity of the peptide in aggregated 
form.  
Investigation of the relationship between aggregated Aβ peptide size, structure and 
toxicity is ongoing. In an aggregated state containing fibrils, protofibrils, and low 
molecular weight intermediates/oligomers, Aβ peptide has proven to be toxic to cultured 
neuronal cells (Koh et al. 1990; Pike et al. 1993; Lambert et al. 1998; Kayed et al. 2003). 
Aβ structures reported to be toxic include a non-fibrillar species of approximately 17 to 
42 kDa (Lambert et al. 1998), protofibrils species with hydrodynamic radii on the order 
of 9 nm to 367 nm (Wang et al. 2002), and fibril species, with some investigators 
suggesting that the smaller oligomeric Aβ species are more toxic than fibril and 
protofibril forms (Dahlgren et al. 2002).  Many believe that one strategy for preventing 
neurodegeneration associated with AD is the prevention of aggregation of Aβ into its 
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toxic oligomeric or fibril forms. 
A number of investigators have developed inhibitors of Aβ aggregation with the 
aim of preventing Aβ toxicity (Ghanta et al. 1996; Lansbury 1997; Pallitto et al. 1999; 
Cairo et al. 2002).  Some of these inhibitors have been small peptides with sequences 
that mimic the sequence of Aβ believed to be essential for aggregation and fibril 
formation (Pallitto et al. 1999). Peptide inhibitors of this class have been able to prevent 
Aβ toxicity by altering the aggregated structure when added at inhibitor to Aβ molar 
ratios of near 1:1 (Tjernberg et al. 1996; Pallitto et al. 1999). The use of molecular 
chaperones including α-crystallins and other small heat shock proteins has also been 
explored as a means of preventing Aβ aggregation and toxicity. Human sHsp27 inhibited 
Aβ1-42 fibril formation (Kudva et al. 1997). When αB-crystallin was examined, it was 
actually found to increase toxicity and β pleated sheet content of Aβ1-40 although it 
prevented fibril formation of Aβ in vitro at inhibitor to Aβ molar ratios of 1:1 or 1:5 
(Stege et al. 1999). 
In work described here, I use a novel small heat shock protein, Hsp20, isolated 
from the erythrocyte parasite Babesia bovis to prevent aggregation of Aβ and Aβ toxicity.  
Using two different Hsp20 constructs, a maltose binding protein fusion (Hsp20-MBP) 
and a polyhistidine fusion (his-Hsp20), I show that Hsp20 has α-crystallin-like 
properties, and that it can prevent aggregation of denatured alcohol dehydrogenase.  
Hsp20 is able to prevent amyloid formation of Aβ as indicated by Congo red binding at 
molar ratios of Hsp20 to Aβ of 1:1000.  Hsp20 attenuates the toxicity of Aβ in SH-SY5Y 
and PC12 neuronal cells at analogous molar ratios. Hsp20 appears to be able to prevent 
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Aβ aggregation via a novel mechanism and at much lower concentrations than what has 
been necessary to prevent aggregation with other inhibitors.  Hsp20 may be a useful 
molecular model for the design of the next generation of Aβ aggregation inhibitors to be 
used in the treatment of AD. 
 
MATERIALS AND METHODS 
Materials   
Aβ(1-40) was purchased from Biosource International (Camarillo, CA). Cell 
culture reagents were purchased from GibcoBRL (Grand Island, NY). All other 
chemicals were obtained from Sigma (St. Louis, MO) unless otherwise stated.   
 
Hsp20 Preparation  
Hsp20 was produced in two forms, as an N-terminal fusion protein with maltose 
binding protein (Hsp20-MBP) and as an N-terminal polyhistidine fusion protein (his-
Hsp20).  Both proteins were produced in E. coli.  The production of the maltose binding 
protein fusion has been previously described. (Brown et al. 2001)  The N-terminal 
polyhistidine fusion protein was made with an intervening Tobacco Etch Virus (TEV) 
protease site (Carrington, et al., 1998) between Hsp20 and a polyhistidine tract. The 
construct was created through PCR of the Hsp20 coding sequence using a primer 
containing a 5’ 21bp extension encoding the TEV protease site. The PCR product was 
introduced into the pTrcHis2 TOPO protein expression vector (Invitrogen) and 
transformed into chemically competent TOP10 cells (Invitrogen). His-Hsp20 was 
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prepared by growing cells to OD600 of 0.5 followed by induction with 1mM IPTG for 5 
hours, and removal of media.  The cells were then lysed in PBS using a French pressure 
cell and the insoluble his-Hsp20 pellet collected. The pellet containing his-Hsp20 was 
suspended in Denaturing Binding Buffer (Invitrogen) containing 8M urea and incubated 
with Probond resin for 1 hour to allow binding of his-Hsp20 to the nickel 
chromatography resin. The protein was eluted from the resin using 100 mM EDTA, 
dialyzed overnight into PBS pH 7.0, 20% glycerol and frozen at –80oC. Protein purity 
and molecular weight were confirmed by SDS PAGE. 
 
Aβ Peptide Preparation  
Stock solutions of 10 mg/ml Aβ(1-40) peptides were dissolved in 0.1% (v/v) 
trifluoroacetic acid (TFA) in water.  After incubation for 20~30 min. at 25°C, the peptide 
stock solutions were diluted to concentrations of 0.5 mg/ml by addition of sterile 
phosphate buffered saline (PBS; 0.01 M NaH2PO4, 0.15 M NaCl, pH 7.4). The peptides 
were diluted to final concentrations of 20 µM, 50 µM, and 100 µM by addition of PBS 
for Congo red and electron microscopy (EM) studies.  Cell culture medium (below) 
replaced PBS in toxicity studies. These solutions were rotated at 60 revolutions per 
minute at 25°C for 24 hours to ensure aggregation.  
 
Cell Culture   
Human neuroblastoma SH-SY5Y cells (a gift of Dr. Evelyn Tiffany-Castiglioni, 
College of Veterinary Medicine, Texas A&M University, College Station, Texas) were 
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cultured in minimum essential medium (MEM) supplemented with 10% (v/v) fetal 
bovine serum (FBS), 3 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 
and 2.5 µg/ml amphotericin B (fungizone) in a humidified 5% (v/v) CO2/air 
environment at 37°C.  Rat pheochromocytoma PC12 cells (ATCC, Rockville, MD) were 
cultured in RPMI medium supplemented with 10% (v/v) horse serum, 5% (v/v) FBS, 3 
mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, and 2.5 µg/ml fungizone 
in a humidified 5% (v/v) CO2/air environment at 37°C.  For the toxicity assays, cells 
were plated at a density of 1 x 105 cells/well in 96 well plates and aggregated peptide 
solutions were added to the cells 24 hours after plating. 
 
Congo Red Binding   
Congo red studies were performed to assess the presence of amyloid fibrils in Aβ 
solution.  Congo red dye was dissolved in PBS to a final concentration of 120 µM.  
Congo red solution was added to the peptide solutions at the ratio of 1:9.  The peptide 
solution and control solution were allowed to interact with Congo red for 30~40 minutes 
prior to absorbance measurement with a Model 420 UV-Vis spectrophotometer (Spectral 
Instruments, Tucson, AZ) at 25°C.  The fibril formation of the samples was estimated 
from the absorbance using equation 5-1; 
( ) ( ) ( )8620/A6830/A4780/A]A[ CR403t403t541Fib −−=β                    (5-1) 
where [AβFib] is the concentration of Aβ fibril, 541At , 403At and 403ACR are the 
absorbances of the sample and Congo red at the wavelength of 541nm and 403nm, 
respectively (Klunk et al. 1999). From these data, relative fibril concentrations were 
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calculated as the ratio of sample fibril concentration to pure Aβ fibril concentration.  
 
MTT Reduction Assay   
Cell viability was measured 24 hours after peptide addition to cells using the 3, 
(4,5-dimethylthiazol-2-yl) 2,5-diphenyl-tetrazolium bromide (MTT) reduction assay. 
10µl of 12mM MTT was added to 100µl of cells plus medium in a 96 well plate. The 
cells were incubated with MTT for 4 hours in a CO2 incubator.  Then, 100µl of a 5:2:3 N, 
N-dimethylforamide (DMF): sodium dodecyl sulfate (SDS): water solution (pH 4.7) was 
added to dissolve the formed formazan crystals.  After 18 hours of incubation in a 
humidified CO2 incubator, the results were recorded by using an Emax Microplate 
reader at 585 nm (Molecular Devices, Sunnyvale, CA).  Percentage cell viability was 
calculated by comparison between the absorbance of the control cells and that of peptide 
or peptide: Hsp20 treated cells. Relative cell viability increase, was calculated from the 
ratio of the difference in cell viability of Hsp20: Aβ treated cells and cells treated with 
pure Aβ, divided by viability of cells treated with pure Aβ.  
 
Electron Microscopy (EM)   
200µl of Aβ peptide solution, prepared as described above, was mixed, placed on 
glow discharged grids, and then negatively stained with 1% aqueous ammonium 
molybdate (pH 7.0).  Grids were examined in a Zeiss 10C transmission electron 
microscope at an accelerating voltage of 80 kV.  Calibration of magnification was done 
with a 2,160 lines/mm crossed line grating replica (Electron Microscopy Sciences, Fort 
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Washington, PA). 
 
ADH Turbidity Assay  
Light Scattering of ADH and Hsp20 was performed as previously described 
(Horwitz 1992).  Briefly, the aggregation of ADH and Hsp20 in solution was measured 
by the apparent absorption due to scattering at 360 nm in a Gilford Response II 
spectrophotometer at 58oC.  Solutions were mixed at room temperature in 50mM 
phosphate buffer, pH 7.0 and analyzed immediately. 1.625 µM ADH was used in all 
experiments.  Hsp20 concentrations were varied to obtain different molar ratios of 
Hsp20 to ADH.  Absorbance readings were taken at 1 minute intervals for one hour.  
 
Size Exclusion Chromatography (SEC)   
The size of his-Hsp20 oligomers as a function of concentration at room 
temperature was determined using size exclusion chromatography using a Pharmacia 
FPLC system.  Protein samples at different concentrations were loaded on a Superose 6 
HR 10/300 column (Pharmacia) and eluted using PBS.  Eluted proteins were detected 
using UV absorbance at either 280 nm or 254 nm.  Oligomer sizes were estimated based 
on the elution volumes of a set of calibration proteins run on the same column under 
similar conditions. 
 
Statistical Analysis   
For each experiment, at least three independent determinations were made.  
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Significance of results was determined via the student t test with p<0.05 unless 
otherwise indicated. Data are plotted as the mean plus or minus the standard error of the 
measurement. 
 
RESULTS    
Characterization of Hsp20   
Hsp20 is a 177 amino acid, 20.1 kDa protein isolated from Babesia bovis, a 
protozoan bovine erythrocyte parasite. (Brown et al. 2001)  Initial characterization by 
BLAST search of the NCBI database indicated significant sequence similarity with the 
α-crystallin family of small heat shock proteins. Hsp20 contains a region near its C-
terminus that corresponds to the ~95 amino acid α-crystallin domain common to 
members of this protein family.  These proteins are thought to be involved in the cellular 
response to stress.  Previous work (Ficht, unpublished observation) has revealed that 
Hsp20 expression is up-regulated in times of thermal, nutritional and oxidative stress to 
the organism.  Based on the apparent involvement of Hsp20 in the stress response 
coupled with its homology to the α-crystallins, α-crystallin activity assays were applied 
to Hsp20.  A turbidity assay (Figure 5. 1) was used to quantitate the ability of Hsp20-
MBP to solubilize target proteins at elevated temperatures. A solution of alcohol 
dehydrogenase when incubated at 58oC for 60 minutes exhibited a dramatic increase in 
light scattering due to aggregation of the enzyme. When Hsp20-MBP was included in 
the solution at time zero in a molar ratio of 2:1 Hsp20:ADH, a 2.3 fold reduction in light 
scattering was observed at 60 minutes. To determine the most effective molar ratio for  
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Figure 5. 1. Light scattering of ADH at elevated temperature. ADH was incubated in the 
presence and absence of Hsp20-MBP as determined by absorbance at 360 nm. ADH at a 
concentration of 1.625µM is incubated in phosphate buffer alone (open circles) and in 
the presence of 5.75µM Hsp20 (closed triangles) at 58°C for one hour. This data is 
obtained by Allison Rice-Ficht’s group (Department of Medical Biochemistry and 
Genetics, Texas A&M University) 
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the reduction of light scattering, a series of experiments was conducted in which 
different mole ratios of Hsp20 was added the ADH (Figure 5. 2).  At time infinity 
(determined by curve fitting software), the greatest reduction in light scattering was seen 
at a molar ratio of 2:1 (Hsp20 to ADH).  Since Hsp20-MBP was prepared as a fusion 
protein with maltose binding protein, I examined the ability of maltose binding protein 
(MBP) alone to alter aggregation and turbidity of ADH in the same range of 
concentrations.  MBP had no effect on ADH aggregation, suggesting the aggregation 
prevention activity was due to the presence of Hsp20.  Having established the α-
crystallin activity of Hsp20-MBP based standard assays, I then proceeded to test the 
ability of Hsp20-MBP to affect Aβ(1-40) fibril formation. 
 
Effect of Hsp20-MBP on Aβ Fibril Formation Prevention   
Given that Hsp20-MBP was able to prevent aggregation of denatured ADH, I then 
examined its ability to prevent aggregation and amyloid fibril formation of Aβ(1-40).  I 
used Congo red binding as a simple indicator of amyloid formation. In these experiments, 
20µM, 50µM, and 100µM concentrations of Aβ(1-40) were used to create fibrils. 
Hsp20-MBP at concentrations from 1 nM to 5 µM was added to Aβ(1−40) solutions 
prior to aggregation.  This corresponds to molar ratios of Hsp20-MBP to Aβ of 1:20,000 
to 1:20 or 0.00005 to 0.05. After 24 hours of incubation, sufficient time for  typical fibril 
formation, Congo red was added to samples to assess fibril formation.  Representative 
Congo red absorbance spectra are seen in Figure 5. 3.  Hsp20-MBP alone did not alter 
Congo red absorbance.  Pure Aβ(1−40) solutions caused a characteristic shift in  
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Figure 5. 2. Percent reduction of light scattering at time infinity of various solutions of 
ADH and Hsp20-MBP relative to ADH alone. Greatest reduction in light scattering is 
seen at 2:1 molar ratio (Hsp20:ADH). All experiments were performed at 58°C. ADH 
was included at 1.625µM in each experiment. Light scattering at time infinity was 
estimated from absorbance versus time curves for each mixture. This data is obtained by 
Allison Rice-Ficht’s group (Department of Medical Biochemistry and Genetics, Texas 
A&M University) 
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absorbance to longer wavelengths and an increase in intensity.  Hsp20-MBP, 
when added to Aβ prior to aggregation, attenuated the shift in absorption and increase in 
intensity associated with Aβ fibril formation.  MBP alone, when added to Aβ at similar 
concentrations had no effect on fibril formation as assessed by Congo red binding. 
I show in Figure 5. 4A the effect of Hsp20-MBP on reduction of Aβ fibril 
formation at different concentrations of Aβ and Hsp20-MBP.  At Hsp20-MBP 
concentrations below 0.1µM, Aβ fibril formation decreased as a function of Hsp20-MBP 
concentration.  However, Hsp20-MBP became less effective at preventing Aβ fibril 
formation in the higher concentration range.  The concentration of Hsp20-MBP needed 
for optimal prevention of fibril formation appeared to be a function of Aβ concentration, 
with the lowest concentration of Aβ exhibiting the optimum in prevention of fibril 
formation at the lowest Hsp20-MBP concentration.  In Figure 5. 4B, I replotted the fibril 
formation data as a function of molar ratio of Hsp20-MBP to Aβ at the three different Aβ 
concentrations.  It appears from Figure 5. 4B that the three curves are now superimposed.  
The optimum in fibril formation for the three concentrations of Aβ tested occurred at or 
near the same molar ratio of Hsp20-MBP to Aβ, between 0.0005 and 0.001. The molar 
ratio of Hsp20-MBP to Aβ needed to optimally prevent fibril formation was several 
orders of magnitude lower than that needed to prevent aggregation of ADH.  Electron 
micrographs of Aβ fibrils, Hsp20-MBP, and Aβ-Hsp20-MBP mixtures that correspond to 
conditions used in the Congo red binding studies are shown in Figure 5. 5.  In the images, 
100µM Aβ and 0.1µM Hsp20-MBP were used.  As seen in Figure 5. 5A, Aβ formed 
long individual fibrils and groups of long fibrils under the aggregation conditions  
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Figure 5. 3. Representative absorbance spectra of Congo red with Aβ and Aβ-Hsp20. 
100µM Aβ(1-40) was used in all cases. Hsp20-MBP was added at the beginning of the 
24 hour aggregation at room temperature with mixing. [bold line -Congo red alone; fine 
line- Aβ alone; light gray line - 1:100 Hsp20:Aβ; dark gray line - 1:1000 Hsp20:Aβ]. 
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Figure 5. 4. Relative fibril formation as estimated from Congo red binding. Relative 
fibril formation. (a) as a function Hsp20-MBP concentration, and (b) as a function of the 
molar ratio of Hsp20-MBP to Aβ [open circles - 20µM Aβ; squares - 50µM Aβ; triangles 
- 100µM Aβ] 
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employed.  Hsp20-MBP, at 0.1µM and room temperature, formed species of 
approximately 13.6 nm in diameter, composed of 2 subunits, 5.4 nm in width each, with 
a distance of 2.7 nm between subunits (Figure 5. 5B).  In micrographs of the Aβ-Hsp20-
MBP mixture (Figure 5. 5C), small globular species with a 16.3 nm diameter and 
variable length were observed.  These species could be an Hsp20-Aβ complex, large 
Hsp20-MBP aggregates, and/or Aβ-protofibrils.  Aβ fibrils were noticeably absent from 
micrographs of Aβ-Hsp20 mixtures. 
 
Ability of Hsp20-MBP To Prevent Toxicity of Aβ   
Aβ is typically toxic to neuron-like cells (SH-SY5Y cells, and PC12 cells etc.) when 
in aggregated form.  In Figure 5. 6, I show the effect of Hsp20-MBP on Aβ toxicity as 
measured using the MTT assay for 100 µM Aβ added to SH-SY5Y cells and 2 µM Aβ 
added to PC12 cells.  Hsp20-MBP by itself had no effect on SH-SY5Y or PC12 cell 
viability.  However, Hsp20-MBP, when added to Aβ prior to aggregation, had a profound 
effect on Aβ toxicity observed in both cell types.  MBP, when added to Aβ, did not 
attenuate Aβ toxicity. In Figure 5. 6, I plotted cell viability as a function of molar ratio of 
Hsp20-MBP to Aβ.  As with fibril formation data presented in Figure 5. 4B, it appears 
that the two viability curves as a function of Hsp20 to Aβ molar ratio are superimposed.  
The molar ratio of Hsp20 to Aβ needed for optimal toxicity attenuation is approximately 
the same as the molar ratio needed for optimal fibril formation prevention.  
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Figure 5. 5. Representative electron micrographs of Aβ and Hsp20-MBP.  Samples were 
incubated for 24 hours of aggregation (a) 100µM Aβ, (b) 0.1µM Hsp20-MBP, and (c) 
100µM Aβ + 0.1µM Hsp20-MBP. 
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Figure 5. 6. Relative cell viability of SH-SY5Y cells (triangles) and PC12 cells (circles).  
Samples were treated with 100 µM (triangles) and 2 µM (circles) Aβ as a function of 
Hsp20-MBP concentration. Viability is measured via the MTT reduction assay. N is 
greater than or equal to 6. Aβ(1-40) was incubated for 24 hrs in the media prior to 
addition to the cells. Viability as a function of molar ratio of Hsp20-MBP to Aβ; viability 
is reported relative to control cells. 
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Ability of His-Hsp20 to Prevent Aβ Aggregation and Toxicity   
While control experiments demonstrated that MBP alone had no effect on Aβ 
aggregation and toxicity, it was possible that the MBP fusion contributed to the function 
of Hsp20.  To examine this possibility, I next generated a N-terminal polyhistadine-
Hsp20 fusion protein. In experiments parallel to those described above, I examined if the 
polyhistadine-Hsp20 fusion protein could also prevent Aβ aggregation and toxicity as 
measured by Congo red binding and MTT reduction, respectively.  As seen in Figure 5. 7, 
his-Hsp20 prevents Aβ aggregation and toxicity over a wider range of concentrations 
and at lower concentrations than the MBP fusion protein.  Also, attenuation of toxicity 
approached 100% with the his-Hsp20 while the Hsp20-MBP attenuated Aβ toxicity to a 
lesser extent.   However, as with the MBP fusion protein, there was a noticeable loss of 
his-Hsp20 activity at concentrations above 1 µM. 
 
Size Exclusion Chromatography of His-Hsp20   
To know the mechanism of loss of activity of His-Hsp20 at higher concentrations, I 
examined size of His-Hsp20 oligomers in solution as a function of concentration.  Stock 
solutions of His-Hsp20 were diluted to 100 µM, 29 µM and 0.1 µM in PBS shortly 
before analysis.  Chromatograms of His-Hsp20 at the different concentrations can be 
seen in Figure 5. 8.  At the highest concentration (Figure 5. 8A), His-Hsp20 elutes as a 
mixture of a number of oligomers, ranging from an approximate 16-mer, 10-mer, 6-mer, 
tetramer, dimer and monomer, with dimer representing about 15% of total protein eluted 
the column.  At intermediate concentrations, 0.1 µM (Figure 5. 8B), a concentration at 
 
 105
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. 7. Relative Aβ fibril formation and cell viability as a function of His-Hsp20 
concentration. (A) Fibril formation using Congo red is reported relative to fibril 
formation in pure 50 µM Aβ solutions. (B) Cell viability was measured via MTT 
reduction and reported relative to cells untreated with Aβ or His-Hsp20. Aβ or His-
Hsp20 mixtures were mixed, then aggregated with mixing at 37 C for 24 hours prior to 
treatment. 
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Figure 5. 8. Representative size exclusion chromatograms of His-Hsp20.  (A) 1 µM His-
Hsp20, (B) 0.1 µM His-Hsp20, and (C) 0.01 µM His-Hsp20. Separations were 
performed on a Pharmacia Superose 6 column at room temperature using phosphate 
buffered saline as an elution buffer. 
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which His-Hsp20 displays both high aggregation and toxicity prevention activities, only 
dimer was observed.  At the lowest concentration (Figure 5. 8C), Hsp20 was mostly 
composed of dimers. Analytical ultracentrifugation was used to confirm the presence of 
high molecular weight oligomers of his-Hsp20 at high concentrations (data not shown). 
 
Ability of Hsp20-MBP to Reverse Aβ Aggregation   
I examined if, once Aβ was aggregated, addition of Hsp20-MBP could reverse 
fibril formation.  I aggregated Aβ under conditions analogous to those described 
previously, and after 24 hours aggregation, I added Hsp20 at optimal concentrations for 
fibril formation prevention (100 nM), incubated for up to 2 days, and then assessed fibril 
content via Congo red binding.  At all time points measured, fibril formation after 
addition of Hsp20 was equal to or greater than fibril formation of Aβ alone after 24 
hours aggregation (data not shown).  In all cases, viability of SH-SY5Y cells, as 
measured by the MTT assay, treated with solutions in which Hsp20 was added after 24 
hour Aβ aggregation was not significantly greater than viability of cells treated with Aβ 
that had been allowed to aggregate for 24 hours (data not shown). 
 
DISCUSSION 
The superfamily of small heat shock proteins, sHSPs, are a diverse group of 
proteins involved in prevention of protein misfolding and the onset of programmed cell 
death (van den et al. 1999; Bruey et al. 2000).  They typically exist as large multimeric 
complexes containing 4 to 40 subunits, with molecular masses of 40 kDa or less per 
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subunit.  The sHSPs bind to their substrates with high affinity and   prevent protein 
misfolding in an ATP independent reaction (Jakob et al. 1993). 
Generally, the α-crystallins are considered to be sHSPs (Horwitz 1992; MacRae 
2000). Circular Dichroism spectroscopy (CD) studies predict that β-pleated sheet 
dominates the secondary structure of the α-crystallins (Horwitz 2000; van Montfort et al. 
2001). A conserved 90 amino acid sequence, located near the C-terminus, termed the α-
crystallin domain, is the hallmark of all α-crystallins. 
A protein, Hsp20, isolated by Rice-Ficht and coworkers from the bovine 
erythrocyte parasite Babesia bovis (Brown et al. 2001) has repeatedly demonstrated α-
crystallin activity in vitro. The apparent light scattering of alcohol dehydrogenase in 
solution at 58°C was reduced when in the presence of equimolar concentrations of 
recombinant Hsp20 (Figure 5. 1). This indicates reduced aggregation of denatured ADH 
at the elevated temperature due to an interaction with Hsp20. The optimal Hsp20 to 
ADH binding ratio was 2:1 (Figure 5. 2), consistent with the stoichiometry of binding 
one Hsp20 dimer to one ADH molecule.  This is consistent with the observations of van 
Montfort et al (van Montfort et al. 2001) that other alpha crystallins are active as dimers.   
In addition, Hsp20 is upregulated under heat shock conditions (42°C) and oxidative 
stress (molecular O2 and H2O2); and, as other α-crystallins, it also forms higher order 
complexes as revealed through dynamic light scattering analysis (unpublished 
observation).  Hsp20 has limited nucleotide and amino acid sequence homology to 
members of the α-crystallin family, with the majority of the identical/conserved amino 
acids occurring in the region corresponding to the α-crystallin domain. (Brown et al. 
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2001)  The α-crystallin-like activity and ability to prevent protein aggregation of Hsp20 
indicate that it may be potentially useful as an aggregation inhibitor (or a model for an 
aggregation inhibitor) for Aβ. In view of its divergent sequence, this α-crystallin may 
have entirely unique properties.  
I show, in Figures 5. 3 – 5. 5 and Figure 5. 7, that Hsp20-MBP and his-Hsp20 
prevent Aβ fibril formation as indicated by the absence of Congo red binding and of 
visible fibrils in electron micrographs, at molar ratios near 1:1000 Hsp20 to Aβ or lower.  
This is in sharp contrast to the near 1:1(2:1, or even 4:1 if ADH is considered a dimer) 
molar ratio needed to prevent ADH aggregation. A number of investigators have 
explored the ability of other small heat shock proteins, molecular chaperones, and α-
crystallins to prevent fibril formation in several systems including Aβ (Kudva et al. 
1997; Hughes et al. 1998; Stege et al. 1999; Hatters et al. 2001). Most have found that 
the chaperones or small heat shock proteins can inhibit Aβ aggregation at molar ratios of 
chaperone to Aβ of 1:10 to 1:100.  The low concentrations of Hsp20 and other α-
crystallins needed to prevent fibril formation, relative to that needed to prevent ADH 
aggregation, could be related to specificity of the α-crystallins for β-sheet or fibril 
forming proteins.  Alternatively, the difference in molar ratios needed to prevent ADH 
aggregation relative to those needed to prevent Aβ fibril formation could be related to 
the temperature differences at which the experiments were carried out.  The ADH 
aggregation experiments were carried out at elevated temperature, while the Aβ fibril 
formation experiments were carried out at room temperature.  The quaternary structure 
of α-crystallins are generally temperature dependent; however, most often, more highly 
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active oligomers (dimers) are formed at higher temperatures (Abgar et al. 2001; van 
Montfort et al. 2001).  Indeed, when I performed fibril formation and toxicity prevention 
experiments with Hsp20-MBP and Aβ at 37 C instead of room temperature, 
approximately 10 times less Hsp20-MBP was needed to prevent fibril formation (or 
1:10,000 Hsp20 to Aβ mole ratio) relative to that needed to maximally prevent fibril 
formation at room temperature (data not shown). 
Another plausible explanation for Hsp20 activity is that Hsp20 interacts with an 
oligomer of Aβ in a near 1 to 1 molar ratio; however, the Aβ oligomer may be very 
dilute in Aβ solutions.  In models of Aβ aggregation, investigators postulate that Aβ 
forms micelles or multimeric nuclei from Aβ monomers or dimers via a high order 
process (Lomakin et al. 1997; Pallitto and Murphy 2001; Yong et al. 2002).  It is from 
these micelles or nuclei that fibril growth is initiated.  Micelles or nuclei would be far 
less abundant than monomeric Aβ.  I propose that binding to or removal of these fibril 
initiating species from solution would be sufficient to prevent Aβ fibril formation. 
The difference in fibril prevention activity of the two Hsp20 constructs tested, 
Hsp20-MBP and his-Hsp20 are clearly demonstrated in Figure 5. 7.  I spectulate that the 
almost 100 fold increase in effectiveness of the his-Hsp20 compared to the Hsp20-MBP 
at preventing fibril formation is due to higher affinity of the his-Hsp20 for Aβ than 
Hsp20-MBP affinity for Aβ.  Differences in Hsp20 structure or stability in the two 
different constructs may also affect fibril prevention activity of the protein. 
As seen in Figures 5. 4 and 5. 7, there is an optimum concentration of Hsp20 for 
Aβ fibril formation prevention.  I suggest several possible explanations for this 
 
 111
observation.  Oligomerization dynamics of α-crystallins are concentration dependent 
(McHaourab et al. 2002).  Hsp20 may aggregate to form a less active structure at higher 
concentrations.  High molecular weight oligomers of heat shock proteins, which tend to 
form at high concentrations, are less active than the low molecular weight oligomers 
(Liang 2000).  Additionally, equilibrium distribution of oligomeric Hsp20 species are 
likely dependent upon conformers or oligomers of substrate Aβ present in solution. Size 
exclusion chromatography (SEC) data presented in Figure 5. 8 supports the hypothesis 
that Hsp20 oligomerization is concentration dependent.  At concentrations where his-
Hsp20 has high Aβ fibril prevention activity, his-Hsp20 elutes as a dimer from the SEC 
column, suggesting that the active form of his-Hsp20 is a dimer.  At concentrations of 
his-Hsp20 where the protein displays less fibril prevention activity or no activity, a 
complex mixtures of oligomers were detected via both SEC (Figure 5. 8) and analytical 
ultracentrifugation (data not shown).  These data suggest that oligomers larger than the 
dimer are inactive.  Hsp20-MBP becomes inactive in the fibril formation assay at lower 
concentrations than his-Hsp20, suggesting that the MBP construct contributes to the 
destabilization of the active dimer.  Changes in oligmerization of Hsp20-MBP at low 
concentrations could not be confirmed because of limits of sensitivity of detection of the 
FPLC system in the range of concentrations where Hsp20-MBP was active. 
Analogous to fibril formation prevention data, Hsp20 attenuates Aβ toxicity at 
similar molar ratios (Figures 5. 6 and 5. 7).  These data suggest that the Aβ species 
which bind Congo red and have fibril appearance in electron micrographs are toxic, or, 
more probably, Aβ species which are associated with the formation of Congo red 
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binding or fibril species are toxic. While non-fibrillar ADDLs, low molecular weight 
oligomers, protofibrils, and fibrils have all been found to be toxic (Iversen et al. 1995; 
Lambert et al. 1998), recent evidence suggests that oligomeric Aβ are the toxic (or most 
toxic) species (Wang et al., 2002, Kayet et al., 2003, Dahlgren et al., 2002, for example). 
A careful examination of electron micrographs of Aβ-Hsp20 mixtures under 
optimal fibril formation and toxicity prevention conditions (Figure 5. 5) reveals the 
presence of small globular species with a 16.3 nm diameter and variable length. The 
globular species are not yet well characterized, however, size analysis suggests that the 
species may be an Hsp20-Aβ complex rather than Aβ protofibrils since the width of 
these species (16.3nm) is atypical for Aβ micelles (5 ~11 nm), protofibrils (4~8nm), or 
fibrils (6~10nm) (Yong et al. 2002).   
A number of different approaches have been explored for prevention of Aβ 
amyloid fibril formation and toxicity. Pentapeptides such as KLVFF (Pallitto et al. 1999), 
LPFFD (Soto et al. 1998), GVVIN, and RVVIA (Hetenyi et al. 2002) have been used to 
disrupt Aβ fibril formation and neurotoxicity.  These pentapeptides have the same or 
similar residues as segments of Aβ essential for fibril formation, bind to Aβ, and alter the 
structure that Aβ adopts (Soto et al. 1998).  Generally, 1 to 1 molar ratios of peptide 
inhibitors to Aβ are needed in order to effectively prevent fibril formation (Pallitto et al. 
1999). Amphipathic molecules such as hexadecyl-N-methylpiperidinium (HMP) 
bromide or sulfonated molecules such as Congo red have also been used to prevent Aβ 
fibril formation and toxicity.  
Other small heat shock proteins and α-crystallins have also been examined for 
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their ability to prevent Aβ and other amyloid fibril formation, with good success at 
relatively low molar ratios of α-crystallin to amyloid (Kudva et al. 1997; Hughes et al. 
1998; Stege et al. 1999; Hatters et al. 2001).  However, in none of these studies has 
toxicity inhibition been reported.  Indeed, in work reported by Stege and coworkers 
(Stege et al. 1999), αB-crystallin prevented Aβ fibril formation but enhanced toxicity.   
Thus, I believe that I have found, with Hsp20, a novel protein, which both reduces Aβ 
fibril formation at very low molar ratios, and reduces Aβ toxicity at similar molar ratios.  
Upon further investigation of the mechanism of Hsp20 fibril formation and toxicity 
prevention, I hope to identify essential interactions between Aβ and Hsp20 essential for 
prevention of the formation of toxic Aβ species.   
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CHAPTER VI 
THE EFFECT OF VARIOUS SMALL HEAT SHOCK PROTEINS ON 
PREVENTION OF Aβ AGGREGATION AND TOXICITY  
 
OVERVIEW 
β-amyloid (Aβ) is a main component of senile plaques in Alzheimer’s disease 
(AD). Aβ readily forms fibrils via conformational changes.  Aβ is toxic in vitro when it 
is aggregated.  Many research groups have focused on prevention of Αβ aggregation and 
toxicity. Recently I found that Hsp20 from B. Bovis prevented Αβ aggregation and 
toxicity at very low mole ratios of small heat shock protein to Aβ. (Lee et al. 2005)  In 
this work, I explore the mechanism of Hsp20 interaction with Aβ and compare its 
activity to several other small heat shock proteins.  Our results suggest that Hsp20 
interacts with Αβ via multivalent binding, which leads to productive aggregation 
prevention and toxicity prevention over a very limited range of protein concentrations.  
Other small heat shock proteins interact with Aβ via different mechanisms and while 
they are able to prevent Aβ aggregation, they can’t prevent Aβ toxicity.  These results 
highlight the unique properties of Hsp20 in Aβ aggregation and toxicity prevention.  
Understanding the mechanism of Hsp20-Aβ interaction may provide insights on how 
best to design the next generation of aggregation and toxicity inhibitors for AD. 
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INTRODUCTION 
Alzheimer’s Disease (AD) is the progressive disease that destroys a person’s 
memory, judgment, and personal abilities gradually. Senile plaques and neurofibrillary 
tangles are two hallmarks of AD. β-amyloid peptide (Aβ) is the major component of 
senile plaques, which are clumps of proteins in fibril form that accumulate 
extracellularly in the brain. Αβ forms fibrils via a conformational change. Αβ toxicity is 
linked to its aggregation.  (Iversen et al. 1995; Lambert et al. 1998) Recent studies show 
that soluble oligomeric forms of Aβ are more toxic than large fibrillar species. (Dahlgren 
et al. 2002; Chromy et al. 2003; Kayed et al. 2003) Aβ-derived diffusible ligands 
(ADDLs) composed of Aβ1-42 are toxic to neuron type of cells. (Lambert et al. 1998) 
Globular ADDLs have molecular weights between 17 to 42kDa with hydrodynamic radii 
between 3 to 8nm (Lambert et al. 1998; Klein et al. 2001; Chromy et al. 2003). 
Protofibrils of Αβ1-40 with hydrodynamic radii ranging from 9 nm to over 300 nm are 
toxic in vitro. (Walsh et al. 1999; Ward et al. 2000; Wang et al. 2002)  Spherical 
aggregates with radii over 15 nm have also been reported to be toxic. (Hoshi et al. 2003)   
Based on the Αβ aggregation hypothesis, many research groups have focused on 
finding the agents that prevent or reduce Αβ aggregation and toxicity. (Ghanta et al. 
1996; Lansbury 1997; Pallitto et al. 1999; Cairo et al. 2002)  Some chemicals such as 
polyphenol (Choi et al. 2001; Ono et al. 2004), apomorphine (Lashuel et al. 2002) and 
hexadecyl-N-methylpiperidinium (HMP) bromide (Wood et al. 1996) are reported to 
prevent Αβ aggregation and toxicity. Pentamer peptides, KLVFF (Tjernberg et al. 1996; 
Pallitto et al. 1999), LPFFD (Soto et al. 1998), GVVIN, and RVVIA (Hetenyi et al. 
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2002)  have been used to prevent Aβ aggregation. Hydrophobic parts in the middle of 
Αβ including KLVFF are known to be very important in Αβ1-42 aggregation. (Tjernberg 
et al. 1999)  Small heat shock proteins (sHsp) which had chaperone like activity have 
also been investigated to prevent Aβ aggregation or toxicity. Human sHsp27 inhibited 
Aβ1-42 fibril formation (Kudva et al. 1997).  αB-crystallin, one of α−crystallin subunits 
prevented Aβ fibril formation in vitro, but increased the toxicity of Aβ1-40 (Stege et al. 
1999).  
Recently I found that novel heat shock protein, Hsp20 from B. Bovis can prevent 
Αβ aggregation and toxicity at very low concentrations of small heat shock protein 
relative to Aβ (1:1000). (Lee et al., 2005)  The protein, however, lost activity at high 
concentrations of Hsp20.  I originally postulated that the loss of activity was due to self 
assembly of the Hsp20 at high concentrations, and suggested that only dimer of Hsp20 
was active, while higher order assembly was inactive.  
In the work presented here, I describe a series of experiments in which I examine 
the mechanism of Hsp20 activity and compare it to activity of other small heat shock 
proteins.  A novel Hsp20 construct was prepared that was missing 11 residues from the 
C-terminus which are partly responsible for Hsp20 assembly. This form of Hsp20 forms 
stable dimers under most conditions.  I compare activity of the non-aggregating form of 
Hsp20 and the aggregating Hsp20, and find little difference in their aggregation 
prevention and toxicity behaviors.    These results suggest that the binding ratio between 
Hsp20 and Αβ (stoichiometric binding) is more important in Aβ aggregation prevention 
than Hsp20 assembly.  I examine aggregation and toxicity prevention properties of two 
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other small heat shock proteins, Hsp17.7 from carrot, and human recombinant Hsp27. 
Both sHsps inhibited Αβ1-40 aggregation but not toxicity. Electron microscope images 
of Hsp-Aβ complexes that formed under conditions and where both aggregation and 
toxicity prevention were observed were compared to Hsp-Aβ complexes that formed 
when only aggregation prevention was seen.  In cases where both aggregation and 
toxicity prevention were seen, a large ring structure was observed repeatedly, which was 
absent when aggregation was prevented, but toxicity was not prevented.  From these 
results, I postulated a mechanism for Hsp20-Aβ interaction that leads to both toxicity 
and aggregation prevention.  Understanding how proteins prevent aggregation and 
toxicity of Aβ may provide insight in how best to design the next generation of Aβ 
aggregation inhibitors to be used in AD.   
 
MATERIALS AND METHODS 
Materials  
β-Amyloid (Aβ)–(1-40) was purchased from AnaSpec (San Jose, CA).  
Recombinant human Hsp27 was purchased from MBL International Corporation 
(Woburn, MA). Human neuroblastoma SH-SY5Y cells (ATCC number: CRL-2266) 
were purchased from ATCC (Manassas, VA). Cell culture reagents were purchased from 
Invitrogen Life Technologies (Carlsbad, CA). Congo red was purchased from Fisher 
Chemicals. (Pittsburgh, PA). All other chemicals, unless otherwise specified Ire obtained 
from Sigma-Aldrich Co..    
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Heat Shock Protein 20 (Hsp20) Preparation  
Hsp20 is isolated from Babesia bovis, (Brown et al. 2001) and Hsp20 was 
produced in two forms, as an N-terminal polyhistidine fusion protein (His-Hsp20) and as 
an N-terminal polyhistidine fusion protein (His-Hsp20) without 11 residues in C-
terminus.  Both proteins were produced in E. coli.  The N-terminal polyhistidine fusion 
protein was made with an intervening Tobacco Etch Virus (TEV) protease site 
(Carrington et al. 1998) between Hsp20 and a polyhistidine tract.  His-Hsp20 was 
prepared by growing cells to OD600 of 0.5 followed by induction with 1mM IPTG for 5 
hours, and removal of media.  The cells were then lysed in PBS using a French pressure 
cell and the insoluble His-Hsp20 pellet collected. The pellet containing his-Hsp20 was 
suspended in Denaturing Binding Buffer (Invitrogen) containing 8M urea and incubated 
with Probond resin for 1 hour to allow binding of his-Hsp20 to the nickel 
chromatography resin. The protein was eluted from the resin using 100 mM EDTA, 
dialyzed overnight into PBS pH 7.0, 20% glycerol and frozen at –80oC. Protein purity 
and molecular weight were confirmed by SDS PAGE. 
 
Heat Shock Protein 17.7 (Hsp17.7) Preparation  
The gene, encoding Hsp17.7 from carrot, was cloned in E.coli. (Malik et al. 1999) 
E.coli was grown in the LB media (Trypton (10g/L), Yeast Extract (5g/L) and NaCl 
(10g/L)) with 50µg/ml kanamycin broth on the wheel for aeration overnight.  The tubes 
of LB broth were inoculated at a 1:200 dilution and put on wheel at 37oC.  100mM IPTG 
was added to cells in order to induce Hsp17.7 when E.coli reached an OD600 of 0.6.  
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E.coli was put back on the wheel and Hsp17.7 was expressed at 37oC overnight.  The 
cells were harvested by centrifugation at 6,000rpm for 10 minutes and frozen at -20oC 
overnight.  The cells were lysed with 20mM imidazole and 10min sonication.  Hsp17.7 
was purified by using a metal affinity column (POROS® MC) (Framingham, MA) with 
copper chromatography resin. (Self PackTM POROS® 20MC Media) (Framingham, MA)  
The protein was eluted by pH gradient from pH 7.4 (Phosphate buffer, 50mM NaH2PO4, 
and 300mM NaCl) to pH 4.5 (Phosphate buffer).  Protein purity and molecular weight 
were confirmed by size exclusion chromatography. 
 
Protein Sample Preparation  
Aβ1-40 was dissolved in 0.1% (v/v) Trifluoroacetic acid (TFA) solvent at the 
concentration of 10mg/ml. This solution was incubated at room temperature for 20~30 
minutes in order to completely dissolve the Aβ.  Filtered phosphate-buffered saline (PBS, 
4.3 mM Na2HPO4, 137 mM NaCl, 2.7 mM KCl and 1.4 mM KH2PO4, pH 7.4) was 
added to the Aβ solution to make the final concentrations used in experiments. For cell 
viability assays, MEM medium was used instead of PBS buffer. For aggregation with 
mixing, Aβ samples were mixed on the rotator at 18 rpm and 37oC, and samples were 
taken out as a function of time. For aggregation without mixing, Aβ samples were 
incubated without disturbance in a 37oC incubator.  sHsps were added to the Αβ samples 
before the samples were incubated (prior to aggregation). 
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Congo Red Binding  
Congo red was dissolved in PBS at the concentration of 120µM and syringe 
filtered. The Congo red solution was mixed with protein samples at 1:9 (v/v) ratios to 
make the final concentration of Congo red 12µM. After a short vortex, the mixtures were 
incubated at room temperature for 30~40 minutes. Absorbance measurements from 
400nm to 700nm were taken (UV-Vis spectrometer model UV2101, Shimadzu Corp.; 
Kyoto, Japan).  Alternatively, Congo red absorbance was read at 405 nm and 540 nm 
using an Emax Microplate Reader (Molecular Devices, Sunnyvale, CA). In both cases, 
PBS buffer was used as a blank. The concentration of Aβ fibrils was estimated from 
Congo red binding via equation 6-1:  
[AβFIB] =(541At/4780) −(403At/6830) −(403ACR/8620)                       (6-1) 
where 541At and 403At are the absorbances of the Congo red-Aβ mixtures at 541 nm and 
403 nm,  respectively, and 403ACR is the absorbance of Congo red alone in phosphate 
buffer.(Klunk et al. 1999) In Microplate reader, absorbances at 405nm and 540nm were 
assumed to be same as those at 403nm and 541nm.   
 
Size Exclusion Chromatography (SEC)  
A Superose6 HR 10/30 Column attached to FPLC (Fast Performance Liquid 
Chromatography) (Pharmacia; Piscataway, NJ) was used to separate Hsp20 and Aβ  
complex from small species such as monomer and dimer. PBS buffer was used as a 
mobile phase with flow rate of 0.5mL/min. A 100µL sample loop was used. Aβ and 
Hsp20 mixture was mixed for 4 hours. 100µL of the Aβ and Hsp20 mixture was 
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centrifuged at 7,000rpm for 3 minutes prior to SEC separation.  Supernatants of 
centrifuged samples were loaded in the 100µL loop and injected into the column. Aβ 
species were detected by UV detector at 254nm. 
 
Electron Micrograph (EM)  
200µl of Aβ peptide solution, prepared as described above, was mixed, placed on 
glow discharged grids, and then negatively stained with 1% aqueous ammonium 
molybdate (pH 7.0). Grids were examined in a Zeiss 10C transmission electron 
microscope at an accelerating voltage of 80 kV. Calibration of magnification was done 
with a 2,160 lines/mm crossed line grating replica (Electron Microscopy Sciences, Fort 
Washington, PA). 
 
Cell Culture  
SH-SY5Y cells were grown in Minimum Essential Medium (MEM) supplemented 
with 10% (v/v) Fetal Bovine Serum (FBS), 25mM Sodium bicarbonate, 100 units/ml 
penicillin, and 100 mg/ml streptomycin.  Cells were cultured in a 5% (v/v) CO2 
environment at 37oC incubator.  Low passage number cells were used ( <p20) in all 
experiments to reduce instability of cell line. 
 
Biological Activity Assay   
For biological activity tests, SH-SY5Y cells at a density of 1x105cells/well were 
grown in 96 well plates.  Cells were fully differentiated by addition of 20ng/mL NGF for 
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8 days.  Aβ samples in MEM medium were added to the differentiated SH-SY5Y cells 
and the cells were incubated with Aβ samples at 37oC for 2 hours.  Negative controls 
(cells in medium with no Aβ) and positive controls (cells treated with 800µM H2O2 in 
50% (v/v) medium for 2 hours) were also prepared.  At least 3 wells were prepared for 
each Aβ treatment, and each positive and negative control.  
Cell viability was determined by using the fluorescent nucleic acid dye, propidium 
iodode (PI). PI is mostly used fluorescent dye for staining DNA in cells. PI can enter the 
dead cells and bind DNA in dead or late apoptotic cells. PI is a DNA specific dye and 
can not cross the membrane of viable cells. In order to stain the dead cells, Aβ treated 
cells were washed with PBS 1~2 times and 150µL of enzyme free dissociation buffer 
from Gibco (Carlsbad, CA) was added to the cells in order to detach SH-SY5Y cells 
from the surface.  The cells were incubated at 37oC for approximately 5 minutes.  5µL of 
33µM PI was added to the cells and cells were incubated for 15~20 minutes at room 
temperature in the dark..  Stained cells in 96 well plates were loaded in the FACS array 
(BD FACSArray, BD Bioscience; San Jose, CA) and fluorescence histograms for cells 
were obtained.  To set up gates for the cell viability assays, 2 sets of staining controls 
were prepared, unstained cells, and cells stained with PI alone. Cells not stained with PI 
dye were taken as live cells, and the relative cell viabilities were calculated using 
equation 6-2. 
100x
)L.C.(L.C.
)L.C.(L.C.
(%)ViabilityCellRelative
H2O2NControl
H2O2sample
−
−=                   (6-2) 
where L.C.sample is live cells (%) of Aβ treatment,  L.C.Ncontrol is live cells (%) of negative 
control, and L.C.H2O2 is live cells (%) of H2O2 treatment (positive control).  
 
 123
Statistical Analysis   
For each experiment, at least 3 independent determinations were made. 
Significance of results was determined via the student t test with p<0.05 unless 
otherwise indicated. Data are plotted as the mean plus or minus the standard error of the 
measurement.  
 
RESULTS    
Effect of Hsp20 Assembly on Prevention of Αβ Aggregation   
In previous work, I found that an optimum Hsp20 concentration existed for 
prevention of Αβ aggregation and toxicity.  I had speculated that Hsp20 self assembled 
at higher concentrations and the assembled forms were not effective at preventing Αβ 
aggregation and toxicity.  Size exclusion chromatography results indicated that at low 
concentrations, when Hsp20 was active and able to prevent both aggregation and toxicity, 
Hsp20 was predominantly in dimer form, however at concentrations higher than the 
optimum observed for activity, Hsp20 was predominantly in the form of large multimers 
with very little dimer present. (Lee et al., 2005)  These results suggested that Hsp20 at 
low concentrations (in dimer form) had more activity than large assemblies of Hsp20.  
Recently Allison Rice-Ficht’s lab (Department of Medical Biochemistry and Genetics, 
Texas A&M University) succeeded in cutting off 11 residues in the C-terminus of Hsp20, 
which was partly responsible for Hsp20 self assembly.  Size exclusion chromatography 
(SEC) results showed that His-Hsp20 self assembly was drastically reduced when the 11 
C terminal residues were removed.  As shown in Fig. 6. 1, Hsp20 are mostly dimer with 
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small amount of small oligomeric species.  Even at concentrations of 20 µM, more than 
70% of the Hsp20 migrated as a dimer when the C terminal truncated protein was tested. 
(data not shown)  If self assembly of Hsp20 resulted in loss of activity at high 
concentrations, then this C terminal truncated protein should have aggregation and 
toxicity prevention activity at concentrations well above that seen in the original 
untruncated protein. 
In Fig. 6. 2, aggregation of 100µM Αβ when mixed for 24 hours with His-Hsp20 
with or without 11 residues in C-terminus is shown.  Extent of aggregation and fibril 
formation was measured with Congo red binding.  Unlike our predictions of improved 
Hsp20 activity with the C terminal truncation, both the original Hsp20 and the C 
terminal truncated protein exhibited the same concentration dependence for aggregation 
prevention.  About 80% of Αβ aggregation was prevented at concentration ranges of 
1nM-1µM His-Hsp20.  However, above 1 µM His-Hsp20, aggregation prevention 
activity decreased in both constructs.  At 5µM of His-Hsp20 with and without the 11 C 
terminal residues, both proteins were able to decrease Aβ aggregation to 40% of that 
observed in Aβ samples not treated with Hsp20.  
Based on these results, it was clear that mechanism of interaction of Aβ with Hsp20 was 
not as originally envisioned.  Therefore, I carried out several experiments designed to 
help elucidate how Hsp20 interacted with Aβ. 
 
Kinetics of Hsp20-Aβ Interaction   
For Hsp20 to be a useful aggregation inhibitor (or model for an aggregation 
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Figure 6. 1. SEC of His-Hsp20 without 11 residues in C-terminus. (A) 0.1µM of His-
Hsp20 and (B) 5µM His-Hsp20 
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Figure 6. 2. Effect of His-Hsp20 with or without 11 residues on Αβ aggregation. Congo 
red was used as an indicator of Αβ aggregation.  100µM Aβ was mixed with His-Hsp20 
at the beginning of Αβ incubation and the samples were mixed at 37oC for 24 hours.  
[closed diamonds -  His-Hsp20 with whole sequence, and open diamonds -  His-Hsp20 
without 11 residues in the C-terminus] 
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inhibitor) for Aβ, it was important to discern if Hsp20 simply slowed the rate of 
aggregation of Aβ, or actually altered the aggregation pathway of Aβ.  To that end, I 
measured kinetics of Aβ aggregation as assessed via Congo red binding in the presence 
and absence of Hsp20.  As seen in Fig. 6. 3, Aβ aggregation increases slowly at first, 
followed by a period of rapid increase in fibril content, which eventually saturates over 
time.  When Hsp20 was added at the beginning of aggregation, fibril formation and 
Congo red binding followed a very different pattern.  Initially, aggregation was 
accelerated, followed by a rapid loss in fibril content and ability to bind Congo red.  
These results suggest that Hsp20 does not simply slow the rate of Aβ aggregation, but 
actually changes the fibril formation pathway, possibly sequestering a fibril initiating 
species that forms early during aggregation and preventing further fibril growth. 
In Fig. 6. 4, size exclusion chromatograms taken at different times during Aβ-Hsp20 
incubation are shown.  These chromatograms were collected in an attempt to isolated 
Aβ-Hsp20 intermediates to try to identify species formed in the mechanism of fibril 
formation prevention.  Two peaks shown in Fig. 6. 4 corresponded to the molecular 
weights of around 87kDa, and 42kDa.  The big peak of around 42kDa was the mixture of 
Aβ monomer and dimer and Hsp20 dimer.  The small peak of around 87kDa was 
expected to be the complex of Aβ and Hsp20.  I used mass spectrometry to try to 
confirm the presence of both Aβ and Hsp20 in complexes formed and to infer 
stoichiometry of binding, but with inconclusive results.  
 
 
 
 128
 
 
0
10
20
30
40
50
0 10 20 30 40
Incubation Time(hrs) 
A
β F
ib
ril
 F
or
m
at
io
n 
 (µ
M
)
50
 
 
Figure 6. 3. Kinetics of Aβ aggregation using Congo red. [black diamonds – 100µM Aβ, 
gray triangles - 100µM Αβ and 0.1µM His-Hsp20] 
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Figure 6. 4. Size Exclusion Chromatograms of the mixture of 100µM Aβ and 0.1µM 
His-Hsp20.  Samples were mixed at the beginning of incubation, and incubated at 37oC 
for 4 hours. After the incubation, samples are centrifuged at 7,000rpm for 3minutes and 
the supernatant is used for SEC.  
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Effect of His-Hsp20 on Non-Mixed Aβ Fibril Formation   
I have shown in earlier work that Aβ aggregates via a different mechanism and 
forming different intermediates when aggregation is with mixing versus under static 
non-mixed conditions.  If Hsp20 interacts with a fibril initiating species during 
aggregation that forms when Aβ is mixed, I wanted to assess if Hsp20 also interacted 
with Aβ when aggregation occurred without mixing.  In Fig. 6. 5, I examined the effects 
of His-Hsp20 on the prevention of Αβ aggregation under static (non-mixing) conditions.  
A comparison of Fig. 6. 2 and Fig. 6.5 clearly indicate that while Hsp20 still reduces Aβ 
aggregation when aggregation occurs without mixing, Hsp20 is not nearly as effective at 
reducing aggregation as the maximum reduction in aggregation is 60 to 70% of the level 
of Aβ aggregation without Hsp20, while with mixing, between 90-100% of aggregation 
is prevented.  In earlier work (Lee et al., 2005, Protein Science) I showed that the 
concentration of Hsp20 needed for optimal fibril prevention shifted to lower 
concentrations of Hsp20 when lower concentrations of Aβ were used.  This appears to 
still be true when Aβ is aggregated without mixing. In Fig. 6. 5, 20µM, 50µM, and 
100µM concentrations of Aβ1-40 were used for non-mixing aggregation experiments 
and 0.01nM to 5µM of Hsp20 was used for the prevention of Αβ aggregation. A broad 
range in optimal concentrations for fibril formation prevention was observed, with the 
lower end of the concentration ranges being near 1 nM, 2.5 nM, and 5 nM Hsp20 for Aβ  
concentrations of 20 µM, 50 µM, and 100 µM, respectively.  At -Hsp20 concentration 
above 1 µM, His-Hsp20 was less effective at preventing fibril formation.  
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Figure 6. 5.  Αβ aggregation with His-Hsp20 in non-mixing condition. 20, 50, 100µM 
Αβ was mixed with His-Hsp20 at the beginning of incubation, and those samples were 
incubated without mixing at 37oC for 24 hours.  After the incubation, Congo red binding 
experiment was done. [open circles – 20 µM Αβ, closed squares – 50 µM Αβ, and closed 
triangles – 100 µM Αβ]   
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 Ability of His-Hsp20 To Prevent Toxicity of Aβ Under Mixing and Non-Mixing 
Condition.   
Aβ is toxic to neuron-like cells when it is aggregated.  The ultimate goal of Aβ 
aggregation prevention is to find agents which not only prevent aggregation, but also 
prevent Aβ toxicity. In order to assess the ability of His-Hsp20 to prevent Αβ toxicity, 
His-Hsp20 was added to mixed and non-mixed Αβ samples prior to Aβ aggregation, and 
toxicity of the Aβ-Hsp20 mixtures were tested as a function of time after incubation.  As 
seen in Fig. 6. 6, His-Hsp20 was more at preventing the toxicity of mixed Αβ than non-
mixed Αβ.  This is consistent with data from Figures 6. 2 and 6. 5, where Hsp20 was 
more effective at preventing Aβ aggregation when mixed as compared to static non-
mixed samples.  Statistically, cell viabilities of mixed Αβ samples with His-Hsp20 at 2, 4, 
8 hours were not different from negative control. (p = 0.862, 0.087, and 0.140 for 2, 4, 
and 8 hours respectively, p vales were obtained by two-tailed paired t test between 
samples and negative control, all p values were greater than 0.05)   His-Hsp20 reduced 
the toxicity of non-mixed Αβ samples (viability was statistically different between Αβ 
sample and Αβ with His-Hsp20), but the non-mixed Αβ samples with His-Hsp20 still 
showed higher toxicities (about 30-40% toxicity) relative to negative controls.    
 
 Effect of His-Hsp17.7 on Αβ Aggregation and Toxicity   
Results to date indicated that His-Hsp20 is very promising as an Aβ aggregation 
and toxicity inhibitor.  However, while other research groups have investigated the use 
of other small heat shock proteins to prevent Aβ aggregation and toxicity, they have not 
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Figure 6. 6.  Relative biological activities of Αβ species with His-Hsp20. 100 µM Αβ 
was mixed with 0.1 µM His-Hsp20 at the beginning of incubation. Some samples were 
mixed at 37oC and taken out at 2, 4, 8, and 24 hours.  The other samples were not mixed 
at 37oC and taken out at 4, 8, 24, and 72 hours.  These samples were added to SH-SY5Y 
cells, and incubated with the cells for 2 hours. [light solid bar -  negative control (no Αβ 
treatment), dark solid bar – Αβ with His-Hsp20 in mixing condition, and stripe bar - Αβ 
with His-Hsp20 in non- mixing condition] 
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seen the same success.  Thus, I set out to determine if other small heat shock proteins 
could prevent Aβ aggregation and toxicity in our hands, and if not, to elucidate 
differences between small heat shock protein activity in order to determine the 
mechanism of activity of Hsp20.  I examined His-Hsp17.7, a small heat shock protein 
derived from carrot and cloned into E.coli., for its ability to prevent Αβ aggregation and 
toxicity.  Congo red was used as an indicator of Αβ aggregation. 20 µM of Αβ was used 
for aggregation and biological activity experiments.  As seen in Fig. 6. 7A, His-Hsp17.7 
prevented Αβ aggregation at all concentrations about 1 nM, without the apparent loss of 
activity seen Hsp17.7.  Addition of Αβ to cells resulted in about 30% toxicity.  Samples 
in which Aβ was treated with His-Hsp 17.7 had statistically the same toxicity as when 
Αβ alone was added to cells(all p values were greater than 0.05 between Αβ sample and 
other samples containing Hsp17.7).  Thus, unlike Hsp20, Hsp17.7 prevented aggregation 
without preventing Aβ toxicity. 
 
Effect of Hsp27 on Αβ Aggregation and Toxicity   
Hsp27 is a human small heat shock protein and has been reported to be expressed 
in the brain of AD patients. (Renkawek et al. 1999)   In experiments analogous to those 
used to examine the activity of Hsp20 and Hsp17.7, the aggregation and toxicity 
prevention activities of Hsp27 were examined.  100 µM of Αβ and 1nM-5 µM of Hsp27 
were used for aggregation and biological activity experiments.  As shown in Fig. 6. 8A, 
Hsp27 prevented Αβ aggregation at high concentrations as in the case of Hsp20. At 
higher concentration of 0.1µM up to 20µM, His-Hsp17.7 still exhibited the same or 
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Figure 6. 7. Activities of His-Hsp17.7 to prevent Αβ aggregation and toxicity. All 
sample preparations were same as Αβ with His-Hsp20 in mixing condition. (A) Αβ 
aggregation with His-Hsp17.7 using Congo red  (B) Biological activities of Αβ with Hsp 
17.7 using two dyes in FACS array.  
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better activity at Αβ aggregation prevention. Fig. 6. 7B shows the biological activity of 
Αβ when incubated with His- with near the same effectiveness and at similar 
concentration ranges as Hsp17.7.  Unlike Hsp20, Hsp27 did not loose its ability to 
prevent Aβ aggregation at high concentrations (5µM of Hsp27).  In the toxicity 
experiments shown in Fig. 6. 8B, the samples containing Hsp27 incubated with Aβ had 
the same or more toxicity than the toxicity of Aβ alone. Statistically, cell viabilities of 
100 µM Αβ with 5nM – 1 µM Hsp27 were not different from that of 100 µM Αβ. (all p 
values are greater than 0.05)  1nM and 5 µM Hsp27 increased the toxicity of 100 µM Αβ.  
In other words, Hsp27 did not protect the cells from the toxicity of 100 µM Αβ.  
 
Electron Micrograph (EM) Images of Αβ with Small Heat Shock Proteins  
I have data from 3 small heat shock proteins, each which prevent Aβ aggregation 
as measured by Congo red binding, however only one prevents Aβ toxicity.  It is clear 
from these results that preventing extended β-sheet structure formation, the property 
which Congo red assesses, is necessary but not sufficient to prevent Aβ toxicity.  To 
further exam the relationship between Aβ structure, sHsp-Aβ interactions, and 
aggregation and toxicity prevention activities, I used electron microscopy to examine 
structures formed by Aβ in the presence of the small heat shock proteins.  
In one stet of experiments, I examined structures formed by 100 µM Αβ and 
0.1 µM His-Hsp20 as a function of time during incubation with mixing, analogous to the 
kinetic data shown in Figure 6. 3.  As seen in Fig. 6. 9, as early as 1-hour after 
incubation, Αβ and Hsp20 began to complex ring-like structures.  At two hours, a more  
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Figure 6. 8. Activities of recombinant Hsp27 to prevent Αβ aggregation and toxicity. All 
sample preparations were same as Αβ with His-Hsp20 in mixing condition. (A) Αβ 
aggregation with Hsp27 using Congo red  (B) Biological activities of Αβ with Hsp27 
using two dyes in FACS array.  
 138
well defined multi-ring structure was observed.  The appearance of this large multi-ring 
structure corresponds to the maximum in Congo red binding seen in Aβ-Hsp20 mixtures 
seen in Figure 6. 3.  At later times, the ring structures seem to fall apart, with few rings 
observed in micrographs at 24 hours after incubation. The large multi-ring structure was 
only seen in micrographs of Aβ and Hsp20 when 100 mM Aβ and 0.1 mM Hsp20 were 
used.  When the same concentration of Aβ, but higher and lower concentrations of 
Hsp20 were used (1nM, 0.01 µM, 1 µM, and 5 µM Hsp20), the complex ring structure 
was not observed (data not shown). Thus, the formation of the large multi-ring complex 
observed in Figure 6. 9 appears to be dependent upon the stochiometery of the Aβ-
Hsp20 interaction.  
As seen in Figure 6. 10, similar electron microscopy studies were performed with 
Aβ and Hsp20 in non-mixing condition or Hsp17.7.  At no time during incubation of Aβ 
and Hsp17.7 were the large multi-ring complexes observed in micrographs. I also 
examined structures formed 24 hours after incubation of Aβ and Hsp20 in non-mixing 
condition or Hsp17.7, as these structures would represent the complexes added to cells in 
culture for toxicity assays.  Differences in these structures might point to clues as to the 
differences in structures formed and their relationship to cell toxicity.   
 
DISCUSSION 
Small heat shock proteins (sHsps) are expressed in almost all organisms when cells 
become stressed during exposure to unfavorable environments.  Small heat shock 
proteins exist as large oligomeric complexes of 300-800kDa with monomeric molecular  
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Figure 6. 9. Electron micrograph images of Αβ with His-Hsp20 in mixing condition. 
100 µM Αβ with 0.1 µM His-Hsp20 in (A) 1 hour, (B) 2 hour, (C) 4hour, and (D) 24 
hour incubation respectively.  The length of scale bar is 100nm. 
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Figure 6. 10. Electron micrograph images of Aβ with His-Hsp17.7 and His-Hsp20. 
100 µM Αβ with 2µM His-Hsp17.7 in mixing condition (A) 2 hour, (B) 24 hours, and 
100 µM Αβ with 0.1 µM His-Hsp20 in mixing condition. (C) 8hours, (D) 72 hours 
incubation respectively.  The length of scale bar is 100nm. 
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mass of 15-43kDa. (van den et al. 1999; Clark and Muchowski 2000; MacRae 2000)   
The primary roles of sHsps are to stabilize other proteins under stress conditions and  
protect them from aggregation. (van den et al. 1999; Bruey et al. 2000)  sHsps are 
composed of three parts in the primary sequence, the N-terminal domain, the α-crystallin 
domain, and the C-termial extension. The α-crystallin domains, highly conserved 80-100 
amino acid sequences located in the C-terminal regions, are very important for substrate 
binding. (de Jong et al. 1993)  The N-terminal domain is responsible for sHsp assembly, 
which results in polydisperse sHsp.   Some sHsps are active when they are assembled in 
large multimeric complexes, whereas some other sHsps are active when they are 
dissociated. In a previous chapter, I showed, using SEC that the dominant species of 
Hsp20 at concentrations below 0.1µM are dimers which are the active form to prevent 
Αβ aggregation.  In the first Hsp20 constructs prepared, Hsp20 self assembles into large 
heterogeneous complexes at concentrations higher than 0.1µM. In this range, Hsp20 was 
less effective at preventing Αβ aggregation. (Lee et al., 2005)  I suggested that the loss 
of Hsp20 activity at high concentrations was a result of its assembly into inactive 
multimers.  In this work, I used a new Hsp20 construct, which is predominantly dimer at 
high concentrations, however, as seen in Figure 6. 2, its activity is indistinguishable from 
that of an Hsp20 construct which aggregates at high concentrations.  These results 
suggest that the loss of activity at high concentrations of Hsp20 is not due to aggregation, 
but to some other phenomena. There are several possible explanations for the loss of 
Hsp20 activity at high concentrations, or the presence of an optimal activity at 
intermediate concentrations.  Hsp20 could form micelles at high concentrations, thus 
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effectively reducing the concentration of Hsp20 available for binding to Aβ. Micelles of 
Hsp20 would fall apart under SEC conditions and thus not be detected.  However, if 
micelles were formed, one would expect a critical micelle concentration at which Hsp20 
looses activity regardless of the concentration of Aβ added.  This is not the behavior I 
have seen, either in earlier work (Lee et al., 2005) or in this work (Figure 6. 5).  Instead, 
I see that the range of activity of Hsp20 and the concentration at which Hsp20 begins to 
loose activity is always proportional to the concentration of Aβ used in the experiment. 
 Another possible hypothesis to explain the optimum Hsp20 activity at intermediate 
concentrations is that Hsp20 binds Αβ stoichiometrically. I still postulate  that the Hsp20 
dimer is the active form in Αβ aggregation prevention, but I postulate that there is 
multivalent binding between an Aβ species and the Hsp20 dimer, and at specific ratios of 
concentrations of active species, large complexes of the active species can form, much 
like an agglutination reaction with antibody and polyvalent antigen.  Such an explanation 
would explain the formation of large multi-ring complexes of Aβ and Hsp20 (Figure 6. 
9), much larger than what one would expect of dimer or Aβ species alone, that only form 
at specific concentration ratios.  
Although the mechanisms of action and structures associated with the interaction 
between sHsps and their substrates are still under investigation, two possible 
mechanisms have been suggested.  One mechanism is that partially unfolded proteins are 
refolding in the sHsp cavity which is formed by assembly of sHsp subunits. The other 
mechanism is that partially unfolded proteins interact with multiple α-crystallin domain 
of sHsp in the cleft of sHsp subunits. (Ganea 2001)  It is not clear that Hsp20 can form a 
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large assembly with a cavity by itself.  In electron microscope images, Hsp20 forms 
relatively disordered assemblies composed of subunits (dimers) at higher concentrations 
(data not shown), however, no cavity was observed in these assemblies.  Based on two 
observations (Hsp20 dimer is the active form, and no cavity is observed in Hsp20 
assemblies), I postulate that Hsp20 could prevent Αβ aggregation via the interaction of 
multiple α-crysatllin domains in Hsp20 with Αβ.  In the stoichiometric binding 
hypothesis, at low concentrations of Hsp20, there is not sufficient Hsp20 to completely 
prevent Αβ aggregation.  However, at higher concentrations of Hsp20, Hsp20 interferes 
with the interaction between Hsp20 and Αβ.  According to Congo red results from 20µM, 
50 µM, and 100 µM Αβ, those data are well overlapped when they are plotted as a 
function of mole concentration ratio (Hsp20/Αβ) rather than mole concentration of 
Hsp20.  EM and MALDI-MS results show that the large ring structures are formed only 
at the optimum ratio between Αβ and Hsp20. Figures 6. 3 and 6. 9 indicate that Hsp20-
Aβ complexes form a large species at 2 hours incubation.  When an optimum ratio 
mixture of Hsp20 and Aβ (0.1 µM His-Hsp20 and 100 µM Αβ) were incubated for 2 
hours, centrifuged (12,000 rpm for 3 minutes), then subjected to MALDI-MS, 
approximately 90% of both proteins were found in the centrifuged pellet, suggesting 
both proteins participated in forming a the large complex seen in EM.  At concentrations 
other than the optimum ratio, only 50% of Aβ and Hsp20 were in the pellet. Congo red, 
EM, and MALDI-MS results suggest that Αβ binds to Hsp20 stoichiometrically to form 
the large multi-ring structure at only an optimum concentration ratio.  
Fig. 6. 5 indicates that when Hsp20 with Αβ and incubated without mixing, that 
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Hsp20 is not as effective at preventing Αβ aggregation as occurs when mixing is used.  
One of the possible explanations for this result is the kinetics problem related to 
diffusion.  In mixing conditions, Hsp20 can collide with Αβ before Αβ forms fibrils, 
whereas Αβ forms fibrils before Hsp20 can bind to Αβ in non-mixed condition (with 
mixing, the rate of Hsp20-Aβ collision and reaction is faster than fibril growth, where as 
without mixing, fibril growth is faster).  Based on data comparing the rate of fibril 
growth with mixing and without mixing, I suggest that the rate of fibril nucleation or 
initiation is the slowest step in both cases, and that mixing greatly increases the rate of 
fibril nucleation.  When Hsp20 is present, I postulate that Hsp20 binds to a fibril 
nucleating species or rare intermediate that forms prior to fibril nucleation.  This species 
would be more abundant during mixing than during static conditions, making it far more 
probable that Hsp20 would collide with this nuclei or intermediate when mixing was 
used. 
Another possibility is that Hsp20 can’t bind multivalently to Αβ (as per the 
stochiometric binding hypothesis) in the non-mixing condition because the conformation 
of Αβ intermediates during aggregation are different when aggregation occurs with 
mixing versus under static conditions.  I have shown in an earlier chapter that under 
static conditions, Aβ appears to undergo an intramolecular rearrangement prior to fibril 
growth that does not occur when Aβ aggregates with mixing.  This would suggest that 
the fibril nucleating species have different structures and exposed hydrophobic surfaces 
when prepared with mixing or without mixing. The α-crystallin domain is known to play 
an important role in the interaction with the hydrophobic region of a partially unfolded 
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protein, (Stevens and Augusteyn 1997; Sharma et al. 1998) and results in protein folding 
of the substrate protein. Mutation studies in α-crystallin domain suggest that the 
substrate binds to the α-crystallin domain by multiple contacts. (Derham et al. 2001)  
The α-crystallin domain of Hsp20 would favor binding to the β-sheet structure of Αβ 
aggregation intermediate that is observed prior to fibril growth in mixing condition 
rather than random coil structure of the Aβ intermediate observed in non-mixing 
condition. 
In Alzheimer’s disease (AD) and in dementia associated with Parkinson’s disease, 
an increased expression of Hsp27 and of αB-crystallin was found (Iwaki et al. 1989; 
Renkawek et al. 1999). These results suggest that chaperone activity of heat shock 
proteins may contribute to the pathogenesis associated with protein aggregation in 
Alzheimer’s disease (Kudva et al. 1997).  Other research groups showed that αB-
crystallin prevented Aβ fibril formation in vitro, but not the toxicity. (Stege et al. 1999) 
Human Hsp27 inhibited fibril formation of Αβ1-42 in vitro, but it was less effective on 
the pre-formed amyloid. (Kudva et al. 1997)  Fig. 6. 7 and 6. 8 show that both Hsp17.7 
and Hsp27 prevent Αβ aggregation but not toxicity. Conclusively, Hsp17.7 and Hsp27 
can prevent only Αβ1-40 aggregation, but Hsp20 prevents Αβ1-40 aggregation and 
toxicity. The α-crystallin domains of these sHsps could be the crucial parts of the 
proteins in preventing Αβ aggregation because the α-crystallin domains are well-
conserved regions and are found in Hsp20, Hsp17.7, and Hsp27.  The results of sequence 
homologies using the software CLUSTALW (EMBL-European Bioinfomatics Institude) 
show that sequences between sHsps are not homologous. (32% - αB-crystallin and 
 
 146
Hsp27, 15% - αB-crystallin and Hsp17.7, 8%  - αB-crystallin and Hsp20, 17% - Hsp20 
and Hsp17.7, 7% - Hsp20 and Hsp27, and 7% - Hsp17.7 and Hsp27)  The sHsps lack 
sequence homology in both the N-terminus, and C-terminal extension.  These 
differences could result in different binding affinity between sHsp and Αβ or in different 
mechanisms by which when they prevent Αβ aggregation. Only Hsp20 forms a large 
multi-ring structure with Αβ (at 2 hours in mixing condition), whereas the other sHsps 
were not observed to form ring structures.  These data suggest that Hsp20 may have a 
unique mechanism of interaction with Αβ that results in different activity in Αβ toxicity 
prevention relative to other sHsps.   
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CHAPTER VII 
FUTURE DIRECTIONS 
The research presented in this dissertation indicates that different Aβ incubation 
conditions in vitro can affect the rate of Aβ fibril formation, the morphology, the toxicity 
and the conformation of intermediates in the aggregation pathway. And a series of 
experiments also show that small heat shock proteins (Hsp20, Hsp17.7 and Hsp27) can 
prevent Αβ aggregation.  However only Hsp20 prevents Αβ toxicity in vitro, whereas 
Hsp17.7 and Hsp27 do not. Future work described in this chapter will focus on 
understanding the kinetics of Αβ aggregation. These studies will be helpful in 
understanding features of Αβ aggregation that lead to the formation of toxic oligomers.  
In other future work, studies to examine the mechanism of sHsps interaction with Αβ to 
prevent aggregation and toxicity will be discussed. 
 
THE KINETICS OF Aβ AGGREGATION 
Based on Congo red binding results, Αβ fibril formation follows a characteristic 
sigmoidal curve, with a lag phase at early incubation times, followed by a fibril growth 
phase, then a saturation phase.  The characteristic lag phase implies that there is a classic 
nucleation dependent mechanism of aggregation.  In this research, the kinetic 
mechanism of Αβ aggregation in with mixing will be based on the assumption that a 
nuclei initiates fibril formation. A proposed mechanism is shown: 
DM2 1k⎯→←                                                            (7-1) 
 
 148
UM 2k⎯→←                                                            (7-2) 
NUn 3k⎯→←                                                           (7-3) 
j
k fUjN 4⎯→←+                                                            (7-4) 
j
k
j Ffm 5⎯→⎯                                                            (7-5) 
where M, and D are monomer and dimer with α-helix/random coil structure, U is 
unfolded monomer with a β-sheet rich structure, N is a nuclei, fj is a filament composed 
of nuclei and j unfolded monomer, Fj is fibril made from lateral aggregation of m 
filaments,.  k1, k2, k3, k4, and k5 are the forward rate constants in each steps.  K1, K2, K3, 
and K4 are equilibrium constants corresponding to reactions 1 thru 4.  n, j, and m are 
constants. The rate equation for fibril production based on this mechanism is 
m
j5
j fk
dt
dF =                                                            (7-6) 
Integration of equation (7-6) based on mass balance and equilibrium relationships gives 
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where M is the Αβ monomer concentration with time, Mo is initial Αβ monomer 
concentration, t is incubation time, A1, A2, C, and D are constants composed of 
equilibrium constants, rate constant, m, n, and j. 
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Equilibrium constants, rate constants, and stochiometric constants m, n, and j can be 
determined from experimental data. 
Figure 7. 1 shows a preliminary result of a study of the kinetics of Αβ aggregation 
from SEC and turbidity data.  Open diamonds are fibril amounts obtained by turbidity at 
405nm.  Closed triangles and circles are Αβ dimer and monomer respectively from SEC 
data.  From these data, equilibrium constants, rate constants, m, n, and j can be estimated 
by nonlinear regression. 
This type of analysis will enable us to examine the relative rate of different steps in 
Aβ aggregation, and how manipulation of individual rates (i.e. of nucleation or fibril 
growth) will affect the final morphology and toxicity of the Aβ aggregation species 
formed. 
 
THE MECHANISMS OF HSP20 TO PREVENT Aβ AGGREGATION AND 
TOXICITY 
All types of Hsp20 (Hsp20-MBP (maltose binding protein fusion), His-Hsp20 
(polyhistidine fusion) and His-Hsp20 without 11 residues in C-terminus) are able to 
prevent Aβ1-40 aggregation and toxicity.  However, Hsp17.7 and Hsp27 can inhibit 
Αβ1-40 aggregation but not its toxicity.  For future drug development, it will be very  
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Figure 7. 1.  Concentration change of Aβ species with time.  Concentrations of monoer 
(closed circles) and dimer (closed triangles) were detected by SEC and fibrils (open 
diamonds) were detected by turbidity assay at 405nm. 
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important to understand the differences between Hsp20 and Hsp17.7/Hsp27. 
One of the plausible hypotheses to explain the difference between Hsp20 and 
Hsp17.7/Hsp27 is that all sHsps prevent Αβ aggregation by a hydrophobic interaction of 
Aβ with the α-crystallin domains of the sHsps, but only Hsp20 inhibits Αβ toxicity by 
an electrostatic interaction with Αβ.  In fibril formation, hydrophobic forces in the 
middle of Αβ sequences and at the end of C-terminus are very important. (Tjernberg et al. 
1999)  Electrostatic interactions in Αβ are associated with Αβ binding to membrane 
mimicking lipids. (Ege and Lee 2004)  These data suggest that hydrophobic forces and 
electrostatic forces could be the dominant driving forces in Αβ aggregation and toxicity, 
respectively. Partially unfolded proteins interact with multiple α-crystallin domains of 
sHsp in the cleft of sHsp subunits. (Ganea 2001) The α-crystallin domain is known to 
play an important role in interaction with hydrophobic regions of partially unfolded 
protein, (Stevens and Augusteyn 1997; Sharma et al. 1998) and results in the correct 
folding of substrate protein.  sHsps could prevent Αβ aggregation via the interaction of 
multiple α-crysatllin domains composed of hydrophobic β-sheet structures.  According 
to a Kite and Doolittle  (hydrophobicity) analysis, Hsp20 has less hydrophobic character 
(or more hydrophilic character) at the end of N-terminal domain and/or the beginning of 
α-crystallin domain, whereas other sHsps have less hydrophilic character (or more 
hydrophobic character in those regions.)  The y axis of Kite and Doolittle plot is the 
hydrophobicity (positive values indicate hydrophobic character and negative values 
indicate hydrophilic character) and the x axis is the protein residues.  In preliminary 
results of a Kite and Doolittle analysis, αB-crystallin (light line) and Hsp20 (dark line) 
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are shown in A, αB-crystallin (light line) and Hsp17.7 (dark line) in B, αB-crystallin 
(light line) and Hsp27 (dark line) in C.   
In the result shown in Figure 7. 2A, both αB-crystallin and Hsp20 have 
hydrophobic character in the α-crystallin domain.  Hsp20 has more hydrophilic residues 
at around 70-90, whereas αB-crystallin is hydrophobic at the corresponding residues.  In 
the results shown in Figure 7. 2B and C, Hsp17.7 and Hsp27 have hydrophobic residues 
at α-crystallin domains like αB-crystallin and Hsp20.  However, Hsp17.7 and Hsp27 
have more hydrophobic residues like αB-crystallin where Hsp20 has more hydrophilic 
residues.   
In order to determine if electrostatic binding between Αβ and sHsp plays a role in 
aggregation or toxicity prevention, a method of examining protein-protein interaction 
could be helpful.  One of the programs used for predicting protein-protein interactions is 
Hex.  First of all, Hex calculates all possible positions between ligand protein and 
receptor protein based on 3D parametric function by surface shape, electrostatic charges, 
and potential distributions.  From these results, orthogonality properties (translational or 
rotational properties) can be calculated.  After this step, steric hindrances and residue 
refinements are calculated. From a series of calculations, this program seeks protein-
ligand positions which minimize the interaction energy.  With the Hex program, better 
predictions are possible with smaller rigid proteins than larger molecules, and 3D 
structure information is necessary.  Unfortunately, 3D structures of Hsp20, Hsp17.7, 
Hsp27, and αB-crystallin have not been characterized.  Among sHsps, 3D structure 
information is only available for Hsp16.9 and Hsp16.5.  The good news is that Hsp16.5 
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    A                                      B                      
 
 
 
 
 
 
 
 
 
   C  
 
 
 
 
 
 
 
 
Figure 7. 2. Hydrophobicities of small heat shock proteins by using Kite and Doolittle. 
Light color lines – αB-crystallin and  dark color lines - (A) Hsp20, (B) Hsp17.7, and (C) 
Hsp27
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has a similar hydrophobic profile to Hsp20, and Hsp16.9 has a profile similar to αB-
crystallin, Hsp17.7 and Hsp27. (Kite and Doolittle data are not shown).  In order to 
examine the effect of electrostatic interactions, Αβ1-16 was used instead of whole 
peptides.   
Figures 7. 3A and B are the result of the prediction of the interaction between Αβ1-
16 and Hsp16.5 (A), and Hsp16.9 (B).  Total energies of interaction between Aβ and the 
sHsp in A and B are –63.71, and –0.43, respectively.  These results imply that Αβ1-16 is 
interacts more strongly with Hsp16.5 than with Hsp16.9, and that the electrostatic 
interactions between Aβ and Hsp16.5 (and by analogy Hsp20) are greater than those 
between Aβ and Hsp16.9 (and by analogy Hsp17.7, 27, and αB-crystallin).  
The preliminary results of Hex protein-protein interaction predictions, and Kite and 
Doolittle analysis suggest that Hsp20 can bind to Αβ1-40 by hydrophobic forces as well 
as electrostatic forces.  However, more evidence will be needed to confirm these results 
because I used models of all proteins Hsp16.5 and Hsp16.9 as model small heat shock 
proteins and Aβ1-16 instead of the full length Aβ sequence) in Hex program.  I can try 
other computational approaches to predict protein-protein interaction, or I could block 
electrostatic forces experimentally (e.g. by changing pH or ionic strength). 
Short term goals for future work include research into the factors that affect kinetic 
of Αβ aggregation and the mechanisms of Hsp20-Aβ interactions. Long term goals 
include the design of peptides (proteins) or chemicals to prevent Αβ aggregation, and 
toxicity.  The drugs designed in the future research will be useful in treatment of AD or 
could be helpful in the treatment of some of the 20 other diseases related to amyloidoses. 
 
 155
Aβ1-16 
Hsp16.5 
Hsp16.9 
Aβ1-16 
A 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
Figure 7. 3. Protein-protein interaction between Aβ1-16 and Hsps by using Hex.  (A) 
Hsp16.5, substitution of Hsp20,  (B) Hsp16.9, substitution of other Hsps. 
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CHAPTER VIII 
SUMMARY AND CONCLUSIONS 
The objectives of this research are to understand the characteristics of Aβ 
aggregation under different incubation conditions, and the role of small heat shock 
proteins in prevention of Aβ aggregation and toxicity.  β-amyloid peptide (Aβ) is the 
main protein components of senile plaques that are one of the histopathological 
hallmarks in Alzheimer’s disease (AD).  Aβ readily forms fibrils via conformational 
changes to high β-sheet content, (Walsh et al. 1997; Walsh et al. 1999) and this fibril 
structure is associated with senile plaques in AD.  Numerous environmental factors such 
as solvents, pH, temperature, and ionic strength that are associated with how 
investigators aggregate Aβ in vitro may affect Aβ structure. (Barrow and Zagorski 1991; 
Barrow et al. 1992; Snyder et al. 1994; Shen and Murphy 1995; Fezoui and Teplow 
2002; Kawooya et al. 2003; Stine et al. 2003) 
In work presented here, I determined that different Aβ incubation conditions 
(mixing and non-mixing condition) in vitro can affect the rate of Aβ fibril formation, the 
morphology, the toxicity and the conformational stability of intermediates in the 
aggregation pathway.  According to Congo red binding results, the kinetics of Aβ 
aggregation appears similar regardless of the presence or absence of mixing.  In both 
cases, fibril formation follows a characteristic sigmoidal curve, with a lag phase at early 
incubation times, followed by a fibril growth phase, then a saturation phase. The 
characteristic lag is typical of a nucleation dependent mechanism of aggregation that a 
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number of investigators propose for Aβ fibril formation. (Lomakin et al. 1997; Tseng et 
al. 1999; Esler et al. 2000; Serio et al. 2000; Pallitto and Murphy 2001) CD data suggest 
that Aβ does not undergo significant structural rearrangements when aggregated with 
mixing, however, when aggregated without mixing, a dramatic shift in structure is 
observed at intermediate times (approximately 4-8 hours after aggregation is initiated), 
which corresponds to the presence of an intermediate sized species in chromatograms 
(approximate molecular weight as estimated from elution volume on SEC of 53kDa) and 
a large globular species in electron micrographs. When Aβ is aggregated with mixing, 
fibrils undergo conformation change in denaturant more readily than monomer, 
suggesting that a less stable or higher energy species is formed during aggregation with 
mixing.  When Aβ is aggregated without mixing, aggregation intermediates undergo 
conformation change more easily than either fresh or fibril Aβ suggesting that the 
intermediate is least stable or has the highest energy. Aggregation intermediates formed 
without mixing change structure more readily in guanidine hydrochloride than other 
species examined.   The same trends are observed in Aβ stability using urea as a 
denaturant. Toxicity of fibrils is greater when formed with mixing, while toxicity of 
aggregation intermediates formed between 4 and 8 hours after initiation of aggregation 
without mixing are more toxic than other species formed.    The difference in stability in 
denaturants could correlate with toxicity.  A number of investigators have suggested that 
Aβ membrane interactions via Aβ conformational changes are important in the 
mechanism of Aβ toxicity. (McLaurin and Chakrabartty 1997; Terzi et al. 1997; Ege and 
Lee 2004)  Behavior of Aβ in a membrane and in a denaturant might be analogous. 
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Small heat shock proteins (sHsps) are expressed in almost all organisms when cells 
become stressed in unfavorable environments. sHsps exist as large oligomeric 
complexes of 300-800kDa with monomeric molecular mass of 15-43kDa. (van den et al. 
1999; Clark and Muchowski 2000; MacRae 2000)  Important roles of sHsps are to 
stabilize other proteins under stress conditions and protect them from aggregation. (van 
den et al. 1999; Bruey et al. 2000)   
In this research, several small heat shock proteins (sHsps) are tested to prevent Aβ 
aggregation and toxicity as drug candidates. sHsps used in this research are Hsp17.7 
from carrot, human recombinant Hsp27, and Hsp20 from B. Bovis in different constructs, 
Hsp20-MBP (maltose binding protein fusion), His-Hsp20 (polyhistidine fusion) and His-
Hsp20 without 11 residues in C-terminus.  Cutting off the 11 residues from the C-
terminus in Hsp20 improves the assembly properties of Hsp20.  All types of Hsp20 are 
able to prevent Aβ1-40 aggregation at much lower concentrations than what has been 
necessary to prevent aggregation with other inhibitors.  Hsp20 is able to optimally 
prevent amyloid formation of Aβ at molar ratios of Hsp20 to Aβ of approximately 
1:1000 as indicated by Congo red binding.  Hsp20 attenuates the toxicity of Aβ in SH-
SY5Y and PC12 neuronal cells at analogous molar ratios.  A careful examination of 
electron micrographs (EM) of Aβ-Hsp20-MBP mixtures under optimal fibril formation 
and toxicity prevention conditions reveals the presence of small globular species with a 
16.3 nm diameter and variable length. The globular species are not yet well 
characterized, however, size analysis suggests that the species may be an Hsp20-Aβ 
complex rather than Aβ protofibrils since the width of these species (16.3nm) is atypical 
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for Aβ micelles (5 ~11 nm), protofibrils (4~8nm), or fibrils (6~10nm) (Yong et al. 2002).   
EM studies of Aβ-His-Hsp20 at the optimum ratio used to prevent aggregation taken at 
different times during aggregation show that Aβ-His-Hsp20 forms a huge ring structure 
complex at 2 hours.  After 2 hours, the complex rings seem to break down and dissipate 
into the environment. In prevention of Aβ aggregation and toxicity, His-Hsp20 is more 
active than Hsp20-MBP, but His-Hsp20s show almost same activities regardless of the 
existence of the 11 residues in the C-terminus.  Hsp17.7 from carrot and human 
recombinant Hsp27 can prevent Aβ1-40 aggregation, but not toxicity.  Kudva et al., 
reported that Hsp27 inhibited fibril formation of Αβ1-42 in vitro.(Kudva et al. 1997)  
These sHsps do not appear to form the large ring structures when incubated with Aβ that 
are formed with Hsp20, suggesting that the formation of the large ring structure may be 
important in the mechanism of toxicity prevention. 
Conclusively, I report structure and toxicity of Aβ species formed during 
aggregation via different methods.  I show that fibrils formed via different methods, 
while structurally similar, do not have the same toxicity or the same apparent stability to 
denaturants.  Aggregation intermediates that are similar to Aβ oligomer species reported 
by others such as ADDLs, are of comparable toxicity and stability in denaturants as 
fibrils formed during mixing.  This work contributes to the understanding of the 
relationship between Aβ structure, stability and toxicity.  All sHsps used in this research 
prevent Aβ1-40 aggregation, but only Hsp20 can inhibit Aβ1-40 toxicity.  In drug 
development for AD, it will be very useful to understand the mechanism of Hsp20 in 
prevention of Aβ toxicity.  
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